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SUMMARY
METABOLIC AND NUTRITIONAL IMPLICATIONS OF CANCER AND CHEMOTHERAPY
Cancer and chemotherapy are well known to cause metabolic and 
nutritional alterations in patients; the culmination of these being 
the syndrome of cancer cachexia. Theories abound to explain the 
causes of the altered metabolism, however many of the problems 
encountered in the cancer patient remain unresolved. The aims of this 
thesis are to explore, in more detail, some of these metabolic and 
nutritional problems.
The problem of nutritional assessment was considered, and dietary 
histories, clinical evaluation and biochemical estimations of 
nutritional deficiencies were compared amd contrasted in a search for 
the best, easiest and most reliable method of nutritional assessment 
for the cancer patient. The best method of assessing patients was 
found to be a combination of all three types of evaluation. Each type 
of assessment broadly agreed with the others, however clinical and 
biochemical evaluations of nutritional state tended to reflect 
long-standing deficiencies, while 24 hour dietary recall histories 
could be used to predict potential nutritional problems. Twenty-four 
hour dietary recall histories with computer analysis used on several 
occasions allow fluctuations in dietary intake and hence nutritional 
state to be recorded, and provide a fast, easy and reliable way of 
evaluating present nutritional state and anticipating and correcting 
future nutritional problems.
16.
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The effects of cancer and chemotherapy on nutritional and
metabolic status of cancer patients and tumour-bearing animals were 
considered in a number of studies.
Muscle biopsies were performed on cachectic cancer patients and 
showed considerable disruption of muscle fibres with particularly 
striking changes seen in the mitochondria. These changes were shown 
to be unique to cancer patients, illustrating the specific metabolic 
alterations in this group.
A preliminary study to investigate the problems of dry mouths, 
with difficulty in chewing and swallowing food, and changes in taste 
sensations, anorexia, and decreased enjoyment of food, looked at saliva 
composition and production. Cancer patients were found to have
decreased saliva volumes, amylase content, lysozyme and igA content and 
increased microbacteria and yeasts present in the saliva, compared to 
healthy controls. Patients followed over three months from initial 
chemotherapy showed decreasing saliva flow rates and increasing 
microflora colonisation of the mouth over this time. Cisplatin, 
Adriamycin and Mitomycih-C were particularly implicated in micro­
organism colonisation; Cyclophosphamide and Methotrexate were more 
likely to produce decreased saliva volumes and dry mouths. Further work 
is required to correlate the incidence of dry mouths, altered 
taste sensations and anorexia with the changes found in saliva produc­
tion and composition. The results obtained, however, confirm that 
there is decreased saliva flow in cancer patients receiving
17.
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chemotherapy; and that the mouth harbours organisms which % are 
potentially virulent if host defences are impaired.
Metabolic consequences of tumour growth and chemotherapy were 
considered in studies using Wistar rats. The animals were given 
tumour alone, tumour plus Cyclophosphamide or Cisplatin, or drug alone. 
All showed metabolic alterations with weight loss, decreased carcass 
nitrogen content, decreased plasma protein, albumin and iron content, 
increased levels of ketone bodies and deranged liver enzymes. The 
tumour produced the greatest metabolic insult; the drugs also produced 
deterioration in metabolic state. The tumour and drug groups shoved 
less metabolic upset, demonstrating the beneficial effects of response 
to treatment; where there is no response to treatment there are 
increased metabolic problems caused by cumulative effects of drugs and 
tumour. These results can be extrapolated to cancer patients.
cisplatin was studied in more detail using preliminary animal 
studies which showed that Cisplatin affects all organs in the body but 
particularly the kidney; and causes mitochondrial disruption at the 
cellular level. These cellular changes may account for the metabolic 
upsets seen in animals and patients treated with Cisplatin, and future 
studies should look more closely at this aspect,
Clinical studies bn Cisplatin lookediat the effects of treatment 
in patients with teratoma. Trace;metal levels:shoved little;,change 
during and over four courses of treatment: serum iron levels rose with
18
each course and corresponded with the incidence of anaemia. Serum 
magnesium levels consistently fell over four courses of treatment, and 
further studies compared routine magnesium supplementation over four 
courses of treatment with no supplementation over the same period. 
Magnesium supplements had no effect on response to treatment, rate of 
fall of tumour markers, or final outcome. Both supplemented and 
non-supplemented groups had similar weight loss, nausea, vomiting 
and anorexia during treatment. Dietary intake was shown to decrease 
markedly, to less than 50% pre-treatment level, following 
Cisplatin, and to remain low for 8-12 days following treatment. This 
allowed only 4-7 days of normal intake prior to the next course of 
treatment. There is a cumulative effect of Cisplatin on appetite over 
the four courses of treatment, and there may be significant 
nutritional depletion by the end of this regime which may prevent 
further aggressive treatment of the tumour, if required. Future 
studies should examine the usefulness of early nutritional support 
to prevent these problems.
Benefits of magnesium supplementation were fewer treatment delays 
due to neutropenic episodes following treatment, higher serum magnesium 
and potassium levels, and less deterioration in renal function as 
measured by N-acetyIg lucosamine and Beta-2-microglobulin levels in 
urine. These factors will allow regular and aggressive treatment with 
Cisplatin while keeping the safe therapeutic margin as wide as 
possible. Future studies should monitor renal function during and 
after Cisplatin treatment using Ishacetylglucosamine and beta-2-micro- 
globulin levels and should examine in more detail the routine use of 
magnesium supplments.
19.
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Magnesium supplements were given intravenously during inpatient 
treatment, and orally when discharged home. The oral supplements were 
not entirely satisfactory and compliance was poor. Further work is 
required to find the optimum level of supplementation, and a suitable, 
palatable oral supplement.
Anorexia was a major complaint in 43% patients attending the 
oncology outpatient clinic at Gartnavel General Hospital, Glasgow. - A 
double blind crossover study of appetite stimulation using prednisolone 
against placebo over a two week period showed a significant 
improvement in appetite and well-being with prednisolone. Further 
studies should examine the use of prednisolone over longer periods; 
and compare prednisolone with other appetite stimulants.
In conclusion, this thesis has examined some of the effects of 
cancer and chenotherapy on nutrition and metabolismî Many of the 
results obtained beg further studies, and there remains a lot of work 
to be done to fully understand the nutritional and metabolic 
implications of cancer and its treatment.
20,
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ABBREVIATIONS
Very few abbreviations have been used and all are explained when 
they first appear in the text. Those most commonly referred to are:
Aceto - Acetoacetate
ALT Alanine transaminase
AST Aspartate transaminase
BOH Beta-Hydr oxybutyrate
Cisplatin Cisdichlorodiammine Platinum (II)
Cyclo. Cyclophosphamide
Fe Iron
K Potassium
NAG N-Acetyl glucosamine
Ft Cisdichlorodiammine Platinum (II)
Tr i-iodothyronine
21.
METABOLIC AND NUTRITIONAL IMPLICATIONS OF
CANCER AND CHEMOTHERAPY
 :________________
CHAPTER 1; INTRODUCTION - BACKGROUND AND AIMS OF THESIS
A. INTRODUCTION AND BACKGROUND
The implications of cancer extend beyond the cells in which it 
develops to involve the metabolic, nutritional and psychological 
constituents of the host. The resulting alterations in function may be 
caused both by the tumour itself and by many of the types of treatment 
used to combat it.
The syndrome of cancer cachexia - the word "cachexia" from the 
Greek "kakos" and "hexis" meaning bad condition - well describes the 
popular concept of the cancer patient: pale, anaenic, weak, listless,
wasted and depressed,with malabsorption, diarrhoea and massive weight 
loss (Caiman, 1982; Hall, 1979; Strain, 1979; Theologides, 1979). The 
number of deaths attributed to cachexia has varied little from 10-23% 
patients with cancer reported in the 1930's by Warren (1932), v^ o 
originally described the condition (inagaki, Rodriguez & Bodey, 1974).
The frequency of cachexia has been reported in 8-84% all patients 
with cancer (Strain, 1979), although not every patient with cancer will 
develop cachexia, it is often difficult to predict which patients will 
become cachectic; however, many patients have evidence of weight loss 
at some stage of their disease^and 43% patients in a survey carried out 
at the Department of Oncology, Glasgow University, complained of 
anorexia - both cardinal features of the "cachexia syndrome". 
Cachexia and weight loss are considered to be poor prognostic signs in
23.
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the cancer patient, indicating progressive tumour growth and a 
decreased tolerance to treatment, with corresponding: reduction in its 
effectiveness (Dewys, 1980; Kisner, 1982; Strain, 1979).
Weight loss may occur as an isolated sign in the absence of obvious 
tumour and has been found in 29-66% ^ tients starting chemotherapy 
(Gold, 1974; Kisner, 1982). It may occur despite a normal appetite, 
and normal or increased intake of food, and is another indication of 
the disturbed internal metabolism of the patient (Strain, 1979; 
Brennan, 1977) (Fig, 1). Decreased intake of food is often present in 
cachexia and may account for the weight loss seen. It may be due to 
mechanical difficulties in chewing, swallowing, digesting or 
absorbing food caused by surgery, radiotherapy or chanotherapy or 
by the tumour itself altering normal anatomical and physiological 
pathways in the gastrointestinal tract. Anorexia may also contribute 
to poor intake (q.v.) (Fig, 2).
Cancer cachexia has been described in patients with tumours of 
all sizes, sites and stages and its symptoms and signs are markers of 
the underlying, fundamental changes in the metabolism of the patient. 
It has no correlation with food intake (Theologides, 1979; Coheh et 
al., 1978; Sudjian, 1980; Costa, 1977),
■i
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The metabolic changes may begin early in the growth of the timour, 
at a stage not clinically identifiable, and progress insidiously to the
24.
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Radiotherapy Chemotherapy Surgery
Tumour Effects
(1 ) Mechanical
(2 ) Metabolic
Anorexia Weight
Loss
Decreased Food 
IntakeHormones
FIGURE 1 FACTORS CAUSING WEIGHT LOSS IN CANCER PATIENTS
________________________ ______________________
Radiotherapy Chemotherapy
Anorexia ' Decreased ^  
Food Intake
D ifficu lty
Chewing
Surgery
Tumour Growth
(1 ) Mechanical
(2 ) Metabolic
Malab sorption
Dysphagia
FIGURE 2: FACTORS AFFECTING FOOD INTAKE IN CANCER PATIENTS
________________
gross alterations of metabolic and nutritional status seen in the 
cachectic patient (DeWÿs, 1970). These alterations may. be temporarily 
slowed down:ôr even reversed by feeding - either enteral or parenteral 
~ but this serves to produce only a short-term improvement in the 
patient (Brennan, 1981). The only method for complete reversal of the 
changes of cachexia is successful treatment of the tumour (Costa, 1963; 
Terepka & Waterhouse, 1956; Brennan,1981; Caiman, 1982). The problem is 
not simply that of increased energy expenditure exceeding intake 
(Theologides, 1972), there are other factors either induced in the host 
or produced directly by the tumour causing the "metabolic chaos" of the 
cachectic host. Theologides (1976) proposes that small molecular 
weight proteins or peptides are produced by the tumour or its influence 
on the host which interfere with thé normal protein, fat and 
carbohydrate interrelationships, causing a failure of host adaptation 
to the tumour presence (Waterhouse, 1974; Morrison, 1976). A lipolytic 
factor (toxohormone-L) is among a nunter of factors isolated in 
experimental animals with cancer, and it produces increased fat
 mobilisation when injected into control animals (Chalmers, Kekwick &
Pawan, 1958; Costa & Holland, 1962; Liebelt et al,, 1974; Manuno, 
Yamasaki & Okuda, 1981) . Another peptide, which induces anorexia has 
been found in the urine of patients with widespread malignant disease 
(Chalmers et al., 1958) and has been isolated from the urine of fasted 
rats. It was originally thought that these peptides were produced by 
the pituitary, however they have been identified in animals 
without a pituitary gland (Beaton, Szlavko & Stevenson, 1964), This 
provides some support for the theory of tumour-produced substances
25.
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affecting host metabolism.
Tumours are well known to produce hormones which may influence 
host homeostasis (DeWys, 1982), Small cell lung tumours, adrenal, 
pancreatic, breast, ovarian and endometrial tumours are among those 
implicated in hormone production (Strain, 1979; Weller, 1972); and the 
effects of the tumour derived hormones may upset fluid and electrolyte 
balance, glucose regulation and steroid metabolism. Other less well 
known hormones have been identified in cachectic patients such as 
somatostatin, bombesin, cholecystokinin, neurotensin, endorphins and 
encephalin. These hormones have effects both on the central nervous 
system appetite centres and on the gastrointestinal tract and may 
influence the intake and absorption of food (Theologides, 1981; De%s, 
1979).
Ratcliffe et al, (1978) found that in 33% patients with lung 
cancers of various histological types there was a significant decrease 
in triiodothyronine (T^ ) levels in serum compared to control patients 
with other lung disease. This was correlated with a poor prognosis. 
Their work has been confirmed by Axelrod & Costa (1980) who suggest 
that the decreased levels of T ^  in cancer patients may reflect a 
compensatory mechanism for the decreased energy intake in these 
patients.
#
Liver function is generally found to be impaired in cachectic 
patients, and there is an increase in liver weight even in the absence
26.
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of métastasés (Theologides, 1979; Abels et al.,1942; Walsh & Kissanë, 
1968). Fatty infiltration of the liver has been described (Lanza & 
Nelson, 1968) and this may be due in part, to increased fat 
mobilisation and ketone body production (Tisdale, 1982). Decreased 
synthesis of plasma albumin is common, although there may be normal or 
increased synthesis of other liver proteins such as the acute phase 
reactants and immunoglobulins. This continued hepatic synthesis may 
account for a large energy expenditure (DeWys, 1982; Raines et al., 
1981; Steinfeld, 1960; Ehman, 1981). Abnormal levels of liver
enzymes have been found which have no correlation with the dègree of 
cachexia (Lemon, Holland & Holland, 1965; Waterhouse, 1974).
One explanation for the continued weight loss in cancer patients, 
despite normal intake, has been an increase in the basal metabolic 
rate in these patients (WarnoId, Lundholm & Schersten, 1978; Manson^ 
1976; Waterhouse, 1974). Katz, Wals & Rognstad, (1978) suggest that 
"futile" metabolic processes caused by the tumour produce the 
increased energy expenditure. However a number of authors (Knox et 
al., 1983; Strain, 1979) maintain that there is no uniform increase in 
basal metabolic rate in cancer patients and, indeed, Knox et al (1983) 
found in a group of 200 heterogeneous cancer patients that 26% were 
hypermetabolie, while 33% had low metabolic rates. They suggest that 
the duration of disease may have a major influence on energy
metabolism: the patients with the longer duration of disease.
27
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although not necessarily with increased tumour spread, tended to be 
hypermetabolic. It seems^ therefore ^  that at present, energy 
expenditure cannot be confidently predicted in cancer patients.
Carbohydrate metabolism
Carbohydrate metabolism is deranged in cachectic patients with 
most showing à diabetic-rtype glucose tolerance curve and poor 
utilisation of. exogenous glucose (Young, 1977; Bishop & Marks, 1959; 
Jasani et al., 1978; Kisner et al., 1978). The fasting cachectic 
patient may, however, have a normal blood sugar (DeV^ s, 1982), There 
is evidence both for impaired release of insulin from the pancreas 
(Jasani et al., 1978; Bishop & Marks, 1959) and for insulin résistance 
in the peripheral tissues (Kisner et al., 1978). The inhibitory
effects of insulin on lypolysis, however, are normal (Schein et al., 
1979). Some patients show increased levels of glucagon in the 
plasma, antagonising the effects of insulin.
Lundholm, Bylund & Schersten (1977) found cellular evidence of 
altered carbohydrate metabolism with decreased levels of glycolytic 
enzymes in skeletal muscle biopsies of cancer patients compared to 
countrols. Evidence of decreased utilisation of glucose was provided 
by Waterhouse (1974) giving radio-labelled glucose orally and finding 
decreased levels of exhaled radio-labelled carbon dioxide in cancer 
patients compared to controls. a
28.
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At least some tumours derive their energy solely from glycolysis 
(Gold, 1974; Waterhouse, 1974) and So rely heavily on supplies of 
glucose from the host. Once liver glycogen supplies are exhausted, in 
a relatively short period of time, the liver having enough glycogen 
stored for about 2 hours of continuous activity, the process of 
gluconeogenesis begins. The tumour produces lactate from the 
anaerobic oxidation of glucose, and this is recycled via the liver and 
kidney to glucose, requiring 6 moles ATP for each lactate molecule, 
with 2 lactate molecules required for each glucose molecule. The 
tumour derives 2 moles ATP from each glucose molecule and hence 
the host loses a net 14 moles ATP for each molecule of glucose 
metabolised (Gold, 1974), This lactate-glucose cycle, the Gori
cycle, is greatly increased in patients with cachexia and progressive 
tumour growth, and with weight loss; patients with no weight 
loss show no change in Cori cycle activity (Waterhouse 1974; Holroyde 
et al., 1975; Reichard et al., 1963). A high glucose turnover 
rate with a slight overall increase in glucose production rates has 
been described in cachectic patients.
The relative contribution of this increase in oxidative metabolism 
to the overall energy expenditure of the hOst is the subject of some 
debate. Young (1977) maintains that the Cori cycle will account for 
only about 10% daily energy expenditure; Waterhouse (1974) and 
Reichard et al. (1963 and 1964) contend that in those patients with 
increased Cori cycle activity there is an increase of 50% in its 
contribution to daily energy expenditure, which they consider to be a
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significant contribution to increased basal metabolic rate.
There may be another energy-expensive cycle in cachectic patients 
when glucose, instead of being used directly is converted first to 
triglyceride in adipose tissue, then oxidised as free fatty acid in the 
host. This may account for up to 20% extra daily; energy expenditure 
for the cancer patient (Flatt & Blackburn, 1974; Fields et al,, 1982).
Confirmatory evidence that some tumours use glucose for energy can 
be found in those tumours which produce hypoglycaemia in the host. 
These tumours tend to be large, weighing from 1-9 kilograms, and are 
often retroperitoneal tumours, usually hepatocellular carcinomas or 
fibrosarcomas. Their effects may be nediated through the extraction of 
excess glucose from the bloodstream or by producing products 
which have an insulin-like effect (Kreisberg et al., 1970; Costa, 
1977). Fig. 3 summarises the changes seen in carbohydrate 
metabolism in cancer patients.
protein metabolism
Protein metabolism is markedly altered in patients with cachexia 
with 33-100% of all patients with advanced cancer having a negative 
nitrogen balance (Blackburn et al., 1977). There is a progressive loss 
of muscle proteins to provide amino acids for gluconeogenesis. Scxne 
patients with non-gastrointestinal cancers show a decrease in the 
protein content of muscles and viscera as one of the first sighs of
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FIGURE 3: ALTERATIONS IN CARBOHYDRATE METABOLISM IN CANCER PATIENTS
malnutrition, even before fat loss is obvious (Bozzetti et al., 1982). 
Patients with cancers of the gastrointestinal tract have often, in 
addition to the effect of tumour on metabolism, a mechanical block to 
or abnormal absorption of food due to the surgery, radiotherapy, 
chemotherapy or disease (Blackburn et al., 1977). These patients show 
similarities to protein-calorie malnourished patients with early .loss 
of body fat, then later loss of muscle and visceral proteins (Bozzetti 
et al., 1982). Hypoalbuminaemia is common and is due to low synthesis 
rates and normal or increased rates of albumin catabolism (Raines et. 
al., 1981). Those patients with gastrointestinal cancers showing
similarities to protein-calorie malnutrition in their metabolism
may produce an increased synthesis rate of albumin in response to 
feeding. However, so far this has not been shown to be 
sufficient to reverse the long-term net catabolism of albumin (Trotter 
& Caiman, 1981). There may be losses of plasma albimin into 
extracellular fluid or into the gastrointestinal tract via fistulas 
or tumours or treatment-induced damage to the gastrointestinal 
mucosa (Strain, 1979) , Costa (1977) has correlated the degree of 
hypoalbuminaemia in cancer patients with the appearance and number of 
métastasés.
The decreased protein synthesis has been shown by Costa (1977) to
correspond with decreased survival, depressed immune response,
decreased tolerance to chemotherapy, radiotherapy and surgery, and 
decreased drug-carrying ability in the blood causing problems of drug 
toxicity and difficulties in prescribing appropriate drug doses for the 
patient.
31,
 . . _ _ ■ ___________
It has been proposed that some tumours act as "nitrogen traps"
taking all available amino acids for their own use, and depriving the
host of essential amino acids, with consequent decreased utilisation of 
amino acids for protein synthesis in the host (Costa, 1977; Mider, 
1951): the host amino acids are then channelled to gluconeogenesis of
oxidation, with gluconeogenesis predominating (Stein, 1978)1 7^ ^
amount of nitrogen "trapped" by the tumour may not account for the
total loss of protein seen in patients since, although in animals^  
tumours may account for up to 40% body weight and hence may trap large 
amounts of nitrogen, human tumours, at most, will account for 5% body 
weight and would not therefore be anticipated to cause the large 
nitrogen deficit seen (Strain, 1979; Waterhouse, 1974). Norton et al. 
(1980) found evidence of increased uptake of amino acids by tumours in 
studies of blood flow in a tumour-bearing limb compared to its normal 
partner. They found that the tumour bearing limb retained up,to 50% 
more of each amino acid than did the control limb. The release of 
gluconeogenic amino acid precursors from the control limb 
correlated with the glucose uptake recorded in the tumour-bearing limb. 
They suggest that this implies the breakdown of host muscle to
provide precursors for gluconeogenesis in the liver and for 
tumour protein synthesis. Lundholm et al. (1976) confirm this 
view by finding, in vitro, an increased breakdown of protein in 
muscle fibres of cancer patients compared to controls.
Numerous studies have shown abnormal patterns of amino acids in
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the blood of cachectic cancer patients (Stein, 1978; Trotter, Carlyle & 
Caiman, 1980; Clarke, Lewis & Waterhouse, 1972; De%s, 1970) and these 
may, in addition to causing upset protein metabolism, cause anorexia 
via an effect on the central nervous system (Theologides, 1972)•
Fig. 4 summarises the alterations in protein metabolism in cancer 
patients.
Lipid metabolism
Lipid metabolism alters to compensate for the deranged protein and 
carbohydrate metabolism y according to DeViys (1982), Lipid absorption 
in the gastrointestinal tract may be abnormal (Strain, 1979) , and 
Delaney et al. (1982) suggest there is abnormal lipid absorption, or 
disturbed oxidative metabolism in cancer patients prior to clinical 
signs of malnutrition. Costa (1977) showed that early fat loss 
tends to occur in cancer patients; muscle biopsies taken during first 
operation on patients with carcinemas of breast or colon showed, on 
average, 50% of the fat content of control biopsies from patients 
with a variety of acute and chronic surgical conditions, Warhold, 
Lundholm & Schersten (1978) showed decreased body fat in women with 
various cancers when compared to hospitalised controls.
Theologides (1979) found an early increase in cholesterol and 
phospholipid content of carcass, skeletal muscle and intestine of 
tumour animals arid there was a concomitant decrease in fat stores with 
increased mobilisation of free fatty acids. Levels of free fatty 
acids in the blood may be normal or increased, and fall normally in
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response to insulin (Holroyde et al., 1978; Schein et al.,
Changes may be found in the:.composition of circulating lipoproteins and
■ ■ -  . ■ , in the activity of plasma lipase (Theologides, ,1979) .. At a cellular
level, this loss of body fat may affect the lipid content of host cells
and impair synthesis of cellular membranes (Costa, 1977).
There is an increased rate of removal of infused lipid from ; the 
circulation and decreased suppression of free fatty acid oxidation by 
infused glucose in cancer patients (Waterhouse & Nye, 1961; Waterhouse 
& Kemperman, 1971). The tumour itself appears to have no direct offset 
on free fatty acid levels in the blood as Norton et al. (1980) found no 
difference in free fatty acid levels in blood between tumour tearing 
and control limbs.
The increase in free fatty acid oxidation allows the production of 
ketone bodies and of co-enzyme A which stimulates the gluconeogenic 
cycles (Stein, 1978) . Ketone bodies may be used as a source of energy 
by most of the body tissues including the central nervous system, 
although there is some debate as to whether tumours can utilise 
ketones. Some animal tumours have certainly the capacity to oxidise 
ketone bodies to the same extent as heart muscle (Tisdale, 1982). 
Ketone bodies normally inhibit continued lipolysis either direcfly or 
via stimulation of insulin secretion, however this does not happen in 
cancer patients. This may be due to impaired insulin secretion 
(Bishop & Marks, 1959) or decreased response of adipose tissue to 
ketones, and is another indication of the failure of host homeostatic
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mechanisms (Tisdale, 1982).
Fig. 5 summarises the alterations in lipid metabolism in cancer 
patients,
These changes in carbohydrate, protein and lipid metabolism have 
sane similarities both with protein-calorie malnourished patients 
and with patients who have had major injury or sepsis. In the starved 
patient there are two phases of metabolic adaptation (Strain, 1979) . 
Initially there is increased gluconeogenesis designed to compensate for 
the rapid depletion of liver glycogen stores. Protein catabolism
increases to provide glucose precursors and there is increased
uptake of amino acids by the liver. Since this would rapidly lead to 
death, an adaptive mechanism which conserves protein is switched on 
in chronic starvation. Ketone bodies replace glucose as the fuel for 
cells, and there is decrease in gluconeogenesis. Both synthesis and
catabolism of albumin decrease and there is a fall in oxidative
metabolism, metabolic rate and carbon dioxide output. This "fat-fuel 
economy" allows survival for long periods under conditions of near 
starvation, using fat stores for energy (Brennan, 1977) (Fig. 6).
In major injury or sepsis, there is continued protein breakdown 
and high basal metabolic rate which persists until the injury or its 
complications are relieved. There is a high rate of gluconeogenesis 
and also loss of body fat for energy (Brennan, ,1977).
The metabolic changes occurring in cancer patients are difficult
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to define precisely - patients who have the disease for the longest 
time have more obvious abnormalities. Those who show weight loss 
have similar metabolic reactions to non cancer patients with weight 
loss, but there are differences with decreased utilisation of exogenous 
glucose and continued use of amino acids for energy via gluconeo­
genesis in the cancer patients. It appears thus that there is 
incomplete adaptation to decreased food intake; and failure of 
normal homeostatic mechanisms in the presence of tumour (Waterhouse, 
1974) (Fig. 7).
Electrolytes, minerals and vitamins
Fluid and electrolyte balance may be altered in cancer patients 
with increased retention of both intracellular and extracellular water. 
This obscures the amount of weight lost by the patient making him 
appear better nourished than he actually is (Craig & Waterhouse, 1957; 
Rechcigl, Grantham & Greenfield, 1960). Cameron and Hunter (1983) have 
observed increases in intracellular sodium content of host cells in 
three different mouse tumours which were producing anorexia and 
cachexia; and they postulate that this may act to produce or maintain 
cachexia. Rat tumours have shown a similar sodium-retaining effect 
(Rechcigl et al., 1960). In man, low serum sodium levels ^ are found in 
patients with advanced disease, and increased levels of sodium and 
potassium have been reported in the urine of patients with weight loss 
and increased catabolism (Blackburn et al., 1977; Theologides, 1979). 
Oat cell carcinoma of the lung and other hormone-secreting tumours may 
affect sodium and electrolyte balance.
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FIGURE 7: SUMMARY OF METABOLIC ALTERATIONS IN CANCER PATIENTS
potassium levels vary in cancer patients. Adenocarcinomas of the 
colon cause increased losses of potassium into the gastrointestinal 
tract and result in low serum levels; insulin-secreting tumours will 
also produce hypokalaamia, and hypoglycaemia (Blackburn et al., 1977). 
There is some evidence that tumours store potassium thus causing host 
depletion (Warnold et al., 1978).
Calcium levels are increased vÆien there is increased mobilisation 
of calcium from bone with tumour métastasés causing bone destruction, 
and in parathyroid or other hormone producing tumours. Hypercalcaemia 
is associated with thirst, polyuria, anorexia and dehydration, and may 
go on to produce renal and cardiac damage due to calcium deposits in 
these organs. Low serum calcium levels are associated with
hypoalbuminaemia and decreased intake; ionised calcium levels are 
usually normal in these cases (Blackburn et al., 1977; Theologides,
1979).
Magnesium has an uncertain role in cancer. it is an important 
intracellular^  cation and is intimately involved in mitochondrial 
function. Deficiency leads to anorexia, nausea, general weakness, and 
disruption of mitochondrial respiration, and may cause decreased 
potassium and calcium levels with tetany and potentially life- 
threatening cardiac arrhythmias. Cameron and Hunter (1983) found no 
particular change in magnesium levels of intracellular or extracellular 
fluids in cancer bearing hosts compared to controls. High levels of 
magnesium have been found in some specimens of breast cancer
37.
(Santoliquido, Southwick & Olwin, 1976) and parsons et al. (1974)
reported regression of tumour growth in a number of patients depleted 
of magnesium and potassium by dialysis and diet. The evidence 
for a connection between magnesium levels in the host and tumour 
growth is limited, and requires further elucidation (Blackburn et 
al., 1977). This will be discussed more fully in Chapter 6.
Non-specific iron deficiency anaemia may be found in many cachectic 
cancer patients. iron deficiency may be related to hypopharyngeal 
cancer - following the Brown-Kelly-patersonn or plummer-vinson 
pharyngeal web syndrome - and to gastric carcinoma. The incidence of
gastric carcinoma is five times greater in areas where iron deficiency
is common, than in a generally well nourished population (Blackburn et 
al., 1977). There may be a connection between iron deficiency and 
immune deficiency and these factors have both been linked to carcino­
genesis (Vitale, 1975) .
Trace metal changes vary in cancer patients and depend on intake 
and losses, as well as tumour effects. The importance of the trace 
metals is in promoting enzyme activity in the body and deficiency may 
profoundly alter host cellular activity, and may predispose to cancer 
(Blackburn et al., 1977).
Zinc and copper have been most extensively studied. Zinc is a 
co-enzyme for more than eighty enzymes and is necessary for DNA 
and RNA synthesis and repair. Zinc deficiency has been 
found in a number of human and animal studies on tumour-bearing
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hosts. Increased levels of zinc have been found in the urine of
cancer patients (Schwartz, 1975), and Askari, Long & Blackeraore ;(1980) 
maintain that tumours require zinc for growth. Not every tumour 
causes zinc deficiency, and patients with tumours of colon and
lung and advanced disease have been recorded as having increased plasma 
zinc levels (Blackburn et al., 1977).
Copper is a zinc antagonist, in addition to being involved in
enzyme actions in its own right. Copper levels are known to be
increased in the serum of patients with leukaenias and lymphomas and in 
some solid tumours, notably osteosarcomas and carcinomas of breast, 
cervix, bladder, liver, lung and gastrointestinal tract (Askari et al.,
1980). The ratio of serum copper to serum zinc has been used as a
prognostic sign in leukaemias and osteosarcomas and has been proposed 
as a useful marker of successful treatment in the majority of cancers. 
The higher the copper: zinc ratio, the poorer the prognosis and the
more widespread the disease (Askari et al., 1980).
Selenium levels in patients with breast cancer have been found to 
be lower than in normal controls, and populations living in areas with 
high selenium content of soil and crops, have less risk of dying from
cancer (Buzby & Steinberg, 1981; Schwartz, 1975).
Manganese is required for synthesis of connective tissue and has
been found to be increased in malignant breast tissue and in
osteosarcoma tissue (Schwartz, 1975).
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Several studies have shown multiple vitamin deficiencies in 
patients with advanced cancers, but the link between vitamin deficiency 
and the onset of cachexia is not clear (Theologides, 1979). ShiIs 
(1979) maintains that the deficiencies found are due to decreased 
nutrient intake, malabsorption and excessive losses from the 
gastrointestinal and urinary tracts, and that these contribute to the 
continuing vicious circle of malnutrition.
Ascorbic acid levels have,been found to be decreased in patients 
with advanced disease, despite normal food intake (Basu et al,, 1974), 
The lowest levels have been found in patients with metastatic breast 
cancer and skeletal involvement (DickerSon, 1981; Soukop & Caiman, 
1979). Vitamin C is important in maintaining cell and mucous membrane 
integrity and in promoting tissue repair, and deficiency of this 
vitamin has been shown to increase the susceptibility of animals to 
chemically-induced tumours (Gori, 1979; Cameron & Pauling, 1973).
Atukorala et al. (1979) found reduced levels of vitamin A in 
patients with carcinomas of lung, and Ibrahim, Jafarey & Zuberi (1977) 
found similar decreases in patients with squamous cahcers of the mouth 
and pharynx. Dickerson (1981) suggests that low levels of vitamin A 
correlate with low levels both of retinal binding protein and of zinc - 
which is required for protein synthesis. In this case the deficient 
plasma vitamin A is partly due to deficiency of zinc rather than solely 
to decreased intake. vitamin A has an important role in rriaintaining 
epithelial integrity and deficiency may play a part in the occurrence
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and growth of many different cancers (Sporn, 1977).
Abnormalities of folate metabolism have been reported, with low 
levels of plasma folic acid found in patients with metastatic carcinoma 
and in leukaemias and lymphomas (Magnus, 1967). Some tumours have been 
found to have high folate requirements (Rosen & Nichol, 1962) and will 
cause depletion in the host. Folic acid is involved in cell 
replication, and deficiency causes toxic effects on bone marrow and 
gastrointestinal tract - both tissues which have rapid cell turnover. 
This has obvious consequences for host nutritional status and defences 
against infection (Bertino, 1979). Serum vitamin levels have been 
found to be raised in some leukaemias and in metastatic liver disease 
(Shils, 1979; Barry, 1974). The precise reasons for this, and effects 
on the host are not clear.
Basu and Dickerson (1976) report a high incidence of thiamine 
deficiency in patients with both early and advanced malignancy. This 
may be exacerbated by administration of 5-fluorouracil. 
Thiamine deficiency may cause confusion and contributes to 
generalised malnutrition,
Pyridoxine (vitamin B ^ ) is involved in many enzyme pathways for 
metabolism and is important in cell proliferation. Deficiency of this 
vitamin has been found in cancer patients (Basu, 1976) .
Other vitamin deficiencies may occur and Dickerson (1981) contends
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that the vitamins and trace elements are interrelated , with .deficiency 
of one affecting the requirement of the host for the others. He points 
out that ascorbic acid has been shown to affect the requirement for « ànd 
the metabolism of vitamin A, folic acid, vitamin » thiamine and 
some of the other B-cbmplex vitamins.
There appear to be no changes in vitamin, mineral and trace metal 
status of patients which are specific to cancer. It seems likely that 
the changes seen reflect the nutritional and metabolic state of the 
host; and that when they occur they may have major effects oh the 
deteriorating metabolism and nutrition of the host.
Anorexia
Anorexia is a major contributing factor to cachexia; decreased 
appetite causes diminished intake leading to continued malnutrition and 
impaired host defences to infection, tumour growth and spread 
(Garattini et al., 1980). Anorexia may be an early or late feature 
in the growth of the tumour and affects 40-43% of all cancer 
patients (Theologides, 1976). A survey of 110 outpatients attending 
Department of Clinical Oncology, Gartnavel General Hospital, 
Glasgow, found an incidence of 43% patients with this problem (Willox 
et al,, 1984). The loss of appetite may be part of the cachexia 
syndrome ; or it may be produced by chemotherapy or radiotherapy or 
their associated nausea and vomiting (Garattini et al., 1980); or it 
may be an isolated phenomenon occurring, like weight loss, in cancer 
patients at an early stage of disease when there is no
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obvious clinical cause for the anorexia. patients and relatives often 
find this a most distressing problem (Theologides, 1976). It is, like 
weight loss, an obvious sign^appreciated by the layman, that all is not 
well with internal body function. It becomes a reflection of the 
state of the disease for both the patient and relatives; if the 
patient is eating well he feels better and is optimistic about : .his 
progress; if his appetite is poor, he feels weak and becomes depressed 
about the future.
The satiety centre and feeding centre are located in : the 
ventromedial and lateral hypothalamus, respectively (Morley & Levine, 
1983). They are influenced by stimuli from within the brain and from 
the rest of the body. Serotonin is the neurotransmitter which acts 
via the satiety centre to cause anorexia; dopamine initiates feeding 
via the feeding centre; the alpha-adrenergic system acts on the 
satiety centre to stimulate appetite; the beta- adrenergic system 
acts on the feeding centre to cause anorexia (Morley &; Levinè, 1983). 
An imbalance of serotonin and dopamine have been postulated as a cause 
of anorexia in cancer (Krause, Creep & Fischer, 1979; Theologides,
1981; DeWys 1979).
Hormones may directly influence the feeding and satiety centres. 
Calcitonin, and thyroid releasing hormone act to suppress appetite 
(Morley & Levine, 1983).The action of insulin is the subject of some 
debate. Grossman, Cummins and Ivy (1947) found that increased levels 
of circulating insulin in the blood caused increased appetite; porte &
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Woods (1981) however showed that long-term insulin infusion into the 
cerebral fluid of baboons caused decreasing food intake and decreasing 
weight with increasing doses of insulin. Blood glucose levels
influence appetite, although it is probably the rate of glucose 
utilisation rather than the actual level of blood glucose which 
promotes or depresses appetite (Mayer, 1955). The cancer patient
has raised blood glucose levels and a relatively slow rate of 
utilisation of glucose due to delayed insulin secretion, and this must 
contribute to the anorexia (De%s, 1979).
Glucagon, adrenaline, enterogastrone, bombesin, endorphin and 
cholecystokinin all act to produce anorexia. The last four are also 
found in the gastrointestinal tract and are involved in regulation of 
intake and absorption of food (Theologides, 1981; Morley & Levine, 
1983) . In view of the metabolic upsets seen in cancer patients, 
alterations in hormone levels are likely to cause anorexia, and some 
hormone-secreting tumours may cause an imbalance leading to depressed 
appetite (Theologides, 1981) *
Corticotrophin-releasing factor, produced in times of stress, may 
be important in producing anorexia in cancer patients. The stresses 
from the cancer itself and its demands on the host resources, from 
pain, and from the various forms of treatment whether surgery, 
radiotherapy or chemotherapy act to increase the release of 
corticosteroids and of corticotrophin releasing factor, and produce 
anorexia (Morley & Levine, 1983). Stress may induce the production of
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endogenous opiates in the brain and these tend to increase appetite 
(Morley & Levine, 1980; VasWni, Tejwani & Mousa, 1983). Hoover
this may not be so marked in cancer patients where production of these 
opiates may be diminished.
Metabolic abnormalities can cause anorexia. The presence of 
liver métastasés or abnormal liver function tests have been associated 
with anorexia (Theologides, 1977).
High levels of lactate act on the hypothalamus to produce 
anorexia, and this may be relevant in the cancer patient (Pitts & 
MacClure, 1967; Baile et al., 1970; Deykin & Waterhouse, 1972). The 
onset of fat depletion has been associated with the appearance of 
anorexia and is due to the increased levels of free fatty acids and 
ketone bodies circulating at that time (Garattini et al,, 1980)* 
Amino acid imbalances produce ; anorexia and Morley & Levine (1983) 
propose that the effect is mediated through the role of amino acids as 
neurotransmitters, and their known influence on feedlihg (teung & 
Rodgers, 1969; Garattini et al., 1980). Zinc and copper imbalances 
in cancer patients may contribute to the anorexia (Garattini et al., 
1980; Trant, Serin & Douglas, 1982; Blackburn et al,, 1977).
Theologides (1976) proposes that small molecular weight peptides 
are produced by the tumour itself or by its effect on the host, and 
these cause anorexia. They may act via peripheral or central 
neuroreceptors to produce their effect. Peptides have been isolated
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from the urine of fasted rats which cause anorexia in hungry rats (Lee 
& Liichton, 1973); and Barai and DeV^s (1980) found that when urine from 
anorectic cancer patients was injected intraperitoneally into mice, 
appetite was suppressed. Trotter et al. (1981) showed improved 
appetite following plasma exchange which removed circulating factors. 
Further evidence for circulating factors affecting appetite comes from 
Davis, Gallâcher & Ladore (1969) who showed that the intake of food in 
hungry rats decreased by 50% when their blood was mixed with that of 
fed rats; and Myers (1969) took cerebrospinal fluid from fasted donors 
and reported increased eating and drinking in satieted monkeys when the 
fluid was injected into the lateral hypothalamus.
Other theories:of appetite regulation include the theory : of 
thermostatic regulation proposed by Brobeck (1948) where body 
temperature and the heat generated by metabolism regulate feeding. 
This mechanism may have little part to play in cancer patients except 
where there is a great increase in basal metabolic rate, or pyrexia 
associated with infection or tumour. Osmoreceptors in the body monitor 
shift of water from intracellular to extracellular compartments and 
thus signal satiety. This may have a role in cancer patients with 
increased extracellular fluid volume vhich will produce "satiety" 
(Theologides, 1976).
Cachectic cancer patients often complain of early satiety: a meal
eaten early in the day fills them up for the rest of the day (Strain, 
1979; De^s, 1979). This may be due to diminished muscle tone in the
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stomach and intestines from the muscle wasting which parellels the 
loss of skeletal muscle, which therefore causes sluggish or delayed 
passage of food along the gastrointestinal tract (DeVi^ s, 1979). 
Signals produced by the neuroreceptors, baroreceptors, osmoreceptors
and chemoreceptors in the gastrointestinal tract indicate satiety to
the appetite centres. Hyperglycaemia delays gastric emptying and this 
will contribute to the problem (DeV^ s> 1980). Decreased or delayed 
absorption of food may also account for the early satiety of patients 
and it is well-documented that cachectic patients have . pathological 
changes in the small intestine similar to those found in starvation
(Girdwood, 1964; Barry, 1974). There are stunted microvilli and a
greatly reduced area for absorption of nutrients. A decreased 
production of mucosal cells is found rather than an increased turnover 
of cells, and this resembles other wasting illnesses beihg a result of 
decreased intake and weight loss rather than their cause, and 
contributing to their continuation {DeViys, 1979; Creamer, 1964; 
Fischer et al., 1965) . Chemotherapy and radiotherapy may contribute 
to the intestinal pathology by acting on the rapidly dividing
cells of the gastrointestinal mucosa; and some types of 
chemotherapy cause neuropathies which interrupt normal bowel action 
producing delayed passage of food (Hall, 1979).
Abnormalities of taste and smell have been reported in some cancer 
patients and these may contribute to the anorexia by diminishing the 
pleasure of eating  ^ decreasing the secretion of digestive enzymes 
and decreasing the stimulation of the gastrointestinal tract (DeWys,
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1979; Theologides, 1976) . Not every patient with cancer develops 
abnormal taste thresholds although the abnormality has been
correlated with increased tumour burden and decreased energy
intake (De%s, 1978). There may be abnormalities in the taste buds 
similar to the intestinal mucosal abnormalities in some cachectic 
patients (Russ & Dewys, 1978). Trant, Serin & Douglas (1982) 
found no abnormalities of taste perception in patients grouped by 
tumour site, treatment, or appetite. They reported that anorectic
patients preferred lower levels of sweetness compared to controls; 
and that patients on chenotherapy showed no particular preference 
for any of five concentrations of sucrOse. Dewys (1978), however,
analysed several studies involving a total of 133 patients and found
increased recognition thresholds for sweetness (sucrose) in 30-100% 
patients; and decreased recognition thresholds for bitter (urea) 
in 10-20% patients with a wide range of tumours and at various
stages of disease. The alterations were particularly striking 
in the patients who complained of decreased sensation and in those 
Who had developed an aversion to meat. Other taste changes for sour 
and salt tastes were not statistically different for the group as a 
whole, but thresholds were increased in the patients with active 
disease. Response to treatment restored taste to normal; progression 
of tumour increased the frequency of taste abnormalities with 15 
Of 20 patients who had advanced disease showing âltëréa
thresholds for sucirose and urea (De^ ys, 1978). Taste abnormalities 
are present in some patients with cancer, although there ; is no
common specific change found. These changes contribute to the
anorexia of patients by producing decreased sensation and decreased
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pleasure in eating, and may even lead to food aversions.
Learned aversions to certain foods may be produced by the effects 
of the tumour or its treatment, causing discomfort^ vomiting, nausea or 
malaise, which become psychologically associated with the food eaten 
just prior to the unpleasant event. It may be a particularly 
difficult symptom to treat and the patient can become quite anorexic 
during a course of treatment (Holland, Rowland & Plunnb, 1977; DeWys, 
1980; Bernstein, 1982) . Some food aversions and cravings found in a 
number of patients have no identifiable cause. These appear to 
resanble those occurring during pregnancy. Brewin (1980) found 22/24 
wcmen with tumours had specific taste changes with either the same 
craving or aversion as occurred during pregnancy or the opposite 
feeling for the same substance. The changes began before diagnosis or 
were triggered by treatment or tumour recurrence.
Psychological factors have a major role in anorexia in cancer 
patients. The sight of food produces excitatory stimuli to the 
gastrointestinal tract and to the hypothalamus, causing hunger and 
readiness to digest food. The ability of man to eat when he is riot 
hungry, however, demonstrates the power of the higher brain centres on 
the appetite and feeding ceritres (Theologides, 1979).
Holland et al. (1977) propose that psychological factors 
contribute to the anorexia of cancer patients at various stages of the
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disease. At the time of initial diagnosis, the patient is in a state 
of emotional turmoil with uncertainty about the cause and effects of 
the tumour, depression about the diagnosis, and anxiety about the 
treatment and outcome. This stress, with its increase in cortico­
steroid, corticotrophin and adrenaline production, produces anorexia, 
and weight loss of 5-10 Ib.^due solely to the psychological upset is 
not uncommon. Once a plan of action is formulated for the patient and 
ccmmenced, the initial anxiety and depression subsides and the anorexia 
disappears, often with gain of the original amount of weight lost. 
Should there be relapse, treatment failure or periods of pain and 
discouragement, anxiety and anorexia may reappear. This time the
anorexia is more difficult to resolve and depends both on an 
alternative treatment plan or relief of pain and positive psycho­
logical support to alleviate anxiety and restore appetite, and on 
improvement in the metabolic state which may be abnormal at this 
stage of disease.
There is some debate as to the relative importance of the 
psychological component in causing loss of appetite in cancer patients, 
however, it is recognised that it plays a part together with the 
metabolic factors in the genesis of the anorexia, which is a major 
contributing cause of cancer cachexia (Theologides, 1976; Holland et 
al., 1977; De%s, 1979; Trant et al., 1982) (Fig. 8).
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FIGURE 8; FACTORS PRODUCING ANOREXIA IN CANCER PATIENTS
Effects of Treatment on Nutritional and Metabolic State
Surgery, radiotherapy and chenotherapy have major effects on the 
nutritional and metabolic state of the tumour bearing host (Ohnuma & 
Holland, 1977; Costa & Donaldson, 1979).
Surgery
The acute effects of surgery are to produce an increase in basal 
metabolic rate and in protein turnover, with increased circulating 
levels of adrenaline, corticosteroids, fatty acids and glucose 
(Brennan, 1979). After the initial post-operative period metabolism 
returns to its pre-operative state - and the long term effects of the 
surgery become evident (Fig. 9).
Following surgery of the head and neck, there may be difficulties 
in chewing and swallowing and taste is often impaired with obvious 
consequencies for nutrition,. Anorexia is a common complaint due to 
the decreased enjoyment of food and the difficulties and discomfort of 
eating (Brennan, 1977).
Resection of the oesophagus can cause gastric stasis, with 
fistulae, diarrhoea, malabsorption of fat and consequent weight loss. 
Gastrectomy leads to problems of early satiety with anorexia, dumping 
syndrome, hypoglycaenia, steatorrhoea and deficiency of gastric acid, 
pepsin and intrinsic factor. These may cause the later development of
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FIGURE 9: EFFECTS OF SURGERY ON NUTRITIONAL STATE
vitamin deficiencies, particularly of vitamin and of vitamins A
and D and mineral deficiencies of iron and of calcium (Shils, 1979; 
Dionigi & Campani, 1981).
Removal of the small intestine causes little upset apart from 
ileus and anorexia immediately post-operatively (Buzby & Steinberg,
1981). Loss of the terminal ileum may result in decreased absorption 
of vitamin B^2 ^nd of bile salts leading to megaloblastic anaonia and 
neuropathies (in the long term) and to watery diarrhoea and 
steatorrhoea. Massive bowel resection causes malabsorption and there 
may be hyperoxaluria with the formation of renal oxalate stones. 
Rénovai of the colon has few nutritional sequele for the patient apart 
from the occasional problem of excess water and electrolyte loss (Buzby 
& Steinberg, 1981).
Pancreatectomy, with loss of digestive enzymes, leads to 
malabsorption and excessive losses of fat, protein, vitamins and 
minerals. Diabetes mellitus may be induced by removal of the tail of 
the pancreas.
Hepatic resection is usually followed by almost complete
regeneration of liver tissue and restoration of liver function to
normal (Shils,1979). However, there are often severe metabolic
abnonmalities with hypoglycaemia and hypoaIbuminaenia in the immediate 
post-operative period (Costa & Donaldson, 1979).
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Following surgery, patients who have periods pf' intravenous or 
nasogastric feeding may become psychologically dependent on their 
"lifeline" and unable to cope with eating normally. in these oases it 
is necessary to 'wean' the patient from the tubes (Holland et al., 
1977).
Radiotherapy
Radiotherapy is often complicated by malnutrition in -the patient 
prior to treatment, and by its effects on the patient (Fig. IQ). Any 
extensive or prolonged radiotherapy treatment will cause nauSea, 
vomiting, anorexia and consequent weight loss (Butler, 1980). 
Irradiation to the brain causes nausea and anorexia due to cerebral 
oedema, an unavoidable side effect (Donaldson & Lenon, 1979).
Head and neck irradiation may cause both acute and chronic 
sequele. Acute problèns Include dysphagia, dry mouth, anorexia and 
loss of taste - the so-called "mouth blindness" described in 1959 by 
McCarthy-beventhal. There may be loss of smell ahd mucositis leading 
to oral ulceration (Donaldson, 1977). The loss of-taste may persist as 
an altered taste perception and has far-reaching effects on the patient 
both psychologically and nutritionally by predisposing to long term 
anorexia (Shils, 1979; Donaldson, 1977; Donaldson & LenCrt, 1979). 
Salivary gland irradiation leaves a persistently dry mouth with 
decrease in the quantity and quality of the saliva produced, which 
becomes thick and viscous allowing an alteration of the ibsCterial flora
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FIGURE 10: EFFECTS OF RADIOTHERAPY ON NUTRITIONAL STATE
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of the mouth and leading to dental caries {Donaldson, 1977). The 
changes in saliva, in taste and smell and the increase in dental caries 
makes chewing and swallowing difficult and contributes to decreased 
intake of food and deranged nutritional status, in addition to the
effects of the tumour itself. weight loss was reported in 93% 
patients receiving even a short course of radiotherapy to the head and 
neck, and in 8.7% patients, v^ight loss was greater than 10% body
weight (Donaldson & Lenon, 1979). In an already nutritionally 
canpromised patient this represents a major nutritional upset.
Radiation to the chest causes,acutely, dysphagia by its effects on 
the mucosa of the pharynx and oesophagus, in the long term, there may 
be fibrosis, stenosis or fistula formation in the oesophagus, with 
obvious consequencies for nutrition (Donaldson, 1977).
Gastric, small and large bowel irradiation is usually accompanied 
by nausea, anorexia, vomiting and diarrhoea. In the stomach, there 
may be decreased acid and pepsin secretion and chronic ulcer formation 
in the long term. These may contribute to anorexia, malabsorption and 
weight loss (Donaldson & Lenon, 1979).
Small and large bowel irradiation results in variable degrees of 
malabsorption of glucose, protein, electrolytes and fat. Fistula 
formation can occur, and there may be ulceration or strictures and
bacterial overgrowth due to altered gastrointestinal flora (Donaldson, 
1977). 88% patients undergoing abdominal or pelvic irradiation had
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weight loss during therapy; in 13% this weight loss was greater than 
10% body weight. This reflects the poor nutritional state of many of 
these patients (Donaldson, 1977).
Chemotherapy
Chemotherapy and its effects are potentially damaging to the 
nutritional state of the patient; and the nutritional status affects 
the effectiveness and toxicity of the chemotherapy (Donaldson & Lenon,
1979) (Fig. 11). Chemotherapy unavoidably affects host cells as well
as tumour cells and causes a variety of side effects and damage to
organs in the body resulting in major nutritional problems (Ohnuma & 
Holland, 1977). Combination chemotherapy intensifies the toxicity of 
each of the single agents used (Costa & Donaldson, 1979).
Nausea and vomiting occur with almost every major class of 
chemotherapeutic agent (Ohnuma & Holland, 1977). This action is 
mediated by an effect on the chemoreceptor trigger zone located in the 
floor of the fourth ventricle (Borison, 1974; Cockel, 1971). There are 
a few chemotherapeutic agents which do not cause nausea and vomiting
and these include some of the alkylating agents such as Chlorambucil 
and Busulphan, the vinca alkaloids and steroids. Nausea and vomiting
and the anorexia which frequently accompanies them cause diminished 
food intake, electrolyte imbalance, dehydration, general weakness and 
weight loss.
Altered taste sensations are found with Cyclophosphamide, which
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FIGURE 11; EFFECTS OF CHEMOTHERAPY ON NUTRITIONAL STATE
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may produce a metallic taste in the mouth, and 5-Pluoro,uracil which 
causes decreased sensitivity for salt and sweetness. These contribute 
to anorexia as previously discussed (Carson St Gormican, 1977).
Stomatitis, mucositis, glossitis and pharyngitis occur with many 
chemotherapeutic agents. The rapid turnover of cells in the gastro­
intestinal tract leave it vulnerable to the effects of the drugs. 
Dose-limiting and severe oral mucosal toxicity has been described 
following treatment with Actinoraycin D, Adriamycin, Azaserlne, 
Daundrubicin, 5 Fluorouracil, Methotrexate and Methyïglyoxàl Bisguanyl- 
hydrazone. Cyclophosphamide and phenylalanine mustard may produce 
ulceration in the mouth (Ohnuma & Holland, 1977). These effects cause 
decreased uptake of food and fluids and, if prolonged, lead to 
nutritional problems.
The effects of chemotherapeutic drugs on mucus membranes are a 
likely cause for the malabsorption syndrome seen in cancer patients 
receiving chemotherapy. Diarrhoea is another manifestation of this 
toxicity. Actinomycin D, 5 Fluourouracil and Methylglyoxal BisqUanyl- 
hydrazone may cause severe diarrhoea with abdominal pain. Methotrexate, 
Hydroxyurea, Nitrosoureas and 5-Azacytidine frequently cause 
diarrhoea, while 6-Mercaptopurine, Cyclophosphamide, Procarbazine and 
Levamisole . are less frequent causes. In severe cases there is 
■proctitis, mucosal ulceration, bleeding, and even perforation with the 
drug - induced diarrhoea; and prolonged diarrhoea results in 
dehydration, electrolyte imbalance, malabsorption, general weakness and
56.
  : :________________________________
'Wi
malnutrition (Ohnuma & Holland, 1977). Constipation, and ileùs may 
follow vinca alkaloid administration; the constipation at times 
alternating with diarrhoea. Jaw pain is a feature of Vincristine use 
(Ohnuma & Holland, 1977; Holland et al,, 1973).
Liver damage can be induced by a number of chemotherapeutic 
agents, and this leads to anorexia, hypoalbuminaemia, deranged liver 
function and even jaundice. Asparaginase, Rzasèrine, Duazomycin and 6 
Mercaptopurine commonly cause liver daitage. Methotrexate, nitrosourea 
compounds. Mithramycin and S-Azacytidine also cause liver dysfuhctibn 
(Einhorn & Davidsohn,1964; Ohnuma & Holland, 1977).
Pancreatic dysfunction occurs with asparaginase, Streptozotocin 
causes hyperglycaemia and abnormal glucose tolerance tests due to its 
effects on the islet of Langerhans cells in the pancreas (Sadoff, 
1972). Hyperglycaemia has been found with Methylglyoxal BisgUanyl- 
hydrazone (Ohnuma & Holland, 1977).
Cardiac damage leading to cardiac failure with water retention and 
electrolyte imbalance may follow treatment with Daurtprubicih or 
Adriamycin (Blum & Carter, 1973) .
*
ï ï 'S t
A large number of chemotherapeutic agents, apart from the vinca 
alkaloids. Bleomycin, Asparaginase and steroids, cause bone marrow 
suppression with consequent immune depression, infection, fever, 
increased energy consumption and anorexia which Contribute to the
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increasing deterioration of the nutritional state.
The central nervous system is affected by many drugs which cause 
confusion, drowsiness, disorientation and lethargy with their 
consequent nutritional problems. Drugs most commonly implicated in 
these problems include Methotrexate, Procarbazine, Vincristine, 
Asparaginase, Cycloleucine, steroids and Cis-dichlorOdiammine platinum 
(II) which has been associated with confusion, cpima, increasing 
cerebrospinal fluid pressure and death. Azoserine, 5 Fluorouracil and 
Levamisole rarely cause central nervous system effects (Ohnuma & 
Holland, 1977). Narcotics given to cancer patients to relieve pain 
affect the central nervous system causing sleepiness and constipation 
leading to missed meals and anorexia (Ohnuma & Holland, 1977).
Renal problems may be encountered after treatment with CiS-di- 
chlorodiammine platinim (II), Methotrexate and Streptozotocin. The 
increasing levels of urea and creatinine which may follow administra­
tion of these drugs leads tp anorexia and metabolic upsets. 
Cisdichlorpdiammine platinum (il) induces renal tubular damage with 
losses of magnesium and potassium in the urine (see Chapter 6). 
Streptozotocin toxicity involves proteinuria with increasing uraemia. 
Other drugs which cause electrolyte imbalance through effects on the 
kidney include Cyclophosphamide. which may induce Inappropriate 
anti-diuretic hormone secretion from the pituitary and produce"low 
plasma sodium levels. Mithramycih, Methptrexate arid Actinomycin D can 
produce low serum calcium levels (Ohnuma & Holland, 1977).
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Protein synthesis may be impaired by Asparaginase, arid 5 
Fluorouracil has been particularly implicated in thiamine deficiency 
(Dickerson, 1981) .
Pulse chemotherapy allows time for nutritional recovery between 
courses (DeVSÿs, 1982) although the time interval between courses 
determines the extent of improvement.
Surgery, radiotherapy and chemotherapy all influence nutritional 
status and contribute to cachexia directly by causing weight loss, 
decreased intake and deranged metabolism; and indirectly by effects on, 
the appetite and on taste sensations. In patients who are hot 
successfully treated, these therapies may exacerbate the nutritional 
problems and promote the continued nutritional and metabolic decline to 
cachexia.
In summary, therefore, there are many factors influencing the 
nutritional and metabolic state of the cancer patient (Fig, 12).
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B. AIMS OF THESIS
The Introduction to this thesis outlines some of the numerous
metabolic and nutritional problens encountered in the cancer patient, 
many of which are unresolved. The aims of the thesis are to
investigate in more detail several of the metabolic and nutritional 
implications of cancer.
Three main areas will be considered. Section one will examine 
methods of assessing the nutritional status of cancer patients and will 
compare the reliability of clinical evaluation, dietary intake 
histories with computer analysis of diet, and biochanical estimations 
of nutritional deficiencies. This section will also evaluate a fast, 
easy and reliable method of anticipating potential nutritional 
problens, which will allow their early correction.
Section two will examine some of the nutritional and metabolic 
problems caused by cancer and its treatment. The extrade effects of
cancer and chemotherapy are seen in the cachetic cancer patient who
has major nutritional and metabolic alterations. The effects of 
cachexia on muscle composition will be investigated in a preliminary 
study using cachectic cancer patients.
The effects of cancer and chanotherapy on saliva production and 
composition are monitored over a 3 month period, in patients receiving
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choonotherapy for a variety of tumours. Saliva production is important 
in enjoyment and mastication of food, and changes in saliva composition 
may be reflected in the anorexia and abnormalities of taste seen in 
cancer patients. A second study will follow saliva production and 
composition over a 3 month period with assessments before, after one 
month, and after three months of chenotherapy.
The effects on metabolism of two cytotoxic drugs in conmon ; use : 
Cis-dichlorodiammine platinum (II) and Cyclophosphamide will be 
examined in animal studies. Wistar rats with and without tumour and 
with and without one of the drugs will have measurements of weight, 
ketone body production and intermediary metabolism made.
Further animal and clinical studies will evaluate the effects of 
Cis-dichlorodiammine platinum (II), The animal studies will examine 
the effects of the drugs on heart, liver, muscle and kidney tissues, 
looking at the metabolic results of treatment at the subcellular level. 
Clinical studies will use teratona patients - a group of cancer 
patients who are young and in a good nutritional state prior to the 
onset of disease - and will look at the nutritional and metabolic 
consequencies of the tumour and of treatment with Cis-dichlorodiammine 
platinum (II). Trace metal and magnesium, potassium and calcium 
status, dietary intake, weight loss and other nutritional parameters 
will be considered. The use of magnesium supplements and their effects 
on tumour growth, final outcome, renal function and magnesium and 
potassium levels in urine and serum will be examined. The problems of
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magnesium supplementation, of finding effective ways Of 
mentation, and of checking compliance in taking supplemeints will also 
be discussed.
Section three is concerned with the ways of improving nutritional 
status of cancer patients and will examine the problem of anorexia. 
The incidence of the problen in cancer patients will be discussed and a 
double-blind crossover study using prednisolone and placebo tablets in 
an attenpt to find a useful appetite stimulant will be reported;.
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SECTION 1:
THE ASSESSMENT OP NUTRITIONAL STATUS IN
CANCER PATIENTS
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CHAPTER 2: NUTRITIONAL ASSESSMENT OF GANGER PATIENTS
Introduction
Considerable controversy has raged over the simplest and nost 
effective methods of assessing nutritional status of patients, and 
over the most acceptable compromises in assessing patients quickly and 
easily using labour-saving methods. It seems^  however, as Baker et 
al. (1982) point out, that there is no one definitive test of 
nutritional status available at the present time.
Clinical examination is the oldest method of nutritional 
assessment and Baker et al. (1982) propose that a careful history and 
physical examination is sufficient for the nutritional assessment of 
most patients and will allow predictions of morbidity. Baker, et al. 
(1982) found in 81% patients good correlation between clinical 
assessment of nutritional state and anthropometric and laboratory 
measurements on the same patients. Grant, Custer & Thurlow (1981), 
however, warn that clinical evidence of nutritional deficiencies 
develops late in the deficiency state, and usually reflects gross 
deficiencies of longstanding. They regard history and clinical 
examination simply as Useful pointers to the presenceof
nutritional abnormalities.
Dietary histories may give a reasonable guide to the likely 
nutritional state of a patient, as they reflect the food intake over
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varying periods of time. Shapiro (1979) has compared the "in depth" 3 
day dietary history - which assesses usual food intake, portion size 
and takes a three-day record of food eaten - to a 7- day record of food 
consumed and a 24-hour recall history, which assesses food intake: in
the previous 24 hours. Dietary histories were also compared to 
weighed food intakes over longer periods of time. She concludes that 
the 24 hour recall dietary history is useful when used with other 
information gathered about a patient, it is not a good indicator of 
long-term intake of an individual,' although when used on several 
occasions it may reflect the pattern of eating of the patient. It may 
also be used when assessing a group of individuals on one or two 
occasions only (Shapiro 1979; Woods et al., 1981). Problems with this 
method of assessment have increased with the variety of foods and 
methods of preparation and presentation now available, and variations 
in daily and weekly food intake may be considerable. Recommended daily 
allowances of food intake apply to groups rather than to individuals, 
and intake of any nutrient which is below the recommended daily intake 
is not, in itself, diagnostic of malnutrition (Shapiro, 1979) .
Anthropometric tests use weight, height, muscle bulk and estimates 
of body fat to give an assessment of nutritional status. Weight loss 
has been cited by Shenkin (1979) as the single most important 
factor available in assessing nutritional status. Body weight gives 
an indication of energy reserves and may be compared to tables of 
normal ranges (Jelliffe, 1966). Rate of weight loss is important too;
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with 5% weight loss over one month and 10% of normal weight 
lost over six months indicating significant weight loss^which will be 
associated with poor energy reserves and increasing morbidity
(Blackburn & Harvey, 1982), Serial measurements of weight are useful 
in monitoring the progress of patients. Among the problems of
measuring weight is in finding accurate weighing machines and tables
which correspond to the population group being observed. Changes
in body weight do not indicate which body compartment has been
affected, and do not take account of changes in fluid balance, as
in oedema or dehydration. Changes also in the amount of body fat
or muscle may cause marked alterations in body weight, causing
tables to be unreliable (Goode, 1981).
Measurements of midarm circumference give a reasonably accurate index 
of lean body mass and are useful in following progress over the
longterm (Blackburn & Harvey, 1982).
Triceps skinfold thickness gives an estimate of total body fat, 
and hence of the major energy stores in the body (Shenkin, 1979). 
Durnin S Warnersley (1974) recomend measuring skinfolds at four sites 
(triceps, biceps, scapula and suprailiac) for good correlationywith 
body fat; however Burgert & Anderson (1979) maintain that for
clinical purposes, measuring triceps skinfold thickness is adequate.
Thèse methods are useful in hospital practice where they can be
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standardised with a single observer and inexpensive equipment. Good 
reproducibility can be achieved, and as objective measurements on 
repeated occasions, anthropometric data are as accurate as other 
methods of estimating body composition (Hooley, 1980; Woods et al.,
1981), Anthropometric measurements do not however indicate the 
degree of malnutrition, and not every patient who is nutritionally 
deficient shows decreased anthropometric data (Blackburn & Harvey,
1982). Skinfold thickness results indicate total body fat and energy 
reserves. Changes in subcutaneous fat, however, occur slowly in 
starvation and refeeding and do not reflect acute nutritional changes 
(Grant et al., 1981), Some patients become hypoproteinâamic, with 
attendant oedema ^ which masks the state of severe malnutrition 
underlying the apparently well-nourished patient who shows no 
change in weight, arm muscle circumference or triceps skinfold 
thickness (Blackburn & Harvey, 1982),
Laboratory assessment of nutritional status is useful but results 
often require careful interpretation. The state of visceral protein 
stores in the body and the ability of the liver to synthesise 
proteins can be assessed by measuring serum levels of total protein, 
albumin, transferrin, prealbumin and retinol-binding protein 
(Jeejeebhoy, 1981). The former three are easiest to measure; 
however the prolonged half lives of albumin (20 days) and 
transferrin (5-7 days), makes then less useful for assessing early 
malnutrition or in monitoring periods of nutritional depletion and 
repletion. The shorter half lives of prealbumin (2-3 days) and
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retinol-binding protein (12 hours) give them a decided 
monitoring (Wright, 1980)'.
in
Protein loss may be exacerbated by diseases o£ the gastro­
intestinal tract; and production may be decreased in liver disease. 
Both of these may cause ntisleading assessments of nutritional state if 
protein levels alone are used for estimation (Baker ét al., 198 2). 
serum albumin levels are influenced by ' a number of factors 
including infection, oedema, surgery, decreased lymphatic return/ and 
sodium retention, so interpretation of serum albumin levels must■take 
these factors into account in estimating nutritional depletion 
(Blackburn & Harvey, 1982) .
Serum transferrin levels may be affected by deficiency of serum 
iron and will,be increased in cases of chronic bleeding (Goode, 1981; 
Shenkin, 1979).
The excretion of creatinine has been used to assess muscle
breakdown, creatinine being a measure of skeletal muscle mass (Wright,
1980). Various indices have been proposed using creatinine - such as 
creatinine/height index to assess nutritional state, however 
measurement of creatinine requires normal kidneys, accurate urine 
collections over 24 hours, and there is, a wide, range of normal 'values
depending on age, sex and muscle mass (Grant et al..
Nitrogen balance studies are not particularly useful in assessing
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nutritional status as the results vary with intake and metabolic rate;, 
however, they provide a useful check on whether nitrogen intake is 
meeting losses of nitrogen (Shenkin, 19.79) .
Other tests of protein status are less relevant for general 
assessment of patients. Total body nitrogen may be estimated using 
neutron activation analysis, requiring specialised equipment, not 
readily available in a general hospital. Measurements of protein
synthesis and catabolism may be Useful also, but are time-cortsuming 
requiring intravenous infusions, repeated blood and urine samplingyand 
complicated calculations. Amino acid levels may indicate protein 
turnover. Interpretation of the pattern of amino acids in the blood 
is difficult since chronic protein depletion gives a general reduction 
in amino acid levels; while in the earlier stages of muscle 
breakdown, there is a high urinary nitrogen with increases in the serum 
levels of the branched chain amino acids leucine, isoleucine and 
valine. Amino acid analyser facilities are not present in every
hospital; and a quantitative indication of protein loss is not
possible from the amino acid pattern (Goode, 1981) . 3 methyl
histidine is produced where actin and myosin in muscle breaks down. 
It is excreted, unchanged, in the urine and is not re-cycled. It has 
been used as a measure of protein catabolism; however errors arise 
where there is active synthesis of muscle, and if there has been recent 
intake of meat in the diet. There is controversy over whether 3 
methyl histidine is really representative of the behaviour of muscle 
protein as a whole, as it is present in only 65% muscle protein; and
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age, sex, diet, trauma, stress and infection all influence 3 methyl 
histidine levels. An amino acid analyser is required for analysis 
(Grant et al., 1981).
Ketone bodies are produced by the body when fat is broken down and 
used as an energy source, and their presence in the serum indicates 
insufficient energy intake (Shenkin, 1979). Sane patients do not 
produce ketone bodies, despite decreased intake, and in these cases 
there is no suppression of gluconeogenesis; with rapid and continued 
protein breakdown to supply precursors for glucose. These patients have 
increased morbidity and mortality (Goode, 1981).
Total body potassium measurements have been used to estimate body 
cell mass. However this is difficult to measure routinely
(Jeejeebhoy, 1981).
Biochemical estimations of mineral deficiencies are very 
difficult to interpret, as serum levels of trace metals such as zinc 
or copper may bear no relationship to body stores of the element 
(Hall, 1982). In some cases, urine levels together with serum levels 
may be helpful, such as when low urinary levels of magnesium or 
phosphorus indicate dietary deficiencies of , these elements. Zinc 
excretion in the urine is markedly increased in catabolism, and 
monitoring urinary levels of zinc will allow the metabolic switch to 
anabolism to be identified, and supplements Of zinc and other elements 
commenced accordingly. The picture may be further complicated in
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cases with renal damage where inappropriate losses of zinc or -magnesium 
are occurring. The other problem in identifying mineral
deficiencies is the difficulty of measuring trace elements in the 
blood (Shenkin, 197 )^. .
Vitamin levels in serum may also be misleading. Plasma levels of 
vitamins A, B, C and folic acid often reflect recent dietary intake 
rather than body status. Shenkin (1979) maintains that a good dietary 
history is important in assessing:vitamin status. Most vitamins have 
large body stores, and ; the most reliable method of determining 
deficiency is by loading tests which require serum and urine 
estimations of vitamin levels before and after a loading dose of 
vitamin. These tests are time consuming and are rarely performed. 
Intracellular measurements of vitamins, such as leucocyte ascorbic acid 
and red cell folate estimations may îæ taken to indicate whole body 
status (Shenkin, 1979; Goode, 1981) .
other laboratory measurements used to assess nutritional status 
include haaaoglobin and packed cell volume, both of which are decreased 
in simple starvation, and tests of inmune status. Total lymphocyte 
counts have been used to indicate protein depletion and malnutrition 
(Wright, 1980).
There has been some controversy over the usefulness of tests of 
cell-mediated iirmunity to assess nutritional status. Blackburn & 
Harvey (1982) and Daly, Dudrick & Copeland (1978) consider that
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cell-mediated immunity reflects protein-energy malnutrition and can be 
used to predict surgical morbidity in patients. Jeejeebhoy (1981) 
and Bancewicz et al. (1981) contend that although associated with 
malnutrition, cell mediated immunity is an unreliable index of 
protein-energy malnutrition in ill patients, and does not predict 
surgical morbidity. Tests of cell mediated immunity are difficult to 
standardise, reproduce and interpret, and it is not known at what stage 
of nutritional depletion that immune status declines (Woods et al., 
1981). Patients with cancer may be anergic due to the tumour or its 
treatment, and there may be a circulating suppressor factor for cell- 
mediated immunity in addition to the other problems (Blackburn & 
Harvey, 1982; Daly et al.,1978). These factors make cell mediated 
immunity an unreliable method of assessing nutritional state in cancer 
patients.
A number of authors have proposed combinations of several tests to 
give an index of nutritional status. Smale et al. (1981) propose a 
prognostic nutritional index using serum albumin, transferin, triceps 
skinfold thickness and delayed hypersensitivity in surgical patients 
to predict the chances of post operative complications. Baker 
et al, (1982), however, contend that as individual tests of 
nutritional status are of low predictive value y combining several 
tests into a statistically derived index will not result in 
improved identification of high-risk patients.
On balance, it appears that the most consistently reliable tests
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of nutritional status are weight loss, with assessment of rate of 
weight change; an estimate of dietary intake to allow prediction of 
present and future nutritional state; biochemical assessment of 
protein status; and general clinical examination. A combination of 
these will give the best assessment of nutritional status at 
present , available.
Aims
The aims of this study were to look for a reliable, reproducible, 
fast and easy way of assessing the nutritional status and the 
nutritional requirements of cancer patients, preliminary studies
using 24 hour recall dietary histories with computer analysis to give 
accurate information about dietary intake, showed this to be a quick 
and easy way of identifying dietary deficiencies (Trotter et al.,
1981). Correlation with clinical and biochemical evidence of 
deficiency, however, was not carried out. This study aimed to
examine the reliability of, and correlation between, clinical 
evaluation, dietary intake assessment and biochemical measurements of 
nutritional status in a random group of oncology in-patients.
Methods
42 patients were randomly selected from in-patients admitted to 
the oncology unit at Gartnavel General Hospital, Glasgow over a six 
week period. Patients were admitted for investigation, cytotoxic = i
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treatment or pain control. Each patient's nutritional status was 
assessed by clinical examination, dietary intake analysis and 
biochemical and haematological estimations. ■ ' »
Clinical evaluation
A general history was taken from the patients with specific 
questions to highlight any nutritional problems. A detailed clinical 
examination was carried out, looking particularly for signs of 
nutritional deficiencies. Figure 13 illustrates the type of form used 
to record findings and Table 1 lists the signs and symptoms of the 
major nutritional deficiencies. Weight loss was assessed as moderabe 
loss (3 Kg - 6 Kgiï) or severe loss (> 6 Kg ) .
Dietary evaluatibn
A 24 hour dietary recall history wUs taken ffom the patient at the 
time of clinical examination, taking account of all food and,drink con­
sumed in the previous 24 hours (see Figure 14). This vjas coded using 
the McCance and Widdbwson Tables of Food Composition (1978) into food 
groups and portion size (Table 2). Computer analysis of. the data, using 
a programme supplied by Tayside Health Centre gavé a comprehensive 
account of the amounts of nutrients consumed (Table 3).Recommended 
daily allowances issued by theDepaftmënt of Health;and Social Security 
(1979) were used as standards; and a ; value of 80% of the recommended 
daily intake was taken as the lower limit of normal, thus allowing for 
the wide variation in "normal" dietaty intakes (Table 4).
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NUTRITIONAL ASSESSMENT FORM
Name Age/DOB
Diagnosis
Treatment
Weight Weight Loss
Date of Admission
Height
Known or probable metabolic problems 
Impaired food intake _ _ _ _ _ _ _ _ _ _ _
Bowel habit
Physical Strength
1. Skin disease
2. Hair
Activity (ECOG)
3, Eyes
4. Mouth
5. Nails
6. GIT
7. CNS
External
Fundi
Dysphagia
Ascites
Cranial nerves
Power
Tone
Reflexes
Cerebellar
Peripheral Sensation
FIGURE 13: NUTRITIONAL ASSESSMENT FORM
___ ______________________________________ ___
SITE
Skin
Hair
Eyes
Mouth
Nails
CVS
SIGN
Dry Skin
Depigmentation 
Bruising, Petechiae 
Clinical Anaemia 
Nasolabial Seborrhoea 
Squamous Metaplasia 
Follicular Keratosis 
Dermatitis
Perifollicular Haemorrhages 
Poor Wound Healing
Thin, Depigmented
Follicular Keratosis 
"Corkscrew Hair"
Dry Eyes (Xerophthalmia) 
Night Blindness 
Keratomalacia 
Amblyopia
Fundal Haemorrhages
Apthdus Ulceration 
Angular Stomatitis 
Angular Cheilosis 
Atrophic Glossitis 
Gingival Haemorrhages
Brittle, Striated
Koinychia
Leuconychia
Low Blood Pressure 
Oedema
Congestive Cardiac Failure
DEFICIENCY
General'Undernutrition 
Vitamin Ç
General Undernutrition 
Vitamin K
Iron; Folic Acid 
Riboflavin,
Vitamin A 
Vitamin A 
Nicotinic Acid 
Vitamin C 
Vitamin C, Zinc
General Undernutrition 
Vitamin C
Vitamin C
Vitamin C
Vitamin A 
Vitamin A 
Vitamin A
Vitamin 8^2
Vitamin K
General Undernutrition 
Riboflavin 
Riboflavin 
Iron; Folic Acid 
Vitamin C
General Undernutrition 
Calcium
Iron
Iron
General Undernutrition 
General Undernutrition 
Thiamine
i
TABLE 1. SIGNS OF NUTRITIONAL DEFICIENCIES
GIT.
SITE
GIT
Musculo­
skeletal
CNS
SIGN
Ascites
Diarrhoea
Diarrhoea, Dermatitis, Dementia
Dysphagia
Atrophic Bowel
Decreased Power
Peripheral Neuropathies 
Subacute Combined Degeneration 
Spinal Cord 
Encephalopathy
DEFICIENCY
General Undernutrition 
General Undernutrition 
Nicotinic Acid 
Iron
Folic Acid 
General
General, Thiamine,
®12
General, Thiamine
TABLE 1 (CONTD): SIGNS OF NUTRITIONAL DEFICIENCIES
______
Breakfast
MENU
porridge + milk Cup of tea + milk + 2 sugar
***********
Mid Morning Cup of milk 
* * * * * * * * * * *
Lunch soupCup of tea + milk + 2 sugar
***********
Mid Afternoon Nil
* * * * * * * * * * *
Dinner
Supper
Extras
1 Boiled potato Custard 
Cup of tea + milk + 2 sugar
* * * * * * * * * * *
Cheese + tomato sandwich 
Cup of tea + milk + 2 sugar
* * * * * * * * * * *
1 Glass of lemonade 1 Glass of orange squash
***********
FIGURE 14; SAMPLE MENU FOR COMPUTER CODING
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Energy (Kcal)
Men 
Wcmen
protein (g)
Men 
Women
Calcium (mg) 
iron (mg)
zinc (mg) 
Magnesium (mg)
Thiamine (rag)
vitamin C (mg)
vitamin B (/ug) 12
Folic acid (ng) 
Retinol (;ug)
men
women
Recommended 
Daily intake
2500
2000
60
50
800
10• 18
10
250
1.0
30
3.5
300
750
80% Recotimended 
Daily intake
2000
1600
48
40
640
8
14.4
8
200
0.8
25
2.8
240
600
TABLE 4: REFERENCE VALUES FOR DIETARY INTAKE
;________________   L________________ ■  :_______ ...
Biochemical Evaluation
Venous blood samples were taken from each patient at 9 a.m. on the 
day of examination to eliminate any diurnal variation which might 
influence results. Aliquots of whole blood, serum and plasma were
sent for full blood count and platelet estimation and for vitamin 8^2 
and folic acid assay to the Department of Haematology, Gartnavel 
General Hospital, Glasgow. Further samples were sent to the 
Department of Biochemistry, Gartnavel General Hospital, Glasgow, for 
urea and electrolye, total protein, albumin, iron and calcium estima­
tion using the SMAC autoanalyser (Standard Technicon Methodology). 
Magnesium and zinc levels were measured by atomic absorption spectro­
photometry. Miss Jean Bell at Department of Biochemistry, Western 
Infirmary, Glasgow undertook analysis of samples for vitamin A
(retinol) using a High Pressure Liquid Chromatography method.
The remainder of the blood from the patients was sent to the 
Clinical Oncology Research Laboratories, Glasgow University, and 
analysed for ketone bodies and for thiamine and vitamin C levels. The 
ketone bodies, acetoacetate and D-beta hydroxybutyrate were measured 
by enzymatic analysis using the method of Mellanby and Williamson
(1975) and Williamson and Mellanby (1975) respectively. Thiamine
(vitamin Bj) levels were measured by assessing erythrocyte transketo-
lase activity using the method of Bayoumi & Rosalki (1976). This gave 
some indication of tissue levels of the vitanin. Levels of leucocyte 
ascorbic acid were measured using Denson & Bower's (1961) colometric
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method. This gives a good assessment of tissue levels of vitamin 
C, There were, however, some technical problems with : the 
spectrophotometer, and a number of the samples,-were discarded> er 
gave readings which were unreliable.
Table 5 shows the reference biochemical values used in assësslng 
the results,
Results :
Of the 42 in-patients participating in the study, the majority 
had solid tumours, with teratoma forming the largest group (Table 6). 
Ages ranged from 15 to 79 years (mean age 49 years) and male:female 
ratio was 22:20. Thirty two patients were receiving chemotherapy, 
two were receiving radiptherapy, and eight received no Cytotoxic 
treatment and had been admitted to the ward fot investigation of - pain 
control.
Results of the clinical, dietary and biobhamical evaluations of 
the patients are shown in tables 7, 9, 11 and 13.
Clinical Evaluation (Table 7)
Weight loss (> 3 Kg) and brittle nails were found in 63% patients, 
these being the most common clinical signs of nutritional deficiency 
found in the group of patients studied. Patients receiving
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Normal Range
Male
Female
Male
Female
Total Protein 
Aibuiiiin 
Haemoglobin
WBC
Platelets 
Calcium 
Iron
Zinc
Magnesium 
Thiamine 
Vitamin C 
Vitamin B12Folic Acid 
Retinol
8/Hydroxybutyrate 
AcetoAcetate
62 - 82 g/1 
35 - 53 g/1 
14 - 10 g/dl 
12 - 16 g/dl 
4 - 10 X 10^/1 -
140 - 440 X 10^/1 
2.20 - 2.65flimol/l 
18 - 45 Umol/l , ;
14 - 32 /jmol/1 V
14 - iW/Umdl/l 
0.7 - l.Ommol/1
15 - 24/0 marginal 
1.1 - 2,8 fmol/wbc
140 - 900 pg/ml 
75 - 400 pg/ml 
0.7 - 1.7/umol/l 
0 
0
Deficient
C  62 g/1 
C  35 g/1 
< 1 4  g/dl 
< 1 2  g/dl
<  4 X 10^/1
<140 X 10^/1
< 2.20mmol/l
<  18/Umol/l 
: <  14 /U mo 1/1
<  144umol/l
<  0.7mmol/l 
> 2 5 %
< 1.1 fmol/u/bc 
< 1 4 0  pg/ml
<  75 pg/ml
<  0 .7 /jmol/1 
> 0
> 0
TABLE 5: REFERENCE VALUES FOR BIOCHEMICAL RESULTS
_________ _
Site Number of Patients
Teratoma (Testis) 8
Breast 6
Ovary 5
Gastrointestinal 5
Lung 3
Bladder 2
Prostate 2
Seminoma (Testis) 2
Melanoma 2
Others 7
TABLE 6: TUMOUR TYPES OF PATIENTS PARTICIPATING IN
NUTRITIONAL ASSESSMENTS
    •
Sign Patients
Non-
Chemotherapy Chemotherapy Total
(31) __________(9)____  (40)
Weight Loss >3Kg 21 (68%) 4 (44%) 25 (63%
Brittle Nails 19 (61%) 6 (67%) 25 (63%
Apthous Ulceration 15 (48%) 3 (33%) 18 (45%
*12 (39%) *15 (38%
Dry Skin <. 60 years 9/23 (39%) 2/5 (40%) 11/28(39%
> 60 years 6/8 (75%) 3/4 (75%) 9/12 (75%
Glossitis 11 (35%) 3 (33%) 14 (35%
Bruising 10 (35%) 3 (33%) 13 (33%
* 3 (10%) * 6 (15%
Peripheral Neuropathy 12 (39%) 1 (11%) 13 (33%
* 6 (19%) * 7 (18%
Dry Eyes 9 (29%) 3 (33%) 12 (30%
* 8 (26%) *11 (28%
Dry Hair 9 (29%) 1 (11%) 10 (25%
Generalised Weakness
(Decreased Power & 
Tone) 6 (19%) 1 (11%) 7 (18%
Koilonychia 3 (6%) 0 3 (8%
Nasolabial Seborrhoea 2 (6%) : 1 (11%) 3 (8%
Dysphagia , 2 (6%) . 1 (11%) 3 (8%
Depigmentation 2 (6%) 0 2 (5%
* Corrected values to exclude side effects of chemotherapy - see text /■if
TABLE 7: CLINICAL SIGNS OF MALNUTRITION IN FORTY CANCER PATIENTS
chanotherapy had more weight loss than the non chenotherapy group 
(Table 8), presumably due to the increased nausea and vomiting# and 
decreased appetite and dietary intake in these patients. Brittle 
nails correlated with weight loss in all cases, and shovied no 
difference in incidence between chemotherapy and non chemotherapy 
groups.
Patients with aphthous ulceration included 3 patients receiving 
methotrexate chemotherapy, which may cause this symptom, and when 
these patients are excluded from the results, there is no difference 
in the incidence of this problem between chemotherapy and non 
chemotherapy groups. All of the patients with aphthous ulcers had 
weight loss, and most complained of glossitis also.
Dry skin, a common and normal finding in those over 60 years of 
age, is also a sign of general malnutrition and especially, of 
vitamin C deficiency. It occurs in this study in association with 
weight loss in 39% patients under 60 years of age, and 75% over 60 
years. Chemotherapy .does not seem to influence its incidence.
Other signs of specific or generalised nutritional deficiencies 
may be misleading, and the influence on clinical signs of the 
cytotoxic treatment received by the patient may also be important. 
Bruising has many causes other than general malnutrition or vitamin K 
deficiency, and of the 13 patients with this problem, 7 were 
thrombocytopenic due to cytotoxic drugs. The vinca alkaloids
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Weight Loss Patients
Non-
Chemotherapy Chemotherapy Total
(32) (10) (42)
Nil 5 (16%) 2 (20%) 7 (17%)
Moderate 
0 - 3 Kg 5 (16%) 3 (30%) 8 (19%)
Severe 
3 - 6 Kg 13 (41%) 4 (40%) 17 (40%)
6 -12 Kg 6 (19%) 1 (10%) 7 (17%)
>  12 Kg 3 (9%) 0 3 (7%)
TABLE 8: ANALYSIS OF WEIGHT LOSS IN L4 2 CANCER PATIENTS
- - - - . _   ' _________  ■ C
are well known to produce peripheral neuropathies as side effects of 
treatment, and of the 12 patients found to have neuropathies, 6 were 
receiving these drugs as part of their treatment. For both of these 
signs, the true incidence of deficiency states producing clinical 
signs is much lower than it at first appears.
Dry hair is another difficult sign to interpret^as many patients 
who receive chemotherapy will experience hair loss and this may 
progress to alopecia in some cases. On regrowth, hair texture may te 
altered and feel dry, despite good nutritional state; and this 
reflects either a previous period of poor nutrition or drug-induced 
damage. This was the case in all patients with this complaint.
Chemotherapy, however, does not account for all signs of 
nutritional deficiency. Dry eyes are often ascribed to methotrexate 
chemotherapy, as mucositis is a well known side effect of this drug. 
However, of the 9 patients who complained of this symptom and who were 
receiving chemotherapy, only 1 had teen given methotrexate. Thus 
there is a 28% incidence of this problem, with 91% of the patients 
with dry eyes having deficient intakes of vitamin A, Only 28% of 
those with dry eyes, however, had also decreased serum retinol levels.
Dysphagia was caused by mechanical compression of the oesophagus 
in all cases reported; and depigmentat ion was induced by chamottef apy 
rather than malnutrition, in the 2 patients who noticed it.
78.
Koilonychia and nasolabial seborrhoea occurired fni patients who 
were clinically severely malnourished, and who had grossly deficient 
dietary intakes and multiple biochemical nutritional abnormalities.
Dietary evaluation (Table 9)
73% patients were eating less than 80% recommended daily 
allowances of energy and 59% were eating less than 80% daily 
protein requirements. There were more patients in the chemotherapy 
group (81%) vho were not meeting the recommended daily requirements, 
than in the non-chemotherapy group (50%). This difference reflects 
the effects of rigorous cytotoxic treatment on appetite causing 
nausea, vomiting and anorexia.
Dietary déficiences of the trace metals iron, calcium and zinc 
and of magnesium were common, ranging from 68-80%. Vitamin intakes 
were particularly low for folic acid (98%) and for thiamine
(80%) and vitamin A (78%). The majority of patients had
multiple dietary déficiences.
Three patients were reassessed for dietary intake after 3 weeks, 
and similar dietary compositions were obtained on both occasions.
Comparing the results for patients in this study with results
obtained for 59 oncology out-patients in a study by Trotter et al., 
(1981), there are broad similarities. Table 10 summarises the two
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Nutrient
Chemotherapy (31)
Energy 25 (81
Protein 19 (61
Calcium 23 (74
Iron 25 (81
Zinc 26 (84
Magnesium 26 (84
Thiamine 26 (84
Vitamin C 21 ' (68!
Vitamin B./ 1/ 20 (65
Folic Acid 30 (97!
Retinol 27 (87!
Patients (41)
Non-
Chemotherapy (10)
5 (50%) 30 (73%)
5 (50%) 24 (59%)
5 (50%) 28 (68%)
9 (90%) 34 (83%)
6 (60%) 32 (78%)
7 (70%) 33 (80%)
7 (70%) 33 (80%)
5 (50%) 26 (63%)
7 (70%) 27 (66%)
10 (100%) 40 (98%)
5 (50%) 32 (78%)
Total
TABLE 9: DIETARY DEFICIENCIES IN 41 CANCER PATIENTS
EATING < 80% RDI
% Patients Deficient Intake
Nutrient
Energy
Protein
Iron
Zinc
Magnesium 
Thiamine 
Vitamin C 
Folic Acid 
Retinol
Outpatient
Study
(59)
64
31
68
53
78
58
66
98
53
Inpatient
Study
(41)
73
59
83
78
80
80
63
98
78
TABLE 10: COMPARISON OF DIETARY DEFICIENCIES IN CANCER
OUTPATIENTS AND INPATIENTS
studies which show similar numbers of patients having reduced intakes 
of folic acid, vitamin G and magnesium; although . there are more 
patents in the inpatient group with deficient intakes of most of the 
other nutrients assessed. This difference between the studies is 
accounted for by the fact that Trotter et al. (1981) used out­
patients of vAiom more than 50% had no complaints regarding diet or 
appetite; while the present study used in-patients, the majority of 
whom were receiving chenotherapy which required hospital admissipn for 
control of nausea and vomiting, and which produced anorexia of 
variable duration in most patients. Of the patients in the present 
study not on chemotherapy, most had been admitted for investigation of 
some deterioration in their condition, or for relief of pain or some 
other symptom. Both studies, however, demonstrate the pattern of 
multiple dietary deficiencies present in the cancer patient.
Biochemica1 evaluation (Table 11)
Total protein levels were reduced in 56% patients; and 44% had 
albumin levels below 35 g/1. 27% showed severe protein depletion
with albumin levels below 30 g/1.
All patients had ketone bodies detectable in serum, indicating 
fat breakdown for energy.
70% patients receiving chemotherapy, and 44% patients not on 
chemotherapy were anaemic. Cytotoxic drugs are known to cause
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Patients Studied.
NoP'
Chemotherapy (9) Total
Total Protein 18 (60%) 4 (44%) 22 (56%)
Albumin <  35g/l 14 (47%) 3 (33%) 17 (44%)
< 30g/I 9 (30%) 1 (11%) 10 (27%)
4 Haemoglobin 21 (70%) 4 (44%) 25 (64%)
4 White Cell Count 6 (20%) 1 (11%) 7 (18%)
4 Platelets 7 (23%) 0 7 (18%)
4 Calcium 12 (40%) 2 (22%) 14 (36%)
4 Iron 13/24 (54%) 6/7 (86%) 19/31 (61%)
4 Zinc 19/22 (86%) 7/7 (100%) 26/29 (90%)
4 Magnesium 10/23 (43%) 1/7 (14%) 11/30 (37%)
4  Thiamine 8/14 (57%) 4/7 (57%) 12/21 (57%)
4 Vitamin C 4/20 (20%) 2/10 (20%) 6/3 (20%)
4 Vitamin B^^ 1/20 (5%) 1/5 (20%) 2/25 (8%)
4 Folic Acid 1/20 (5%) Q 1/25 (4%)
4' Retinol 2/12 (17%) 0 2/16 (13%)
B Hydroxybutyrate 28/28 (100%) 8/8 (100%) 36/36 (100%)
Acetoacetate 29/29 (100%) 9/9 (100%) 38/38 (100%)
TABLE 11: BIOCHEMICAL ABNOeMAblTIESlN39CANCER PATIENTS
anaetùa and failure of iron utilisation, due to their effects on the 
haamopoiittic system, and this is reflected in the results obtained with 
a smaller percentage of the chemotherapy group (54%) showing serum 
iron deficiency than the non-chanotherapy group (86%), Both groups 
had similar intakes of iron.
Zinc levels were markedly reduced in 90% patients, and calcium 
levels were reduced in 36%, with only one patient, who had bony 
métastasés, showing evidence of raised serum calcium. Chemotherapy 
influences the levels of magnesium found, with 43% of the chemotherapy 
group showing depletion compared to 14% of the non-chemotherapy group. 
This difference is caused by the excessive urinary nmgnesium losses 
induced by Cisplatin chemotherapy (see Chapter 6 ),
Vitamin levels are also reduced, with thiamine showing the most 
depletion, this deficiency occurring in 57% patients overall.
The results obtained for the in-patients compare well with 
results published by Soukop & Caiman (1979) from a study of 120 
patients with malignant disease. Table 12 summarises the results of 
both studies, which show good correlation. Differences in the 
results for vitamin C and folic aci^ are accounted for by technical 
problems encountered in these assays in the present study. Some of 
the samples collected for vitamin and mineral estimations went astray 
and the results were never received. By the time this problem 
came to light, as some results took up to a month to be reported, most.
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Serum Albumin < 35j/^  
< 3(ÿi«
Anaemia
Thiamine 
Vitamin C 
Folic Acid 
Vitamin A
Soukop & Caiman 
(120 Patients)
47%
20%
49%
37%
71%
23%
15%
Present 
(39 Patients)
44%
27%
64%
(44% untreated) 
57%
20%
4%
13%
TABLE 12: COMPARISON OF BIOCHEMICAL DEFICIENCIES IN
■TWO STUDIES OF CANCER PATIENTS
patients had been discharged fron the ward, and some had by then shown 
marked changes in nutritional state. These gaps in the results 
collected make the biochemical results obtained less statisti­
cally significant when comparing them to the dietary and 
clinical evaluations of the patients’ nutritional status.
Discussion and Conclusions
The aim of the study was to look for a method of simply and 
quickly evaluating the nutritional status of oncology patients, which 
would allow early identification and treatment of nutritional 
problems. The study looked at the three main areas of nutritional 
assessment: clinical evaluation, dietary-history taking, and
biochemical estimation of serum proteins, vitamins and minerals, and 
assessed the value of each.
Table 13 shows the frequency of clinical signs of deficiency and 
biochemical nutrient deficiencies in the oncology patients with 
dietary deficiencies. Table 14 shows the frequency of these signs in 
the patients who were not diet-deficient.
Statistical analysis of the results was performed with the help 
of Mr. D. Hole, Chief Statistician, Cancer Surveillance Unit, 
Ruchill Hospital, Glasgow, to look at the accuracy of 24 hour dietary 
intake histories in predicting specific clinical and biochemical 
deficiencies. it was shown that deficient energy intake accurately
i
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Dietary
Deficiency
Energy
Protein
Calcium
Iron
Zinc
Magnesium
Thiamine
Vitamin C
Vitamin B12
I die Acid
Vitamin A
Clinical Signs
Weight Loss 80%
Brittle Nails 67%
Apthous Ulcers . 40%
Dry Skin (<60yrs) 43%
Weight Loss 72%
Brittle Nails 63%
Apthous Ulcers 42%
Dry Skin (<60yrs) 62%
Brittle Nails 71%
Koilonychia 3%
Glossitis 31%
No Specific Sign
No Specific Sign
CNS Signs 33%
Dry Skin (<60yrs) 35%
Neuropathy
Glossitiî
*Dry Eyes
22;
33;
34;
Biochemical Deficeneies
Total Protein
Albumin
Total Protein
Albumin
Calcium
Haemoglobin 
Serum Iron
Zinc
Magnesium
Thiamine
Vitamin C
Vitamin B
Anaemia 
Folate 
Retinol
12
59;
48%
6I;
56;
42%
:67%
48%
95%
43%
53%
27?
55?
66?
4;
67%,
*Patients receiving methotrexate excluded
TABLE 13; CLINICAL AND BIOCHEMICAL EVIDENCE OF MALNUTRITION IN 
CANCER PATIENTS WITH DIETARY DEFICIENCIES
»
th Dietary 
Deficiency
Energy
Protein
Calcium
Iron
Zinc
Magnesium 
Thiamine 
Vitamin C 
Vitamin 
Folic Acid
Vitamin A
Clinical Signs
Weight Loss 10?o
Brittle Nails 50?o
Apthous Ulcers 30?Q
Dry Skin (<60yrs) 20?o
Weight Loss 50?a
Brittle Nails 63?o
Apthous Ulcers 31?o
Dry Skin 27%
Brittle Nails ^2%
Koilonychia 40 ?o
Glossitis 100%
No specific sign
No specific sign
CNS signs 57%
Dry Skin (<60yrs) 21%
Neuropathy 8%
Glossitis 0
*Dry Eyes 0
Biochemical Deficiencies I
Total Protein 
Albumin
Total Protein 
Albumin
Calcium
Haemoglobin
Iron
Zinc
Magnesium 
Thiamine 
Vitamin C
Vitamin B12
Folic Acid 
Haemoglobin
Retinol
23%^
15%
40%
20%
27%
60%
20%
71%
14%
50%
0
17%
* Patients receiving methotrexate excluded
TABLE 14; CLINICAL AND BIOCHEMICAL EVIDENCE OF MALNUTRITION IN 
CANCER PATIENTS NOT DIETARY DEFICIENT
identified those patients who had lost weight (p < 0.001), and using a 
non-parametric t-test, was significantly correlated with serum total 
protein (p < 0.05) and albumin levels (p < 0.05),
Decreased protein intake showed a trend to correlation with 
decreased serum total protein levels, and significant correlation 
with serum albumin levels also (p < 0.05) , Some patients with low
serum total protein and albumin levels had normal intakes of both 
energy and protein, and these patients had tumours which had
responded to aggressive treatment. This treatment had induced 
anorexia, nausea, vomiting and weight loss over several months 
prior to the study, but at the time of study appetite and intake had
returned to normal. The serum protein levels in these patients had
not yet reflected this change in dietary intake.
Dietary protein deficiency corresponded with dry skin in those 
patients under 60 years, and was weakly significant (p < 0.08).
Dietary calcium deficiency was reflected clinically by brittle 
nails (p < 0.06), and biochemically showed a trend towards
decreased serum calcium levels.
Decreased intake of vitamin A corresponded to complaints of dry 
eyes in patients not receiving methotrexate chemotherapy (p < 0.06),
and appeared to be reflected in a decrease in retinol levels, although 
there were too few biochemical results to allow statistical analysis.
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other clinical signs such as glossitis, aphthous ulcers, 
neuropathies and central nervous system signs are not 
correlated to dietary intake, and are probably produced by other 
factors such as chemotherapy and tumour effects, as well as by 
dietary deficiency. These signs are too non-specific to be of 
value in assessing nutritional status of oncology patients.
Comparing dietary and biochemical results, deficient iron intake 
shows a trend to correlation with decreased serum iron levels.
Serum zinc and magnesium levels show correlations, approaching 
statistical significance, with decreased dietary intakes. The lack 
of results returned for many patients hindered statistical
analysis for vitamin and thiamine. Vitamin C results reflect
this problem also, but do show a trend to correlation with dietary 
intake. Folic acid intake is deficient in all cases and makes 
statistical analysis, comparing dietary deficient patients to 
those meeting dietary requirements, impossible.
Three patients showed gross dietary deficiencies of most
nutrients and these patients showed the greatest weight loss, with 
dry skin, brittle nails, dry eyes, dry hair, koilonychia and 
multiple biochemical deficiencies.
Each of the methods used for nutritional evaluation has its 
limitations. Clinical evaluation is easy to perform with the
minimum of upset to the patient, and with an accurate set of weighing
3 1
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scales being the most important piece of equipment . Weight loss and 
rate of weight loss is particularly useful in assessing nutritional 
deficiency. Clinical signs may, however, be misleading, and maybe 
produced by factors other than nutritional deficiencies, such as 
cytotoxic therapy or tumour growth. Where nutritional deficiencies are 
present, clinical signs are a late feature, hence clinical evaluation 
alone would be of little use in early identification of. patients 
with nutritional problems.
Biochemical analyses require blood samples from the patient and 
the facilities of a hospital laboratory» with equipment to process the 
blood. There may be difficulties in establishing reference values; for 
the particular nutrient assay, and interpretation of results may be 
complicated. In the present study, there were problems with samples 
going astray and equipment breaking down during processing, and there 
is always a time-lag, between taking samples and receiving results. 
There are often large body Storès of vitamins and minerals, and, since 
these are difficult to assess, this makes evaluation of the results 
obtained difficult. Cytotoxic drugs may also influence the biochemical 
picture by producing specific deficiencies or interfering with assays. 
Due to the presence of body stores, biochemical abnormalities of 
nutritional status are probably also a late reflection of deficient 
intake, and indicate an established nutrient deficiency.
Dietary histories are easy to take and cause minimim upset to 
patients. Taking a 24 hour recall history is straightforward, 
providing the patient can ranember his intake in the previous 24 hours.
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However, a computer is required to allow speedy analysis of diet 
composition within 24 hours of taking the history. Without a 
computer, analysis is tedious and laborious. Cytotoxic drugs may 
interfere with a patient's dietary intake, and thus with the assessment 
of nutritional status, by inducing anorexia, nausea, vomiting and 
abnormalities of taste. It is therefore important to take dietary 
histories from a patient on a number of occasions particularly when 
chanotherapy may cause several days of complete anorexia, to gain a 
true picture of nutritional intake.
Dietary histories with computer analysis have advantages oven the 
other methods in allowing the anticipation of nutritional problems, 
rather than simply reflecting their results; and may decrease expense 
in the laboratory by pinpointing specific nutrients to be assayed 
rather than have routine screening of every patient. However, each of 
the methods - clinical, dietary and biochemical - contributes to the 
picture of nutritional status of the patient, and ideally all should be 
used together. From this study, clinical assessment of weight loss, 
dry skin, brittle nails and dry eyes, dietary intake assessment, and 
serum protein and albumin levels are the most useful markers of
nutritional status. Other information such as tumour type and chemo­
therapy and its timing, will allow rational interpretation of the data 
obtained for the patient and must be included in the overall 
assessment.
In conclusion, therefore, all three methods of evaluation of
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nutritional status are useful; however dietary history and 
analysis is singly the most useful,way of predicting which patients 
will require nutritional monitoring and possible nutritional support.
Future studies using dietary assessments to pinpoint potential 
deficiencies should evaluate the effectiveness of early nutritional 
support in preventing or slowing the decline of nutritional status to 
cachexia. The effectiveness of early nutritional support on the 
tolerance of patients to cancer treatment and its sequele, and the 
effects of the nutritional support on tumour growth itself, could then 
be properly assessed.
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SECTION 2
THE EFFECTS OF CANCER AND CHEMOTHERAPY ON NUTRITIONAL
AND METABOLIC STATUS OF CANCER PATIENTS AND TUMOUR-
BEARING ANIMALS
___________________________
CHAPTER 3: EFFECTS OF CACHEXIA ON MUSCLE^  COMPOSITION
Introduction & Aims
The metabolic disturbances associated with cancer and its 
treatment have been discussed in the Introduction to this thesis. The 
syndrome of cachexia, with weight loss and anorexia, represents extraie 
metabolic disturbance and is associated with progressive tumour 
growth. The effects of cachexia on muscle composition in cancer 
patients have not previously been distinguished from the effects of 
protein-energy malnutrition or from the effects of disuse or 
acute infection (Jennekens, 1982).
A preliminary study was devised to examine the changes in the 
muscles of cachectic patients and to compare these to the documented 
changes seen in starvation and acute illness.
Methods
Four patients took part in the study and were selected on the 
basis of weight loss and progressive tumour growth (Table 15). Each 
patient gave informed consent for the procedure of muscle biopsy which 
was performed by Dr. D. Doyle, Consultant Neuropathologist, Southern 
General Hospital, Glasgow.
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The technique involved infiltrating 2-4 ml of 1% lignocaine 
subcutaneously over the vastus medialis muscle of the quadriceps
femoris group in thé mid-thigh. A small skin incision allowed the 
biopsy needle to be introduced, and this was advanced until the tip was 
3-5 mm below the surface of the skin, A small piece of 
muscle was guillotined and secured within the barrel of the needle 
which was then withdrawn and the incision sutured. The muscle 
biopsy was examined using light microscopy, enzyme histochemical 
techniques and electron microscopy. All processing was undertaken 
in the Department of Neuropathology, Southern General Hospital, 
Glasgow.
Table 15 summarizes the patients and their characteristics.
E;S,, a 68 year old fenale had a left ovarian carcinoma diagnosed 
by biopsy a year before the muscle biopsy. During the original
operation, tumour spread to liver, omentum and colon was noted. 
Treatment, comprising monthly intravenous injections of Thiotepa was 
caiimenced after operation, and continued until 2 weeks prior to biopsy. 
Six months prior to muscle biopsy, E,S, developed ascites which 
required to be tapped regularly. Over the two months before the 
procedure, she lost weight and became nauseated and anorexic, with 
voniting at times and feeling generally "weak". Examination at the
time of biopsy revealed a palpable liver, a left-sided lower abdominal 
mass and palpable inguinal lymph nodes. Assessment sho\æd tumour 
progression, despite the treatment. At the time of muscle biopsy 
haemoglobin was 8.3 g|,:j/dl and had been gradually falling during
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the previous 3 months; and serum biochenistry showed reductions in 
total protein, albumin, iron, sodium and chloride. There were in­
creases in serum levels of the liver enzyme glutamine oxaloacetate 
transaminase, glucose and bicarbonate. E.S. continued to deteriorate 
physically and metabolically, and died 1 month after muscle biopsy,
T.R, was a 73 year old man who had metastatic left renal carcinoma 
first diagnosed 6 months prior to muscle biopsy. Métastasés involved 
liver, lungs and abdominal lymph nodes. . Initial treatment with 
Provera tablets, 100 rag. daily, gave, at first, tumour regression; 
however after four months of treatment there was evidence of tumour 
progression and Provera was stopped. Over 5 months prior to muscle 
biopsy he lost 7 Kg weight (13% original body weight) and he became 
nauseated, anorexic, weak, and had episodes of vomiting at times. He 
had required repeated blood transfusions, at monthly intervals for 4 
months prior to muscle biopsy; and at fortnightly intervals in the 
month preceding biopsy. On examination at the time of biopsy, 
hepatomegaly and a left-sided abdominal mass were noted. Haemoglobin 
was 8.0 gp.i/dl; serum biochemistry shoved decreased total protein and 
albumin, iron, sodium and chloride; alkaline phosphatase and gamma 
glutamyltransferase were raised. T.R. continued to deteriorate and 
died 2 months following muscle biopsy.
J.F. was a 60 year old man with inoperable metastatic carcinoma of 
the stomach diagnosed at operation 7 months prior to muscle biopsy. 
The tumour was noted to be locally invasive, and involved the liver and
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coeliac axis. Treatment with intravenous 5-Fluoroüracil, Adriamycin 
and Mitomycin-C at four-weekly intervals was given for the first 6 
months after diagnosis. Treatment was discontinued after tumour 
progression was noted, with increasing numbers and size of liver 
métastasés and further infiltration of the stomach by tumour. Over 
the four months prior to biopsy he had lost 11 Kg in weight (16% of 
original body weight) and complained of nausea, anorexia and epigastric 
pain, and felt tired and weak. His. haemoglobin fluctuated between 9 
g/dl and 12 g/dl in the 5 months prior to muscle biopsy. He did not 
require blood transfusion. Examination at the time of biopsy revealed 
hepatomegaly. Haanoglobin was 11.3 g/dl; serum biochemistry showed 
decreased levels of total protein and albumin, iron and sodium. J.F. 
continued to deteriorate physically, .with tumour progression, and died 
2 months following muscle biopsy.
J.B, was a 73 year old man with metastatic carcinoma of the 
prostate diagnosed two and a half years prior to muscle biopsy. Bony 
métastasés were present at the time of diagnosis. He was treated with 
Stilboestrol, radiotherapy. Tamoxifen, Estracyt and Aminoglutethimide, 
each for varying intervals prior to the biopsy. The bony métastasés 
however, were becoming more widespread despite treatment. Six years 
prior to biopsy, polymyalgia rheumatica was diagnosed. Over the 4 
months prior to muscle biopsy he had lost 6 Kg in weight (9% original 
body weight) and felt nauseated, anorexic, tired and weak. His 
haemoglobin dropped slowly from 12 g/dl to 9.5 g/dl in the 5 months 
prior to biopsy. At the time of biopsy haemoglobin was 9.5 g/dl;
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serum biochanistry showed normal total protein and albumin, low levels 
of sodium, chloride and iron, and increased levels of gamma glutamyl 
transferase, alkaline phosphatase and bicarbonate. Following muscle 
biopsy J.B. continued to deteriorate slowly and died 4 months later.
None of the patients experienced any side effects from the 
muscle biopsies and had no physical sequele.
Results
All of the muscle biopsies examined showed similar changes, 
although the features in the biopsies of J.F, and J.B. were 
particularly striking. All patients showed variation in muscle fibre 
size with nuclear aggregates in some fibres and necrosis of peripheral 
fibres on light microscopy.
Light microscopy of the biopsy from E.S. showed atrophy of type 2 
("fast") muscle fibres, with increased peripheral enzyme activity 
seen in the mitochondrial enzyme preparations. These appearances 
suggested metabolic disturbance rather than denervation.
Biopsy from T.R. showed general reduction in fibre size, with low 
mitochondrial activity in type 2 fibres. This also was consistent 
with a metabolic disturbance.
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The muscle frcm j.F. showed few changes in fibre size or type on 
light microscopy, and no specific reduction in mitochondrial activity 
was seen with enzyme histochemical studies. Electron microscopy, 
however, revealed considerable disruption of the mitochondria which 
showed circumferential crystals and numerous intra-mi tochondr ial 
crystals (so-called "parking-lot" bodies). These changes are seen 
with severe disturbance of mitochondrial function, and reflect 
metabolie abnormalities.
The features of the muscle biopsy fron J.B, showed changes due to 
polymyalgia rheumatics, as well as metabolic disturbance. Light 
microscopy showed necrosis of some muscle fibres and a "moth-eaten" 
appearance of some of the fibres - a characteristic feature of 
polymyalgia rheumatics. There was atrophy of both muscle fibre types. 
Mitochondrial enzyme preparations showed disturbed internal 
architecture of the muscle fibres. Electron microscopy showed 
disorganisation of some muscle fibres which had decreased amounts of 
contractile protein which was in disarray, and present both focally 
and in larger portions in the muscle fibres. There were numerous 
large mitochondria present in these fibres, and excess lipid was seen. 
The "moth-eaten" appearance of some fibres, the presence of lipid and 
of type 2 fibre atrophy are associated with denervation and reinerva- 
tion and with polymyalgia rheumatics. Superimposed on this are 
mitochondrial changes reflecting severe metabolic disturbance.
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Discussion and Conclusions
All of the patients studied had advanced and progressive tumours 
which had failed to respond to treatment. All were cachectic with 
weight loss, anorexia, weakness and anaemia.
All of the muscle biopsies showed abnormalities, and the presence 
of electron microscopic changes confirmed the cellular disruption. 
Morgan-Hughes (1982) states that changes in ultrastructure of muscle 
cells (including mitochondrial changes) are a response to metabolic 
disturbances both inside and outside the cell.
Starvation results in generalised reduction in fibre size with 
large groups of atrophic fibres. Type 2 fibre atrophy predominates. 
In disuse, there is decreased size of both fibre types. There are few 
abnormalities specific to ageing until after 70 years, when there may 
be variation in fibres size with, particularly, type 2 fibre loss. 
Necrosis of muscle fibres and "ragged" fibres, with internal nuclei, 
cytoplasmic inclusion bodies and decreased numbers of mitochondria are 
seen with ageing and these are the changes of denervation arid 
reinnervation. In sepsis, there is fibre necrosis in isolated 
fibres throughout the muscle (Jennekens, 1982),
The changes found in the cancer patients form a distinct entity. 
There is some overlap with the features of starvation, disuse and 
ageirig, with type 2 fibre atrophy, variation in fibre size, nuclear
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aggregates and peripheral fibre necrosis. However, the internal and 
mitochondrial disruption of the muscle of the cachectic cancer patients 
are more prominent than in these other states (Plate 1). The mito­
chondrial disfunction, with increased;size and numbers of mitochondria, 
inclusion bodies and variable enzyme activity, reflects metabolic 
changes in the body (Morgan-Hughes, 1982). The mitochondrial crystals 
are thought by Land and Clark (1979) to be produced by impaired bio­
synthesis of mitochondrial protein subunits coded for by mitochondrial 
DNA and causing an accumulation of nuclear-coded protein subunits as 
inter- membrane crystals. They suggest, alternatively, that there may 
be impaired nuclear protein subunit biosynthesis, with normal mito­
chondrial biosynthesis, producing excess mitochondrial subunits. The 
crystals' composition is still the subject of debate - however they are 
known to be enzymatically inert, and may be proteins. Other theories 
consider that the crystals represent greatly increased in- foldings of 
the inner mitochondrial membrane which, in cross section, appear as 
"crystals" within the mitochondria (Morgan-Hughes, 1982),
The increased nuclear and nucleolar activity in the muscle 
cells of the cancer patients indicates increased protein turnover. 
This would be consistent with mobilisation of muscle protein to 
compensate for low serum protein levels, and to provide precursors for 
gluconeogenesis to provide energy for further tumour growth 
(Norton et al., 1980). Lundholm et al, (1976) confirm the increased 
breakdown of protein of muscle fibres in cancer patients; and 
Bozzetti et al. (1982) regard decreased protein content of muscle as 
the first sign of malnutrition in cancer patients.
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PLATE 1: ELECTRON MICROSCOPIC EXAMINATION OF MUSCLE CELL
FROM CACHECTIC CANCER PATIENT SHOWING FIBRILLAR 
PROTEIN^AND MITOCHONDRIA WITH INTRAMITOCHONDRIAL 
CRYSTALS® ("PARKING LOT" BODIES)
(MAGNIFICATION x 33, 330)
None of the patients biopsied showed any improvement metabolically, and 
no response to further treatment. In these patients it is impossible to 
distinguish the relative contributions of chemotherapy and tumour 
growth to the muscle picture. Tumour progression, however, is a major 
contributary factor in the metabolic disturbances of cachexia.
In summary, muscle biopsy reflects the metabolic changes seen in 
cachexia. The changes seen in cancer patients are a distinct entity. 
Future studies should biopsy patients prior to chemotherapy,, and at 
early stages of disease, to identify changes due to tumour alone; and 
correlate the earliest changes seen in muscle with the metabolic state 
at that time. A further study in untreated patients with advanced 
tumours, such as lung tumours would allow the separate effects of 
chemotherapy and tumour growth on muscle changes to be determined. It 
would be interesting to look at biopsies from patients who respond to 
treatment, and to show whether the muscle changes are reversible or 
not. These studies would contribute to the information on metabolic 
and nutritional changes in the cancer patients, which in turn may be 
used to improve nutritional state.
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CHAPTER 4: SALIVA PRODUCTION, COMPOSITION AND MICROORGANISM CONTENT
IN CANCER PATIENTS: IMPLICATIONS FOR NUTRITION
Introduction and Aims
Cancer and chemotherapy are known to affect appetite and taste 
sensations^as outlined in the Introduction to thus thesis. Further 
effects may be to alter the production of saliva and to change the 
microflora of the mouth, which will contribute to the anorexia, 
abnormalities of taste, dry mouth and other oral problems encountered 
in the cancer patieht and will promote a decline in,nutritional state 
by decreasing food intake and enjoyment.
Sonis, Sonis and Lieberman (1978) found that 40% patients 
receiving chemotherapy for tumours, developed oral complications as a 
direct result of the drugs. There are several mechanisms suggested 
for the effects of the drugs on the mouth. Some cytotoxic drugs act 
on rapidly dividing basal cells of the oral epithelium causing 
ulceration and necrosis of the buccal muCosa. Methotrexate, in 
particular, has been implicated as a cause of this problem. Both 
tumour and chemotherapy may impair host defence mechanisms and 
exacerbate chronic oral infections, such as periodontitis and pulpitis 
or allow secondary infection of ulcerated mucosa by bacteria, fungi and 
viruses (Lockhart & Sonis, 1979). Drug or tumour-induced thrombo­
cytopenia could produce gingival bleeding and mucosal pv^ pura.
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A common complaint of patients receiving cytotoxic drugs is of a 
dry mouth, which causes problems in chewing, tasting and swallowing 
food (Dreizen, 1981). Both this problem^ and the alteration in 
microflora may exacerbate the nausea and anorexia of some patients, and 
may produce a further deterioration in nutritional status. The aims of 
this study were to examine saliva volume and composition, and 
investigate its microbial content in cancer patients and controls 
before and during chemotherapy.
Methods
The study was split into two parts: the first, preliminary, study 
compared saliva volume, alpha amylase, IgA and lysozyme content^ and 
microflora present in 39 oncology outr-patients who were receiving 
cytotoxic drugs, and 20 healthy volunteers. The second study followed
these factors in 20 oncology out-.patiënts over a period of three
months. The first samples were taken at first attendance at the 
oncology out-patient clinic at Gartnayel General Hospital, Glasgow, and 
prior to starting chemotherapy. Rirther samples were taken after one
and three months of treatment.
Saliva was collected using a "forced spitting" method which 
involved spitting into a container at 10 second intervals for 10 
minutes. This gave a reproducible flow rate of whole mixed saliva 
and included oral microorganisms, epithelial cells and gingival 
crevicular fluid. The saliva samples were transported immediately
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after collection, on ice, to Glasgow Dental Hospital where analysis 
was performed under the supervision of Dr. M. Ferguson. Bacteria 
and yeasts were cultured and identified; and saliva volume, 
alpha- amylase, lysozyme and igA levels were measured.
Records were made of patients’ ages, tumour types, chemotherapy 
regimepsi smoking habits and whether or not they had dental prostheses.
Results
The 39 patients used initially had all received chemotherapy for 
at least 3 months, and had a variety of tumour types (Tables 16 and 
17). M:F ratio was 17:22 and ages ranged from 17-68 years (mean 48 
years),
The control group comprised members of Gartnavel General Hospital 
staff with M:F ratio 8:12 and ages ranged from 19-55 years (mean 
30 years). No attempt was made in this preliminary study to match 
age, sex, or dental status in patients and control groups.
The twenty patients followed for 3 months from the start of 
treatment had M:F ratio 8:12 and ages ranging from 17-66 years (mean 42 
years). Tumour types and chemotherapy used are shown in tables 18 and 
19.
In both studies, neither patients nor controls were receiving
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Tumour Type NO. patients
Breast Carcinoma 12
Teratoma 7
Lung carcinoma 3
Ovarian carcinoma 3
Hodgkin's disease 2
Renal carcinoma 1
Colonic carcinoma 1
pharyngeal carcinoma 1
Oesophageal carcinoma 1
Gastric carcinoma 1
Mesothelioma 1
Rabdomyosarcoma 1
Leiomyoma 1
Lymphoma 1
Chronic granulocytic leukaemia 1
unknown primary 1
TABLE 16: TUMOUR TYPES OF PATIENTS RECEIVING CHEMOTHERAPY
FOR LONGER THAN 3 MONTHS
___________________________________________________
NO. patients
13
11
Drug 
Adriamycin 
vincristine 
Cisplatin 
vinblastine 
Methotrexate 
5-Fluorouracil 
Cyclophosphamide 
Bleomycin 
prednisolone 
Mitomycin C 
Chlorambucil 
procarbazine 
Vindesine 
Hydroxyurea 
Iphosphamide 
D.T.I.C.
TABLE 17: CYTOTOXIC DRUGS USED IN PATIENTS FOR LONGERTHAN 3 MONTHS
Tumour Type 
Breast carcinoma 
Teratoma
Ovarian carcinoma 
Oesophageal carcinoma 
Lymphoma
Hodgkin's disease 
Gastric carcinoma 
Lung carcinoma 
Le i omyos arcana 
Rhabdomyosarcoma
NO, patients
TABLE 18: TUMOUR TYPES OF NEW PATIENTS STUDIED
  :  ____
Drug No. Patients
" !
Adriamycin
Vincristine
Methotrexate
Cyclophosphamide
5-Fluorguracil
Cisplatin
Vinblastine
Bleomycin
Mitomycin C
Chlorambucil
Procarbazine
Prednisolone
DTIC
Iphosfamide
Tamoxifen
TABLE 19; CYTOTOXIC DRUGS USED IN PATIENTS FOLLOWED FOR 
3 MONTHS
   : ^ :___
antibiotic therapy; and no patients were significantly myelosuppressed 
during the studies.
Table 20 shows the results for the cancer patients and control 
groups. It can be seen that saliva volume and alpha-amylase activity 
are significantly decreased, and microbial content of saliva is 
significantly increased in the patients who have received chenotherapy 
for more than three months. Lysozyme activity and IgA concentration 
show no significant difference between the groups.
Table 21 shows the changes occurring in the patients followed for 
the first three months of their treatment. Over the period of study 
saliva volume, and hence saliva flow rate,alpha-amylase activity, and 
igA concentration decreased significantly; candidal colonisation, the 
number of Candida colonies per patient, and the presence of significant 
numbers of bacteria in the mouth increase with duration of treatment.
In both groups of patients, the most commonly occurring organisms 
were coliforms, with Escherichia coli the most commonly isolated, 
Proteus mirabilis, Klebsiella pneumoniae and pseudomonas aeruginosa 
were also found. Three patients had Staphylococcus aureus isolated. 
Of the controls, one volunteer had a coli form isolated and had 
associated candidal colonisation. All patients with coliforms present 
also had candidal infection in the mouth.
'i'R:
Smoking had no effect on saliva volume and composition or on
lOl
  .
Saliva volume (fat-) 
Amylase (i.u./l x 10~^) 
Lysozyme (i.u.^ml)
IgA (g/l)
Candidal infection rate 
Bacterial infection rate
Controls 
(20 patients)
6.94
4.57'
705
0.16
40%^
I- . n/A
Cancer Patients 
(59 patients)
5.99 
3.66 
709 
0.14 
76%A
15!,A
Significance of AA = p< 0.001
CC = p< 0.05
TABLE 20 SALIVA COMPOSITION OF CONTROLS VERSUS CANCER 
PATIENTS RECEIVING CHEMOTHERAPY FOR MORE THAN 
3 MONTHS
_____________
Saliva Volume 
Amylase (i.u./l x Ip" )
Lysozyme (i.u.jli^ ,
IgA (g/i)
Candida infection; rate 
Bacterial infection rate
Duration of Treatment ; 
(Months)
0 1
6.16^ 5,46
4.91^ 3.87
- "^682' 706
■: C - :o.ia'', 0.13
: 70%^ 50%
.-;5%A 10%
3.83
3.09^
833
O.ll'- 
,B805
15!A
Significance of AA = p < 0.001
BB = p < 0.01
CC = p < 0.05
TABLE 21: CHANGES IN SALIVA COMPOSITION DURING 3 MONTHS
CHEMOTHERAPY
candidal colonisation, patients with false teeth, however, showed 
increased candidal colonisation.
Most patients were receiving combinations of chonotherapeutic 
drugs so it was not possible to look at the effects of individual 
drugs. There was a trend however, for patients receiving Cyclophospha­
mide and Methotrexate to show decreased saliva volumes; while those 
receiving Cisplatin, Adriamycin and Mitomycin C shov\ed increased 
incidence of candidal infection, with less effect on saliva volume 
(Table 22) .
Discussion and Conclusions
NO patients specifically complained of mucositis or dry mouth 
during the study, although.there is a significant reduction in saliva 
volume and in saliva flow rate as chenotherapy progresses. It is 
interesting that some cytotoxic drugs seem to have more effect on 
saliva flow rate than others: these effects would indicate damage
to the acinar secreting cells of the salivary glands, and the two 
drugs most frequently implicated in this study. Methotrexate and 
Cyclophosphamide, are both known to cause damage and necrosis to this 
type of cell. The other drugs cause damage to the glands as a 
dose-related side effect of treatment: the more toxic drugs
showing earlier effects on saliva production.
The significant reduction in alpha-amylase production with con­
tinuing cytotoxic treatment reflects the damage to the acinar cells of
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% Cancer Patients
Drug
Adriamycin
Cisplatin
Methotrexate
Cyclophosphamide
Mitomycin C
5-Fluorouracil
Decreased saliva 
Volume
55
20
75
86
80
50
Increased Infections
85
70
50
57
100
50
table 22; EFFECTS OF CYTOTOXIC DRÜGS ON SALIVA VOLUME 
AND MICROBIAL CONTENT
the salivary glands>and the, consequent decreased saliva production.
The amount of IgA antibody present in the saliva decreases with 
duration of treatment, and allows Candida infection of the mouth. 
Epstein et al. (1982) showed that the presence of IgA antibody 
inhibits adhesion of Candida albicans to the oral epithelium. This is 
one reason for the significant increase in Candida albicans 
colonies isolated from the mouths of patients as treatment progresses.
The control group showed 40% incidence of oral candidal 
colonisation, which agrees with results obtained by Odds et al. (1979) 
for several different control populations.
The 70% candidal colonisation of cancer patients prior to 
chenotherapy indicates some decreased resistance to infection, and 
may be due to nutritional depletion caused by the tumour. Nutritional 
assessments, however, were not made on these patients. There was a 
significant (p < 0.01) increase in candidal colonisation as
chemotherapy continued, and some drugs had more effect on this than 
others. Adriamycin, Cisplatin and Mitomycin-C were particularly 
likely to cause candidal growth, and this may be explained by the 
anorexia, nausea and vomiting induced by these drugs producing dehydra­
tion, with decreased saliva flow and poor oral hygiene. The transient 
myelosuppression caused by the drugs may also contribute to the 
problem*
Bacterial infections of the mouth are usually transient and
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opportunistic (Martin, Al-Tikriti & Bramley, 1981). The increased 
numbers of organisms isolated from the patients on treatment are 
significant, and will provide a reservoir for potentially infective 
organisms to become more widespread, producing septicaemia, bacter- 
aemia, endocarditis and multiple abscesses in iramuno-compromised 
patients. The presence of coliforms in the mouth allow increased oral 
attachment of Candida colonies (Centeno et al.,1983), and all patients 
with bacterial infection of the mouth had concomitant Candida 
colonisation.
In summary, cancer and chenotherapy produce decreased saliva 
volume, decreased alpha-amylase production, and decreased IgA antibody 
in saliva, and cause increased oral candidal colonisation and increased 
opportunistic infection. The consequences of these alterations are 
dry mouth, decreased taste sensations, difficulties in chewing and 
swallowing, increased incidence of mucositis and the establishment of a 
reservoir for potential acute and subacute bacterial dissemination, all 
of which will have effects on the nutritial status of patient. Smoking 
has no effect on these changes; the presence of dental prostheses 
increases the risk of Candida colonisation and bacterial infection.
Oral hygiene and regular inspection of the mouth is therefore 
extremely important for all patients on chemotherapy and particularly 
for those with dental prostheses. Those patients who have most 
reduction in saliva flow and are at risk of dry mouth and mucositis, 
may benefit from use of saliva substitutes.
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This is a preliminary study. Future studies should identify those 
cytotoxics which produce the most drastic effects on saliva production 
and composition. The effects of diminished saliva flow and candidal 
infection on taste sensation, appetite and palatability of food should 
be studied; and the effects of improved oral hygiene and the use of 
saliva substitute on these factors should be assessed.
105.
______________
CHAPTER 5: SOME METABOLIC EFFECTS OF,TUMOUR GROWTH AND■CYTOTOXIC
DRUGS IN ANIMALS
Introduction and Aims
The effects of tumours on host metabolism, and the side effects of 
cytotoxic drug therapy causing nutritional and metabolic upset have 
been discussed in detail in the Introduction to this thesis.
The aims of these studies were to examine the metabolic changes 
occurring in the tumour-bearing host ; to define the effects of two 
cytotoxic drugs, Cisdichlorodiammine platinum (II) (Cisplatin) and 
Cyclophosphamide on host metabolism^ and to determine whether 
tumour-induced metabolic alterations may be improved or exacerbated by 
the administration of these cytotoxic drugs.
The drugs chosen for study, Cisplatin and Cyclophosphamide^ are 
both alkylating agents: Cisplatin links DNA base pairs in a single
strand across the helical turns; Cyclophosphamide cross-links one 
strand of . DNA to the other. Both drugs cause nausea, vomiting and 
anorexia. Cisplatin may produce electrolyte problems and renal 
failure, due to an effect on the renal tubules (see Chapter 6 for a 
fuller discussion on Cisplatin toxicity). Cyclophosphamide may 
exacerbate liver disease, and may cause a haemorrhagic cystitis with 
subsequent renal problems. These drugs are often used clinically in 
combination with other drugs; in these studies they have been examined
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as single agents,
Methods
Female Wistar albino rats weighing 150-180 g were used. , These 
animals were bred in the Department of Clinical Oncology, Glasgow 
university and were maintained on a standard laboratory chow (CRM, 
Labsure, Rank-Hovis-McDougal Agricultural Division, Dorset, England). 
Water was supplied ad libitum, and the animals were subjected to 
alternating 12 hour periods of light and dark.
A fast-growing cachectic Walker 256 carcinosarcoma obtained from 
the institute of Cancer Research, Sutton, Surrey, was maintained in 
Wistar albino rats and was used to make a single-cell suspension of 
tumour cells for experimental use. This involved excision of a 14 day 
tumour from a passage animal, the tumour then being immersed in sterile 
phosphate buffered saline (PBS) containing 50yUg/ml penicillin and 100 
jiq/ml streptomycin, and dissected in a sterile laminar flow cabinet 
(Microflow pathfinder) to remove connective tissue and necrotic debris. 
The tumour fragments were incubated overnight at 4° C in lo ml DMEM-FlO 
medium (Flow Laboratories) containing 2.5% trypsin, and then stirred at 
37°C for 25 minutes to disaggregate the trypsinised tumour. Tissue 
was filtered out using sterile 75 micron metal gauze, and the medium 
removed by centrifugation at 800 rpm for 5 minutes. The cells were 
washed three times in sterile phosphate buffered saline, and the 
viability of the suspension determined by trypan blue exclusion. A
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suspension of 2 x 10 Walker 256 cells in 0.2 ml sterile phosphate 
buffered saline was used. Tumour growth in the rats was monitored by 
caliper measurements of length and breadth of tumour on alternate days. 
Tumour weight was noted at sacrifice.
The drugs used for the study were Cisplatin (Neoplatin, Bristol 
Myers Pharmaceuticals, Slough, Bucks.) at the dose of 6.3 mg/kg
body weight; and cyclophosphamide (Endoxana, W.B. Pharmaceuticals 
Ltd., Bracknell, Berks.) at the LD^ g dose of 3I0 mg/kg body weight. 
Both of these dosages were determined by a previous preliminary 
experiment.
For each drug, four groups of rats with at least 6 animals in each 
group weCA/ used. Group 1 received tumour only; Group 2 received 
tumour and drug; Group 3 received drug alone; and Group 4 was the 
control group. All innoculations and injections were performed under 
ether anaesthesia; and animals were killed by ether inhalation. 
Figure 15 indicates the timescale of the experiments. On day 0, Groups 
1 and 2 received subcutaneous innoculations of 0.2 ml tumour cell 
suspension, and Groups 3 and 4 received subcutaneous innoculations of 
0.2 ml sterile phosphate buffered saline. Wien tumour dimensions 
averaged 30 x 25 mm, usually 12-14 days after innoculation, the animals 
in Groups 1 and 4 were injected intraperitoneally with phosphate 
buffered saline and those in Groups 2 and 3 with the LD^ g dose of 
Cisplatin or cyclophosphamide. Six days later, the animals were 
sacrificed, when the tumour dimensions in Group 1 (tumour alone) 
averaged 40 mm x 30 mm. Tumour volume was determined using the formula
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Group 1 2 3 4
T T + D D C
(Tumouralone) (Tumour + drug)
(Drug alone) (Control)
Day 0
Subcutaneous
innoculation
62 X 10 Walker 256 cells
62 X 10 Walker 256 cells
0.2 ml 
P.B.S.
0.2 ml 
P.B.S.
Day 11-14Ihtraperitoneal
injection
P.B.S. LD dose 10
drug
LD dose 10
drug
P.B.S.
Day 17-20 - Sacrifice - -
P.B.S. Phosphate buffered saline (pH n-i+  ^0-15h }
LD dose = amount of drug (mg/kg body weight) 10 required to kill 10% animals in a 
group
FIGURE 15: TIMESCALE FOR DRUG AND TUMOUR ANIMAL STUDIES
 : -'".''"A  ^^
of Daly et al. (1980) for a prolate spherbU^ V = 1/6 AB (where A = long 
diameter and B = short diameter),
After sacrifice, blood was taken from the heart of each animal for 
biochemical analysis for urea and electrolytes, iron, calcium, albumin, 
total protein and liver enzymes, and for ketone body estimation. The 
tumours were excised and weighed. Biochemical analysis was performed 
at the department of Biochemistry, Gartnavel General Hospital, Glasgow 
on a SMAC autoanalyser (Technicon methodology) , Ketone bodies, beta 
hydroxybutyrate and acetoaCetate, were measured enzymatically using 
the methods of Williamson and Mellanby (1975) and Mellànby and 
Williamson (1975) respectively. Determinations of nitrogen and water 
content of the bodies were performed by autoclaving frozen carcasses 
and then homogenising them in twice their carcass weight of water. One 
aliquot was taken for' nitrogen estimation by the microkjeldahl method, 
and an autoanalyser adaptation of thè'Berthéiot reaction (Fleck 1967). 
A second aliquot was taken, and water content determined by lyophili- 
zation.
Statistical significance was computed using a student's t-test for 
non-paired data, and multiple regression analysis.
Results
Weight changes were similar in both drug studies, and are shown in 
Figure 16. In each case, the control group, group 4, was the
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CISPLATIN
T+D
change (g)
CYCLOPHOSPHAMIDE
T+D20
change (g)
20
FIGURE 16: COMPARISON OF WEIGHT CHANGES IN TUMOUR ,(T), DRUG (D)
TUMOUR AND DRUG (T+D) AND CONTROL (C) ANIMAL GROUPS J i
 :_______________
only group to gain weight. This group had a mean weight increase of 7 
y in the Cisplatin study and 12 g/: r ,. ;i in the Cyclophosphamide 
study. Tumour alone (Group 1) produced a small net weight loss; the 
tumour itself accounting for only 5.6% total body weight. Each drug 
on its own produced more weight loss than the tumour alone. Tumour 
and drug caused the greatest weight loss : a mean loss of 13 g:;:;;:&t in
the Cisplatin group and 30 g%#K/ in the cyclophosphamide group.
The nitrogen and water content of the carcasses from each group 
are shown in table 23. Water content shows no statistically 
significant difference between groups. Nitrogen content is 
significantly reduced in the tumour alone (Group 1) groups in both 
studies compared to the controls (Group 4), in keeping with the 
cachectic nature of the tumour causing protein depletion, interest­
ingly the tumour and drug (Group 2) and drug alone groups showed no 
difference in nitrogen content compared to controls.
Figure 17 shows the tumour volumes for groups 1 and 2 in each 
study. In the Cisplatin study, there is a 75% reduction in tumour 
volume in the tumour plus Cisplatin group (group 2) compared to the 
tumour group (group 1); and there is a 98% reduction in tumour volume 
in the tumour plus drug group (group 2) compared to the tumour 
alone group (group 1) for Cyclophosphamide, illustrating the 
cytotoxic effects of the drugs on the tumour.
Table 24 shows the blood ketone results. Ketone bodies are 
greatly elevated in the tumour alone group (group 1) studies. The drug
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Cisplatin
GROUP
1 (T)
2 (T + D
3 (D)
4 (C)
' N::(%) ' H2Û(?0 N,.(%)
19.2^ 70.6 19.2®
22.6 70.3 22.2
21.3 72.7 21.4
22.0^ 72.3 22.0®
Cyclophosphamide
70.6
69.9
70.1
72.3
Significance of AA p < 0.01 
BB p<0.ül
TABLE 23; CARCASS NITROGEN AND WATER CONTENT OF TUMOUR-BEARING 
AND CYTOTOXIC DRUG TREATED ANIMALS
__     ■ ' -  ‘ '1
T & D
TUMOURVOLUME
CYCLOPHOSPHAMIDECISPLATIN
cm
day n day 14
FIGURE 17: COMPARISON OF TUMOUR VOLUMES IN TUMOUR (T) , AND TUMOUR
AND DRUG (T+D) ANIMAL GROUPS
_____________
■ ; Cisplatin,;  ^Î ■
GROUP ' B-OH (mmol/1) .Aceto(mmol/1) B-OHCmmoi/l) Aceto(mmol/I)
1 (T) 0.528 . 11.310 ,0.990 ‘ 0.279
2 (T + i): 0.0,31 0.007 0.042 ovgo6:
3 (D) 0.007 01012 : 0.013 0.006
4 (C) 0.010 : 0,004 0.018 0.005
: Cyclophosphamide
B-OH = B~hydrpxybutyrate 
Aceto = Acetoacetate
T ABLE 24; BLOODj^KETONE LEVELS : IN ; TUIHOUR BEARING AND
CYTOTOXIC. DRUG TREATED ANIMALS
A
Ai
alone and control groups (Groups 3 and 4) show only marginally 
detectable levels of the ketone bodies. The tumour and drug group 
(group 2) for both Cisplatin and Cyclophosphamide shows an increased 
level of ketone bodies, indicating continued fatty acid oxidation, but 
at levels greatly reduced from the tumour alone (Group 1) results.
plasma concentrations of urea and electrolytes, bicarbonate, 
creatinine, alkaline phosphatase, calcium and phosphate were within one 
standard deviation of the mean control values for all groups. The 
results for plasma iron, total protein, albumin, and the liver enzymes 
are shown in Figures 18 and 19.
plasma iron concentration is reduced in the tumour alone groups 
(Group 1) reflecting the adverse effects of the tumour on metabolism, 
and the non-specific iron deficiency found in cancer bearing hosts. 
The tumour and Cisplatin group (Group 2) and the Cisplatin alone group 
(Group 3) produced increases in the plasma iron, with the tumour and 
drug group (group 2) showing the greatest elevation of plasma iron. 
This increase corresponds with the increased plasma iron concentrations 
found in patients receiving Cisplatin chemotherapy which is caused by 
failure of iron utilisation (von Hoff et al., 1979). Both groups 2 and 
3 receiving Cyclophosphamide produced slight decreases in plasma iron 
concentration.
Total protein and .albumin levels are markedly reduced in, the 
tumour alone groups (Group 1). The Cisplatin groups (Groups 2 and 3)
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FIGURE 18: COMPARISON OF PLASMA IRON/ TOTAL PROTEIN AND ALBUMINLEVELS IN TUMOUR (T), DRUG: (D), TUMOUR AND DRUG (T+D) AND CONTROL (C) ANIMAL GROUPS
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FIGURE 19; COMPARISON OF LIVER ENZYMES ASPARTATE TRANSAMINASE (AST) 
AND ALANINE TRANSWlNASE (ALT) IN TUMOUR (T) , DRUG (D) , 
TUMOUR AND DRUG (T+D) AND CONTROL (C) ANIMAL GROUPS
produced a fall in total protein and albumin compared to control 
groups. This decrease is less than for the tumour alone group (Group 
1) and reflects the modifying effects of the drug on the tumour- 
induced nutritional changes. Cyclophosphamide alone, and with the 
tumour (Groups 2 and 3) produces a similar fall in total protein and 
albumin to the tumour alone (Group 1). There is no significant 
difference between the drug alone, tumour alone, and drug and tumour 
groups, showing no additive metabolic injury from drug and tumour.
Figure 19 shows the results obtained for the liver enzymes, 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT). 
These enzymes also reflect damage to organs other than the liver:
skeletal muscle, cardiac muscle and kidney damage producing high plasma 
levels. Z^ p^artate aminotransferase is a mitochondrial enzyme; 
alanine aminotransferase is a cytoplasmic enzyme. High plasma levels 
of these enzymes indicate cellular damage; however low levels may be 
misleading, reflecting the exhaustion of the enzyme supply from 
necrotic cells.
The results of the studies show aspartate aminotransferase is 
elevated up to twice the control value in the tumour alone group 
(Group 1) indicating tumour-induced cellular damage. Alanine amino­
transferase is reduced in this group, due to exhaustion of leakage
of cytoplasmic enzymes from the damaged cells, Cisplatin alone (Group
3) produced a fall in both enzymes, indicating some drug-induced 
cellular damage. The drug and tumour group (Group 2) shows no
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significant difference compared to the control group for either 
enzyme. Cyclophosphamide alone and with tumour caused falls in both 
AST and ALT, with the tumour and drug group (Group 2) showing the most
marked decreases, indicating the cellular injury caused both by the
drug and the tumour.
Discussion and Conclusions
The tumour itself produces marked metabolic upsets in the host, 
with weight loss, decreased nitrogen content, decreased plasma iron 
and plasma total protein and albumin concentrations. Ketone body 
levels are increased markedly and liver enzymes are deranged. All of 
these factors indicate nutritional and metabolic injury to the host, 
and are similar to metabolic changes produced in cancer patients.
The drugs used, Cisplatin and Cyclophosphamide^both cause weight 
loss, although the changes in nitrogen content are not so marked as in 
the tumour alone group. Both drugs produce biochemical upsets in 
ketone body, iron, protein, albumin and liver enzyme levels in the 
serum; with Cyclophosphamide producing the greatest metabolic
upset at the dose used in this study.
The tumour responded to treatment with both drugs, and there is a
marked amelioration of the effects of the tumour on plasma iron, total 
protein and albumin, ketone bodies, liver enzymes and carcass nitrogen 
levels by the drugs,
in summary, both tumour and drugs alone produce distinct
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metabolic and nutritional changes in the host, similar to those in 
cancer patients. The tumour tends to produce the greatest metabolic 
insult; although the drugs, and especially Cyclophosphamide cause 
significant changes in body weight. When the tumour responds to the 
drug, as in the tumour and drug groups, there is improvement in the
metabolic and nutritional state of the host, and this may be useful 
clinically. However, if the tumour is not controlled by the 
cytotoxic drugs administered, there may be superadded metabolic 
problems for the; patient from both the tumour and the drugs.
Since the changes seen in' animals with a cachectic tumour are the 
same as those seen in cachectic human tumours, it will be possible to 
look at ways of modifying tumour effects on metabolism, and of 
minimising unwanted drug effects. The study could be extended to 
look at other cytotoxic drugs which are known to cause nutritional and 
metabolic upset - for example Adriamycin, 5 Fluorouracil and 
Methotrexate. Future studies should look at nutritional manipulations 
such as ketogenic diets or specific inhibitors of some of the
metabolic pathways which are "switched on" in cancer patients, and the
effects of ttiese substances on tumour growth and host metabolism. 
This tumour model will also be useful in allowing predictions of 
likely nutritional and metabolic problems associated with the use of 
new drugs in cancer patients.
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CHAPTER 6t METABOLIC AND NUTRITIONAL EFFECTS OF CISDICHLORODIAMMINE 
(II) PLATINUM
Introduction
Since platinum was found to inhibit bacterial cell division in a 
chance observation by Rosenberg, van Camp and Krigas in 1965, develop­
ments and refinements of the metal have produced Cisdichlorodiammine 
platinum (II) or "Cisplatin", a potent broad-spectrum anticancer agent 
useful in both animal and human tumours. It is particularly 
effective in the treatment of teratomas, ovarian carcinomas, some lung 
tumours, bladder and cervical cancers, tumours of the head and neck, 
and in a number of childhood cancers; and its range of therapeutic 
uses is expanding (Williams & whitehouse, 1979).
with increasing use of Cisplatin, the side effects of treatment 
have become apparent. Early trials found nephrotoxicity to be the 
dose-limiting factor in treatment with Cisplatin (Krakoff 1979) and 
Gonzalez-vitale et al. (1977) found an acute tubular necrosis^  
involving particularly the distal tubules and collecting ducts, in 
the kidneys of patients who had died following Cisplatin 
administration. The nephrotoxicity, with increasing blood levels of 
urea and creatinine was found to be irreversible (Krakoff 1979). 
preventative measures using vigorous hydration and diuretics, usually 
mannitol or frusemide, have helped to diminish the incidence of fatal 
nephrotoxicity, and have allowed the escalation of doses (Madias &
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Harrington, 1978; Krakoff, 1979; Blachley & Hill, 1981). However, 
there is still microscopic renal damage associated with Cisplatin 
chemotherapy as demonstrated by Kuhn et al. (1980) Wio monitored the 
levels of Beta-2-microglobulin in the urine of patients receiving 
chemotherapy, and found increasing levels after treatment with 
Cisplatin, which persisted for at least 6 weeks post therapy, jones, 
et al, (1980) found increased levels of leucine aminopeptidase, 
N-acetylglucosamine and Beta-2-microglobulin in urine of patients 
treated with Cisplatin, indicating renal tubular damage, Whether 
this damage is reversible or not, is not yet clear.
Renal damage has been found to occur after only one dose of 
Cisplatin, and there may be accompanying, inappropriate losses of 
magnesium, calcium, potassium and amino acids in the urine (Bar, 
Wilson & Mazzaferri, 1975; Bitran et al., 1982). Renal toxicity is 
increased in patients who show elevated plasma platinum levels early 
in the course of an infusion, and this sign identifies patients at 
most risk of developing nephrotoxicity (Campbell, Kalman & Jacobs, 
1983). Gentamycin, and other aminoglycosides, produce a similar 
effect on the kidney, and if given concurrently with Cisplatin, may 
increase the nephrotoxicity of the drug (Baum et al., 1979). 
in a patient who has had previous nephrotoxicity with Cisplatin 
chemotherapy, administration of an aminoglycoside may precipi­
tate renal failure (Winkler, Mahr & De Bandi, 1979). Continued use of 
Cisplatin produces bilateral small kidneys on x-ray and ultra­
sound and this sign may precede the onset of renal failure
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(Friedman & Lantin, 1980).
Among the other side effects of Cisplatin, gastrointestinal 
toxicity is seen in the majority of patients. Nausea, in 50-100% 
patients, begins 1-6 hours following treatment with Cisplatin (von 
Hoff et al.  ^1979) . Anorexia and nausea may persist for up to a week 
following treatment, and anorexia tends to increase with continued 
courses of Cisplatin (Ohnuma & Holland, 1979). These side effects may 
be so severe as to cause Cisplatin therapy to be discontinued.
■ii
Diarrhoea is an occasional side effect of treatment; and liver 
enzymes may be mildly, but transiently, elevated (Williams & 
Whitehouse, 1979).
Myelosuppression occurs, and it is dose related and may be
cumulative (Williams & Whitehouse, 1979). Anaemia maybe severe, 
requiring transfusions during treatment. The cause of the anaenia is 
probably not decreased erythropç)«.tin production due to cytotoxic 
effects on the kidney, but a direct cytotoxic effect on the erythroid 
stem cells in the bone marrow, causing decreased production of red 
blood cells with some haemolysis ^ also/ of the circulating red cells 
(Rothmann & Weick, 1981). Leucopenia occurs particularly in patients 
who have been pretreated by cytotoxic drugs or radiotherapy^  with a 
reported incidence of 0-50% (Von Hoff et al., 1979). Throimbocytopenia 
is similarly dose related and frequency related and occurs in 2-50% 
patients (von Hoff et al., 1979).
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Ototoxicity with loss of hearing and tinnitus occurs in up to 30% 
patients and is probably irreversible (Williams & Whitehouse, 
1979) . Other neurological signs and neuropathies have been reported 
infrequently (von Hoff et al., 1979).
Schilsky & Anderson (1979) were the first to report hypomagnes- 
aemia following Cisplatin chemotherapy. Of thirty-seven patients 
studied they found twenty-two patients became hypomagnesaamic 
following treatment. Four of these patients had inappropriately high 
levels of urinary magnesium Implicating renal tubular damage as the 
cause of the hypomagnesaemia. A further study by Schilsky, Barlock & 
Ozols (1982) found hypomagnesaemia in twenty-two of twenty-four 
patients treated with Cisplatin. Eleven of the twenty-two were 
persistently hypomagnesaomic two years after treatment, and eight 
out of nine patients had persistently high urinary magnesium levels. 
This hypomagnesaemia was not related to the total dose of Cisplatin 
administered, or to the serum magnesium nadir during treatment; and 
there was no evidence of gross renal failure, with serum creatinine 
levels remaining normal. None of these patients developed hypo- 
calcaamia or hypokalaemia; although a number of authors have found 
both hypokalcaomia and hypokalaemia in association with the hypo- 
m^nesaamia produced by excessive loss of magnesium in the urine 
(Lyman et al., 1980; Hill & Russo., 1981; Cognetti et al., 1982). The 
symptoms of hypomagnesaemia may at first be vague and non-specific, 
similar to the side effects of Cisplatin treatment, with general 
malaise, anorexia, nausea, depression and irritability. Continued
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and severe hypomagnesaania may cause muscle twitching and induce 
hypocalcaania and severe electrolyte disturbances leading to tetany 
and fits (Stuart-Harris, ponder and Wrigley, 1980; Hayes et al., 
1979), Muscle twitching, and tetany have been reported in 5-10% 
patients receiving Cisplatin {Williams & Whitehouse, 1979) . 
Magnesium deficiency may also produce electrocardiographic abnormali­
ties, with myocardial arrhythmias, and has been implicated in some 
cases of myocardial infarction (Dykner, 1980; Shilsky 1982; Speich, 
Bousquet & Nicolas, 1980).
in summary, therefore, Cisplatin is a good cytotoxic agent but 
has a number of potentially serious drawbacks. Nephrotoxicity is the 
major dose-limiting side effect; and hypomagnesaemia induced by the 
renal damage may exacerbate Cisplatin-induced anorexia, nausea and 
electrolyte disturbances, may have a role in myocardial arrhythmias, 
and may cause further renal problems by inducing nephrocalcinosis 
(Bunce, Saacke & Mullins, 1980).
Aims
The aims of the studies were to examine the effects of Cisplatin 
on the nutritional state and aspects of metabolism in animals and 
cancer patients.
A preliminary study examined the effects of escalating doses of 
Cisplatin on rat tissues, looking particularly at kidney and heart
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muscle, for evidence of the reported toxicity of Cisplatin,
Clinical studies were then designed to monitor the effect of 
Cisplatin treatment on electrolyte, calcium, magnesium and trace metal 
levels in the plasma of patients receiving Cisplatin in the treatment 
of teratoma. The acute effects of Cisplatin on these elements were 
observed during the five day treatment period; the longer term 
effects were assessed by comparing results obtained during the first 
course of treatment with those from the fourth course of treatment. 
Those elements which may require monitoring or supplementation 
during treatment were identified.
Further clinical studies examined the effects of Cisplatin 
administration on dietary intake and on renal function. The use of 
magnesium supplements was monitored to determine their usefulness 
for the patient by their effects on the tolerance to treatment and 
outcome of treatiment. The optimum method of magnesium supplementa­
tion for both patient and hospital staff was also investigated.
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A. EFFECTS OF CISPLATIN ON RAT TISSUES
Methods
Female albino wistar rats, all 10 weeks of age and weighing 
160-170 grams were used for this study, Cisplatin doses ranging from 
2 mg/Kg, 6 mg/Kg, 2Cmg/Kg to 30 mg/Kg body weight were administered
intraperitoneally. Each group of rats contained two animals. the 
rats were sacrificed using ether inhalation six days after the 
administration of Cisplatin.
Following sacrifice, the heart, liver, kidney, soleus and gastro­
cnemius muscles were removed and a sample of each frozen immediately 
in liquid nitrogen for electron microscopic examination and 
histochemical staining. The remaining tissue was fixed in formal 
saline for histological examination. processing of the tissues was 
carried out at Institute of Neurological Sciences, Southern General 
Hospital, and reporting of the results obtained was undertaken by 
Dr, David Doyle, Consultant Neuropathologist, Southern General 
Hospital, Glasgow.
Results
Kidney structure was much more markedly affected than Structure of 
any of the other organs. All organs, however, showed, similar 
patterns of cellular and subcellular damage with the greatest i-
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disruption present at the highest doses of Cisplatin.
in the kidney, there were few microscopic changes evident at 2 
mg/Kg dose of Cisplatin ; at 6 mg/Kg, the LD^dose of Cisplatin, there 
is evidence of mild tubular atrophy affecting^  preferentially,the 
distal tubules (plate 2). At 20 mg/Kg and 30 mg/Kg doses there is 
extensive damage to both proximal and distal renal tubules with 
mineralised cellular debris, protein casts and red cell casts present^  
indicating leakage of these materials from the tubular lining cells 
and failure of reabsorption of filtered protein and minerals. The 
glomeruli appear relatively normal, in all sections examined there is 
evidence of regenerative mitotic activity in the tubular cells, 
following the necrosis caused by the Cisplatin insult. Damage is most 
widespread in the 30 mg/Kg Cisplatin animals (plate 3).
The site of intracellular damage was identified by enzyme 
histochemistry as being in the mitochondrion. in all the tissues 
examined, kidney, heart, liver and muscle, mitochondria were reduced 
in numbers and were shown to be least actively functioning at the 
highest doses of Cisplatin.
Electron microscopy of the tissues showed reduced numbers of 
mitochondria which were large, with increased numbers of internal 
cristae; the changes being most evident at the highest doses of 
Cisplatin.
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PLATE 2: RAT KIDNEY SHOWING MINIMAL ACUTE DAMAGE FOLLOWING
INTRAPERITONEAL ADMINISTRATION OF 6mg/Kg 
CISPLATIN (MAGNIFICATION x 100)
PLATE 3: RAT KIDNEY SHOWING SEVERE, ACUTE TUBULAR DAMAGE
WITH RELATIVE SPARING OF GLOMERULI FOLLOWING 
INTRAPERITONEAL ADMINISTRATION OF 20mg/Kg CISPLATIN 
(MAGNIFICATION x 100)
Conclusions
These findings confirm the presence of renal damage due to 
Cisplatin administration, the severity of damage increasing with 
escalating doses of Cisplatin. The renal tubules are severely 
affected, particularly the distal tubules, while there is relative 
sparing of the glomeruli, even at the highest doses of Cisplatin. 
Magnesium and other minerals are not reabsorbed from the glomerular 
filtrate due to the tubular damage, and are therefore excreted 
excessively.
At a cellular level, the increased size of the mitochondria with 
increased numbers of internal cristae indicate hypertrophy of the 
remaining mitochondria, to compensate for the reduced numbers of 
mitochondria produced by the toxic effects of Cisplatin. The role of 
magnesium deficiency in the mitochondrial changes is uncertain. 
Magnesium is an essential mitochondrial cation which is necessary for 
efficient functioning of the mitochondrion, it may be that magnesium 
loss in the urine is due to mitochondrial damage with consequent 
release of intramitochondrial constituents. The primary cause of the 
mitochondrial changes is the Cisplatin administration; the magnesium 
deficiency produced by this may exacerbate the problem, and further 
diminish mitochondrial activity. The mitochondrial changes may also 
be a reason for the inefficient metabolism, weakness, weight loss and 
anorexia seen in cancer patients.
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In summary, there is evidence of cellular and mitochondrial 
damage in liver, heart, kidney and muscle as a direct result of 
Cisplatin administration. Further studies should aim to elucidate 
the role of magnesium in these changes. Studies should examine the 
effects of a range of serum and tissue magnesium levels on 
mitochondrial function, looking for similarities in the patterns 
obtained to the Cisplatin effects. An evaluation of the use of 
magnesium supplements in reversing or preventing the mitochondrial 
damage should also be undertaken.
It will be difficult to evaluate the contribution of Cisplatin 
induced mitochondrial damage to the metabolic changes seen in tumour 
bearing animals treated with this chemotherapeutic drug (Chapter 5); 
and it will be interesting to repeat the experiment discussed in 
Chapter 5 using varying doses of Cisplatin in animals with and without 
tumour. Measurements of animal weights, tumour growth, liver 
enzymes, ketone bodies, total protein and albumin levels and plasma 
iron levels would be compared in the drug alone, drug and tumour and 
tumour alone groups with escalating doses of the drug, looking for 
the effects of increasing mitochondrial dysfunction.
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Clinical Studies
B. EFFECTS OF CISPLATIN ON TRACE METAL LEVELS IN BLOOD 
Methods
Seven patients with histologically proven teratomas were studied 
in detail during their first five-day course of combination 
chemotherapy using, Cisplatin, vinblastine and Bleomycin in a 
modification of the Einhorn regime (Fig. 20) (Einhorn & Donahue,1977). 
Four patients were studied again during their fourth course of 
treatment. patients were hydrated with 4 litres 0.9% saline, daily, 
to establish a good diuresis, and Cisplatin 20 mg/m^ was administered 
on each day for five days. The Cisplatin infusion was timed to start 
at 6 p.m. each evening, to minimise diurnal variations in the levels 
of trace metals in the samples.
- "ï-Æ'
Blood samples were taken 1 hour prior to the start, and at the 
end of the 4 hour Cisplatin infusion. Samples were taken on each day 
of the first and fourth courses of treatment.
The blood was centrifuged immediately and the plasma stored at 4 
degrees centigrade. plasma was analysed for sodium, potassium, 
calcium, magnesium, zinc, copper, iron, albumin and creatinine, 
urine was collected continuously for the five treatment days and 
was analysed for potassium, calcium, magnesium, zinc, and 
creatinine, A plastic collection bottle was used for the urine to 
eliminate contamination from trace metals present in the disposable 
type of container. All analyses were performed at Department of 
Biochemistry, Gartnavel General Hospital, Glasgow under the 
supervision of Mrs. Jean McAllister.
___
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MODIFIED EINHORN REGIME
Cisplatin 20 mg/m 4 hr. i.v. infusion
vinblastine 0.15-0.20 mg/kg 
i.V. bolus
Bleomycin 30 mg 4 hr, i.v. 
infusion
Days 1-5
Day 2 
Day 2
repeated 
3 weekly
weekly
4 courses of treatment then patients reassessed
Consolidation treatment - 2 courses given
If partial response to original treatment
Cisplatin lOO mg/m 4 hr. i.v. 
infusion Days 1 & 2 )) repeated 
) 3 weekly
vinblastine 0.15 mg/kg i.v. bolus Days 1 & 2 )
i.v. = intravenous 
4 hr. = over 4 hours
FIGURE 20: MODIFIED EINHORN REGIME FOR CISPLATIN COMBINATION
CHEMOTHERAPY
 : : ......
Results
patients ages ranged from 20-32 years. All had histologically 
proven teratoma: 6 were testicular; 1 was mediastinal. All patients
studied had evidence of metastatic spread of disease in the paraaortic 
lymph nodes or lungs, or both sites. Three of the patients had had 
previous radiotherapy. Following initial chemotherapy, four patients 
had two further courses of consolidation treatment (Cisplatin 100 mg/m"^  
on two days, with vinblastine 0.15 mg/Kg on both days) (Fig. 20) and 
six of the original seven patients had no evidence of disease or
recurrence up to two years after the end of treatment. One
patient developed septicaemia and severe electrolyte disturbances 
following course four, and died from these complications.
All patients experienced considerable nausea and vomiting during 
treatment. Five of the patients had treatment delays due to low white 
blood cell counts following the previous course of treatment.
Three patients had septicaemia episodes and three required blood
transfusions during treatment (Table 25).
Two patients gained weight during treatment (8.5 Kg and 2 Kg 
respectively); and four patients lost on average 7.5 Kg weight (range 
2.5 Kg to 11 Kg) during treatment (4% to 15% body weight),
plasma levels of sodium, copper and albumin showed no significant 
change during the 5 days of treatment or between the first and fourth
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Side Effects No. Patients ?□ Patients
Nausea 7 100%
Vomiting 7 100%
Treatment delays 5 71%
Neutropenia 5 71%
Septicaemia 3 43%
Blood transfusion 3 43%
Weight gain 2 28%
Weight Loss 4 57%
TABLE 25: SIDE EFFECTS OF TREATMENT WITH CISPLATIN
courses. Serum creatinine showed no change over the period of 
treatment, indicating no significant renal damage in any patient. 
Plasma calcium, magnesium, zinc and iron results are suntnaris^ in 
Figs. 21,22,23 and 24. During the five days of treatment, plasma 
calcium levels rose; and plasma iron levels showed a particularly 
marked rise, plasma levels of magnesium showed a slight,but not
significant,fall over the 5 days of treatment; while zinc levels fell 
slightly and then returned to pretreatment levels during the treatment 
period.
Table 26 compares the levels in first and fourth courses. The
levels of calcium and zinc in the blood showed no significant 
difference between the first and fourth courses. Two of the four 
patients studied during the fourth course of treatment showed elevated 
levels of plasma iron compared to the first course. plasma magnesium 
levels in three out of four patients were markedly reduced in the 
fourth course compared to the first course. Two of three patients who
had pretreatment radiotherapy showed marked falls in magnesium levels.
Over the five-day treatment periods, urinary excretion of sodium 
increased in keeping with the saline load administered and the
saline diuresis produced in these patients. potassium excretion 
decreased over the five days. Excretion of calcium, magnesium and
zinc remained constant or showed a slight increase in amount. These 
changes were also seen in the fourth course of treatment, and there was
no significant difference in levels between first and fourth courses.
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CALCIUM (Mean ± S.E.M.)
PLASMA CALCIUM 
nrimoi /  L
FIGURE 21; PLASMA CADCIUM LEVEES OVER 5 DAYS INPATIENT TREATMENT, DURING FIRST COURSE OF CISPLATIN CHEMOTHERAPY
__________________________ __________ ______
IRON +  S.E.NI.)
PLASMA IRON
jumol / 150-1
30
1
5
FIGURE 22 PLASMA IRON LEVELS OVER 5 DAYS INPATIENT TREATMENT DURING FIRST COURSE OF CISPLATIN CHEMOTHERAPY
M A G N E S I U M  (Mean ± S.E.M.)
PLASMA MAGNESIUM 
mmoi /  L
10-1
06
FIGURE 23 PLASMA MAGNESIUM.LEVELS OVER 5 DAYS INPATIENT TREATMENT 
DURING FIRST COURSE OF CISPLATIN CHEMOTHERAPY
Z I NC(Meàn ± S.E.Mv)
PLASMA ZINC 
>im6l /  I
20-1
FIGURE 24 PLASMA ZINC LEVELS OVER, 5 DAYS INPATIENT TREATMENT DURING FIRST COURSE OF CISPLATIN CHÉM0THEÎ2APY '
_
' Calcium ■ Magnesium Zinc iron Copper
1st 4th 1st 4 th 1st 4 th 1st 4 th 1st 4 th
JM
A A 
2.25 2.14 0.66 0.64 9.7 8.4 14 32
A
23.9
A
13.8
WS 2.18 2.03
A
0.85
A
0.41 14.6 14.7
B
21
B
33 24.4 21.1
GP
B B 
2.21 2.39
A
0.71
A
0.60 9.6 8.9 25 21 13.2 12.5
SG —
B
0.74
B
0.62 10.6 12.2 29 27 -
significant changes AA p < O.OOl Between 1st and 4th
courses BB p < 0.005
TABLE 26: COMPARISON OF TRACE METAL, MAGNESIUM AND CALCIUM
LEVELS BETWEEN 1st AND 4th COURSES OF CISPLATIN 
TREATMENT
Conclusions
The changes seen in plasma levels of the trace metals and 
electrolytes are similar to those seen during an acute illness and are 
not specific to cancer patients or Cisplatin chemotherapy (Kay, 1981) . 
The "stress response" accounts for the changes in plasma zinc seen 
during treatment (Delves, 1982); and the increased sodium excretion has 
been explained by the forced saline diuresis. The increased plasma 
iron levels were most marked in those patients who required blood 
transfusions during treatment, and would suggest a failure of iron
utilisation in these patients, giving rise to anaemia. This would be
accounted for by the decreased production of erythrocytes due to 
cisplatin effects on the erythoid precursors (Rothman & Weick, 1981). 
Supplementation of iron would be of no benefit to these patients.
From the results obtained, there is no evidence that routine 
supplementation of the trace metals in general is necessary in this 
group of patients. However nutritional support and magnesium 
supplementation may be beneficial. Nutritional depletion was seen in 
50% patients, who had weight loss of greater than 10% body weight; and 
these patients were most likely to have treatment delays due to
neutropenia. poor nutritional status will contribute to^  and prolong
Cisplatin-induced myelosuppression ^ and may influence the eventual 
outcome of treatment by delays which prevent adequate treatment of the 
tumour.
Most patients showed a fall in serum magnesium levels and two
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patients became symptomatic requiring treatment with magnesium 
supplements. These were patients who had lost most weight (11 Kg:and 9 
Kg each) , who had delays of treatment due to low white blood cell 
count, and vho required transfusions for anaemia.
The causes of hypomagnesaemia are multifactorial. The most common 
cause ascribed to Cisplatin treatment, renal magnesium wasting, was 
seen in only one of the seven patients studied; the others shoved a 
tendency to conserve magnesium by reducing its excretion in the urine.
Anorexia and nausea induced by treatment may play a part in 
hypomagnesaemia: decreased food intake with only 30% absorption of
ingested magnesium (Wacker & parisi,1968), may exacerbate the 
deficiency of magnesium. Qhnuma & Holland (1979) state that the 
anorexic effects of Cisplatin increase with repeated exposure to the 
drug. There may, in addition, be malabsorption induced by Cisplatin 
and vinblastine, with diarrhoea which may compound the problem, 
vomiting can account for significant magnesium losses, with up to 25% 
total body magnesium present in gastric juice (Wacker & parisi, 
1968) . The "soft" water in the West of Scotland with its low levels of 
calcium and magnesium ions will not help to replete a depleted 
patient between courses of chemotherapy, Shi1sky et al. (1982) 
also contend that the forced saline diuresis, with mannitol 
infusions, required for the Cisplatin regime of treatment will produce 
increased and inappropriate losses of magnesium in the urine. Some 
or all of these factors may be operating in each of the patients 
receiving Cisplatin.
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Table 27 shows the serum magnesium levels over a nine month period 
in nineteen patients receiving the modified Einhorn regime of
Cisplatin, vinblastine and Bleomycin (Fig. 20) at 3-4 week intervals 
for teratoma. All nineteen patients became hypanagnesaenic (serum 
magnesium less than 0;*7Ommol/1) by the fourth course of chemotherapy; 
and eleven patients developed serum magnesium levels below 0.50 irmol/l. 
These eleven patients had associated abnormalities of serum calcium and 
potassium levels, and had symptanatic hypomagnesaenia. All responded
to intravenous magnesium supplementation which restored levels of
magnesium, calcium and potassium to normal in all but three patients, 
who required potassium supplements in addition.
2Six patients receiving "high dose" Cisplatin (50 mg/m ) over , one 
day at 3-4 weekly intervals for ovarian carcinoma were monitored for
changes in serum magnesium levels (Fig. 25). All six patients had
serum magnesium levels below 0.70 mmpl/1 after four courses of 
treatment. Three of the patients had levels below 0.50 mmol/1 and one
patient's magnesium level fell below 0.30 mmol/1.
in summary, although the trace metals do not require to be
routinely supplemented in patients receiving Cisplatin, there is weight 
loss, anorexia, general nutritional depletion and hypomagnesaemia which, 
if severe and prolonged, leads to potassium and calcium depletion. 
Further studies were performed on teratoma patients receiving Cisplatin 
to examine the effects of magnesium supplementation on outcome, side
effects and toxicity of treatment; and to look at the effects of
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Plasma Magnesium 
(mmol/1) Range
0.60
0.30
0.40
0.30
0.20
0.69 
0.39 
0.49 
0.39 
0.29
Number of Patients (19)
No. with No. with Potassium
Total Calcium *2.2 #01/1 <3.3wmol/l
4 (21%/ : 0 0
: 4 (21%) 0 0
3 (16%) 0 1 (33%)
3 (26%) 1 (10%) 3 (60%)
3 (16%) 1 (33%) 2 (67%)
TABLE 27; LOWEST RECORDED PlAGNESIlH,, CALCIUM AND POTASSIUM
LEVELS DURING TREATMENT IN ALL PATIENTS RECEIVING 
CISPLATIN OVER A NINE MONTH PERIOD
Tv,
_ s i â i s y s
cisplatin 50 mg/m 4 hr.intravenous infusion
Day 1 and 
every 4 
weeks
Adriamycin 45 mg/m intravenous BOLUS
Cyclophosphamide 600 mg/m intravenous BOLUS
4 hr = over 4 hours
CHEMOTHERAPY REGIME FOR OVARIAN CANCERFIGURE 25
_____________________
cisplatin, with and without magnesium supplements^on dietary intake and 
renal function. The palatability of magnesium supplements was also 
tested,
C. EFFECTS OF MAGNESIUM SUPPLEMENTATION IN PATIENTS RECEIVING 
CISPLATIN
Methods
Seventeen patients receiving Cisplatin chemotherapy for the first 
time were randomised to receive supplements of magnesium or not. 
patients received Cisplatin either in doses of 20 mg/n^as the modified 
Einhorn regime (Fig. 20) or in doses of lOO mg/m^over one day (Fig. 
26). Saline diuresis, with the administration of mannitol as re­
quired, was used as in the previous study.
The magnesium status of each patient was assessed prior to 
therapy by giving a loading dose of magnesium sulphate, 0.25 mmol/Kg 
body weight intravenously over 30 minutes and collecting all urine for 
the following 24 hours. Levels of magnesium in the urine Wiich 
exceeded 80% intravenous dose indicated normal body stores of 
magnesium. patients were stratified depending on their magnesium
excretion, whether above 80% or below 80% of the intravenous loading 
dose. Each patient was then randomised to receive magnesium
supplements or not. The levels of supplementation depended on
the dose of Cisplatin used (Fig. 27), and was based on the 
recommended daily intake of magnesium (DHSS, 1979). Intravenous
131.
_________________________
Initially
Cisplatin lOO ng/m 4 hr. i.v. infusion
vincristine 2 mg i.v. bolus
Bleomycin 30 mg 4 hr. i.v. infusion 4 hours)
Days 1, 10, 21
After 3 weeks
Cisplatin 20 mg/m daily 4 hr. i.v. infusion
Days 1-5
Bleomcyin 30 mg. 4 hr. i.v. infusion Day 1 
2
V.P.16 loo rng/m i.v. infusion Days 1-5
3 weekly
i.v. = intravenous 
4 hr. =' over 4 hours
FIGURE 26: "HIGH RISK" CHEMOTHERAPY FOR TERATOMA
  : : ' . _ ■
Randomisation depending on dose of Cisplatin:
21. Cisplatin 20mq/m for 5 days (Modified. Einhorn Regime) 
All patients randomised to:
A - Supplements or 
B - No Supplements
A. Magnesium sulphate:
Magnesium citrate:
8 mmol in 500 mis 0.5% saline intravenously 
over four hours following Cisplatin infusion 
over each five days of treatment,
5 mmol t.i.d. orally daily after intravenous 
infusion is discontinued.
2, Cisplatin lOOmq/m for 1 day 
All patients randomised to:
C - Supplements or 
D - No Supplements
C. Magnesium sulphate:
Magnesium citrate:
24 mmol in 500ml 0.9% saline intravenously 
over 12 hours following Cisplatin infusion.
5 mmol t.i.d. orally daily after intravenous 
infusion is discontinued.
FIGURE 27: RANDOMISATION SCHEDULE FOR MAGNESIUM SUPPLEMENTS
________ ___ _______
supplementation was given as magnesium sulphate, 8 irmol in 500 ml 0.9% 
saline over four hours immediately following the Cisplatin infusion. 
Once the intravenous infusion was discontinued, oral magnesium 
supplements were given to supply 30 mmol magnesium daily (lo mmol 
thrice daily) . This was estimated to provide each patient with the 
recommended daily intake of magnesium of at least 8 mmol, allowing for 
30% absorption of ingested magnesium (Wacker & parisi, 1968).
patients were grouped and compared according to initial prognosis, 
as determined by tumour volume and extent (Fig. 28); and five day and 
one day ("High Dose") Cisplatin groups were also compared. Assessments 
were made for each group of final outcome, rate of fall of tumour 
markers, treatment delays, weight changes and episodes of neutropenia 
and septicaemia. Changes in dietary intake and renal function were
noted, and palatability of and compliance in taking magnesium
supplements were assessed. Tumour growth in each patient was assessed 
weekly using clinical, biochemical and radiological evaluation.
A magnesium infusion test and a creatinine clearance test to
assess renal function were performed prior to the first course of
treatment. Creatinine clearance estimations were also made before
each course of chemotherapy.
Daily measurements of full blood count and platelets were 
performed during each course of treatment at Department of Haematology,
Western Infirmary, Glasgow. Blood levels of urea and electrolytes and
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patients are assessed clinically, radiologically and by tumour marker (human chorionic gonadotrophin and 
alphafeto protein) levels. These place them into 
high volume métastasés (High risk) group or low volume 
métastasés (good prognosis) groups. High risk group 
have 60% complete response rate; good prognosis 
group have 90% complete response rate.
High volume 
métastasés LOW volume métastasés
Clinicalstage
lie
III M3
III N3
IV L2 
IV L3 
Bone 
Brain 
Liver
IIA 
I IB
III Ml
III M2 
III Nl
III N2
IV Ll
■"-II
Tumour
markers
HCG
AFP
> 50,000 ng/ml
> 500 ng/ml
< 50,000 ng/ml
< 500 ng/ml
FIGURE 28: ASSESSMENT OF PROGNOSIS IN TERATOMA
i
magnesium were measured daily; and liver function tests, zinc and 
calcium levels and the tumour markers, human chorionic gonadotrophin
and alphafeto-protein were measured weekly.
urine samples were taken daily during the five day inpatient 
treatment and were analysed for beta-2-microglobulin, N-acetylgluco- 
samine and magnesium levels. All biochemical estimations were 
performed at Department of Biochemistry, Gartnavel General Hospital, 
Glasgow.
During the inpatient treatment period, and at intervals betv^en 
courses of treatment, each patient had 24-hour dietary recall histories 
taken, and computer analysis of these gave an estimate of the dietary 
intake over a course of treatment (see Chapter 2 for method) .
patients who received supplements were assessed for compliance in 
taking the supplements
Results
Seventeen patients were studied in detail, M;F ratio being 16:1. 
Eight patients were randomised to receive supplements of magnesium over 
the first four cycles of treatment; nine patients received no supple­
ments. NO patients were magnesium deficient before treatment. Seven 
of the supplemented group received Cisplatin over 5 days as in the 
modified Einhorn regime; six of the non supplemented group received 
this regime. The other patients, one in the supplemented group and
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two in the non-supplemented group received^initially^ one day courses
of"high dose" Cisplatin at shorter intervals (Fig. 26) The ages of
patients in the supplemented group ranged from 18-39 years (mean 29 
years); in the nonsupplemented group ages ranged from 22-47 years 
(mean 33 years) . Three of the patients in the supplemented group and 
four in the non-supplemented group were in the bad prognosis "high 
risk" group. The cumulative platinum for each group was similar for 
both supplemented and non-supplenented groups (Table 28). One patient 
in the supplemented group and two patients in the non-supplenented 
group had received pretreatment radiotherapy.
Dietary intake
All patients were nauseated during treatment and vomited following 
Cisplatin administration; there was no difference between 
supplemented and non-supplemented groups. Anorexia and dietary intake 
were similar for both groups and the intakes of energy, protein, 
vitamins, minerals and magnesium followed a similar pattern through 
each complete treatment cycle. Figure 29 illustrates the effect of 
Cisplatin treatment on dietary intake, using energy intake to represent 
all dietary components, and taking a typical cycle from one course of 
treatment to the next. All patients, including those receiving high 
dose one-day treatment, and using results from all courses of 
treatment, have been used in this graph. This shows that dietary in­
take decreases from day 3 of Cisplatin treatment, and remains low for 
at least ten to twelve days following Cisplatin. Intake returns to
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Modified Einhorn regime
High dose Cisplatin
Ages (mean)
Prognosis - high risk
- good prognosis
M:F
Cumulative platinum/patient- high risk
- good prognosis
pretreatment radiotherapy
Supplemented Patients (8)
18-39 yrs (29 yrs)
3
5
8:0
890 mg 
740 mg
Non-Supplemented Patients (9)
22-47 yrs (33 yrs)
4
5
8:1
902 mg 
719 mg
TABLE 28: CHARACTERISTICS OF PATIENTS RECEIVING CISPLATINWITH AND WITHOUT MAGNESIUM SUPPLEMENTS
_______ __________   '.......
CISPLATIN CISPLATIN
TREATMENT 'TREATMENT
KCal
3000
2000
1000
PRETREATMENT 1 19
_______  DAYS OF _____
CISPLATIN TREATMENT DAYS POST-CtSPLATIN TREATMENT
EFFECT OF CISPLATIN: TREATMENT ON ENERGY INTAKEFIGURE 29
 :
normal from day 12; however treatment may restart any day from day 16 
onwards, leaving very few days of improved intake to compensate for a 
fortnight of reduced intake, intake falls on average to 50% or less of 
the pretreatment intake.
Figure 30 compares the intake during course one and course four 
of treatment. Although there is a similar decrease in intake over the 
first five days of treatment, the patients during course one recover 
more quickly, with improved intake fran day 3 post-Cisplatin. intake 
returns to pretreatment levels by day 10. Intakes during course four 
start at the same mean pretreatment-level as in course one, but fall 
further following Cisplatin, and renain low for longer than in course 
one. There were too few results of dietary intake analysis for each 
individual patient to allow statistical analysis of the curves 
obtained. This agrees with the suggestion by Ohnuma & Holland (1979) 
that Cisplatin has a cumulative effect on appetite suppression. i
Toxicity of treatment
Table 29 gives the results and side effect of treatment for the 
supplanented and non-supplenented groups; and table 30 compares the 
effects of treatment of the 5 day Cisplatin regime and the 1 day "High 
Dose" regime. There is no significant difference in outcome between 
the supplanented and non-supplanented groups; and the rate of fall of 
tumour markers^ indicating response to treatment, does not differ 
between the groups. Tumour growth as determined by clinical
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CISPLATIN CISPLATIN
{TREATMENTTREATMENT
■ • c y c l e  1
KCal
3 0 0 0 —  X CYCLE 4
2000
1000
PRETREATMENT 1
DAYSOF DAYS POST-CISPLATIN TREATMENTCISPLATIN TREATMENT
COMPARISON OF ENERGY INTAKES BEIWEEN CYCLES 1 AND 4 OE 
CISPLATIN TREATMENTFIGURE 30
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Supplementedpatients Non-Supplenented patients
Good Bad Total Good ' Bad Totalprog­
nosis
(5)
prog­
nosis
(3) (8)
prog­
nosis
(5)
prog­
nosis
(4) (9)
OutcomeComplete response 5 1 6(75%) 5 1 6(67%)Partial response - 2 2(25%) 2 2(22%)Died - - - 1 1(11%)
Treatment delays 2 1 3(38%) 3 3 6(67%)
Weight changes
Gain 1 — 1(13%) - »Stable 1 1 2(25%) 1 - 1(11%)LOSS 3 2 5(63%) 4 4 8(89%)
Neutropenia 4 2 6(75%) 4 4 8(89%)
Septicaemia 1 1 2(25%) 0 1 1(11%)
Anaemia and
transfusions 2 — 2(25%) 1 1 2(22%)
Hypokalaamia (mmol/1)
Borderline (3.0-3.5) 2 1 3(38%) 4 2 6(67%)LOW (< 3.0) 1 1(13%) 1 2 3(33%)
Hypomagnesaemia 
(ntnol/1) 
Borderline (0.70-
0.50) 3 2 5(63%) « 1 1(11%)LOW (< 0.50) 2 2(25%) 5 2 7(77%)
Renal failure 0 0 0 0 0 0
TABLE 29: EFFECTS OF TREATMENT WITH CISPLATIN IN MAGNESIUM
SUPPLEMENTED AND NON-SUPPLEMEÜTED GROUPS
 :
Supplemented Non-Supplenented
OutcomeComplete response 
partial response 
Died
Delays in treatment
Weight changes Gain 
Stable 
Loss
Neutropenia
Septicaemia
5 Day Course 
(7)
Anaemia and transfusion
Hypokala^ia (mmol/1) Borderline (3-0 - 3.5) LOW (< 3.0)
Hypomagnesaemia . (mmol/1 ) . 
Borderline (Ô.70 - 0.50) 4 
LOW (< 0.50) 2
Renal failure 0
1 Day 
Course 
(1)
0
5 Day Course 
(7)
0
1 Day Course 
(2)
2
0
■4'l
*a
'"Si
TABLE.30: EFFECTS OF TREATMENT IN GROUP RECEIVING 5 DAY COURSECISPLATIN VS GROUP RECEIVING 1 DAY HIGE DOSE CISPLATIN
radiological and biochemical (tumour markers) evaluation was similar 
for both groups.
Of the side effects of treatment, the supplemented group shows a 
trend towards fewer treatment delays compared to the non-supplemented 
group, however this is not statistically significant. There is a 
similar trend for prolonged neutropenic episodes, which was the main 
cause of the treatment delays. All patients receiving high dose 
Cisplatin and all patients who had pretreatment radiotherapy had delays 
in treatment and neutropenic episodes, whether on supplements or not.
Anaemia requiring blood transfusion occurred with similar 
frequency in supplemented and non-supplamented groups.
Weight changes showed no signficant differences between 
supplemented and non-supplemented groups. The patient who gained 
weight in the supplemented group gained 3 Kg, and showed complete 
response to treatment. The average weight loss in this group was lo Kg 
with the range being 8 Kg to 12.5 Kg. in the non-supplemented group 
the average weight loss was 11 Kg; the range in this group being from 
2 Kg to 25 Kg. Those patients in both groups with the greatest weight 
loss tended also to be the partial responders to treatment, and had the 
lowest dietary intakes, in general, weight loss correlated with out­
come: those patients, in either group, with the greatest weight loss
tended to respond poorly to treatment. Individual weight variations, 
however, were wide in the complete responder group, so it is probably 
not a useful predictor of outcome for individual patients. Serum
136.
 _ . .
magnesium levels are significantly higher in the supplemented group 
compared to the non-supplemented group (p < O.Ol using paired t-test) 
(Fig, 31; Table 31). Serum potasium levels were not significantly 
different between the groups, although two of the .non-supplemented 
patients required potassium supplements.
Renal function
There is a much higher excretion of magnesium by the supplemented 
group of patients during the 5 days of intravenous therapy* The 
non-supplemented group, however, shows an obligatory average daily loss 
of 3 mmol magnesium. Since the supplemented patients were receiving 8 
mmol magnesium daily as supplements, there is retention of between 1 
and 3 mmol magnesium in the supplemented group. urinary potassium 
levels fall in both groups, with no significant difference,between 
groups. It will be interesting in future to monitor the effect of 
increased levels of supplements on urinary magnesium levels, which will 
allow assessment of the body retention of magnesium. It proved 
impossible in this study to collect urine between courses, , and to 
monitor magnesium excretion over this period, , ‘
■1
...
The results of the renal function tests show that all patients 
have an increase in levels of N-acetyl glucosamine in the urine as 
treatment progresses (Table 32). Beta-2-microglobulin levels parallel 
the changes in N-acetyl glucosamine levels. N-^ acetyl glucosamine is 
an enzyme produced by kidney tubular cells and is an indicator of renal
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FIGURE 31 LOWEST SERUM'MAGNESIUM LEVELS IN MAGNESIUM SUPPLEMENTED AND NON-SUPPLEMENTED GROUPS
______________' :
supplemented
patients:
Non-Supplemented 
patients
Lowest serum magnesium level 
(mean) (mmol/1)
Lowest serum potassium level 
(mean) (rmiol/1)
urinary magnesium 
excretion 
(mean) (irmol/day)
overall urinarypotassium excretion 
(compared to normal)
A
0.59
3.19
8-10
decreased
A
0.47
3.07
decreased
Significance AA p < 0.01
TABLE 31: COMPARISON OF MEAN MAŒESIUM A m  POTASSIUM. LEVELS =----- IN SERUM AND URINE OF MAGNESIUM SUPPLEMENTED AND
NON-SUPPLEMENTED GROUPS OF PATIENTS RECEIVING 
CISPLATIN
________ __ ______ ___ L  J   '
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Patients
Levels of N-acetyl glucosamine 
(x upper limit normal)
No Supplements
A.B.P.W.
M.W.
W.MCA.
W.D.
J.H.W.M.
P.McM.
K.F.
Supplements
Course 1
1.61.71.62.3 
0.3
1.5 
1.9
2.5
6.3
Course 2 
1.8
2.0
2.71.6
1.42.2
3.5
3.8
Course 3
6.6
2.2
2.7
0.92.0
3.6
4.6 
>14
Course 4
5.53.8
1.53.91.62.0 
3.0
>10
C.P. 1.4 : 1.9 1.4 2.6K.MCG 5.9 * 4.0 2.1 2.3A.A. 0.9 0.9 0.7 0.5W.M. — 2.4 1.6 2.0
C.D. 0,9 1.1 1.2 1.5
R.L. 1.6 1.6 1.2 4.1
J.F. 0.3 1.9 1.1 1.4P.MCD. 0.6 0.5 0,9 1.0
Mean levels non-supplemented group to supplemented group comparing magnesium 
levels course 1 to course 3.
Significance p < 0,01
TABLE 32: LEVELS OF N-ACETYL GLUCOSAMINE IN MAGNESIUM SUPPLEMENTED ANDNON SUPPLEMENTED GROUPS OVER 4 COURSES OF CISPLATIN
tubular damage. Beta-2-microglobulin is a low molecular weight protein 
present in the serum, filtered by the glomerulus and reabsorbed in the 
tubules. Measurement of its levels in serum and urine gives an 
estimate of overall renal function (Morgan, 1982). The results 
obtained show that,despite adequate hydration and good diuresis in 
these patients ^  there is progressive renal damage with, 
particularly, renal tubular damage occurring, although this is not 
gross enough to affect creatinine clearance or serum creatinine and 
urea levels,
A non-parametric t-test was applied to the figures obtained for 
N~acetylglucosamine levels, looking at changes for supplemented and 
non-supplemented groups and comparing the results obtained for courses 
two, three and four to those obtained for the first course, in 
general, the increase in N-acetylglucosamine levels above normal were 
higher in the non-supplemented group than in the supplemented group. 
A significant difference in N-acetylglucosamine levels between supple­
mented and non-supplemented groups is found in the third course of 
treatment when compared to the first course (p < O.Ol), By the fourth 
course of treatment there are four patients in the non-supplemented 
group who are receiving magnesium supplements due to low plasma levels, 
and there is no statistical significance (p < 0.11) found between the 
groups when comparing N-acetylglucosamine levels in first and fourth 
courses. These preliminary results suggest that there is less renal 
damage occurring in the magnesium supplemented group, although 
progressive damage does occur in both groups.
It seems therefore, that the magnesium-supplemented group do
138,
retain some of the supplements given, and have less microscopic renal 
damage over the four courses of treatment. Future studies should
monitor the magnesium excretion between courses - which will allow 
assessment of whether or not supplements are being taken, and Aether 
there is body retention of magnesium. Further work looking at 
N-acetylglucosamine levels in patients on varying doses of magnesium 
supplements will be important, and may allow evaluation of the effects 
of increasing the magnesium dose on renal function and treatment 
delays. The long term follow up of these patients will be of value in 
assessing the reversibility of the renal damage.
Magnesium Supplements
From the evidence of serum and urine magnesium levels it 
appears that patients may not be receiving sufficient magnesium 
supplements to maintain serum levels in the normal range (0.70 -
0.90 mmol/1). There may be several reasons for this which include 
insufficient supplementation, to meet the increased output of 
magnesium in urine and vomit; decreased absorption of the oral
supplements due to cytotoxic effects on the intestinal mucosa;
increased metabolic danands for magnesium; failure of the patients 
to take the oral supplements; or a combination of these.
There was no evidence of malabsorption in any patient, and there 
was no excessive loss of magnesium in the urine of the supplemented 
group. All patients experienced considerable nausea and vomiting during
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treatment: the magnesium content of the vomit was not measured. It
was not within the scope of this study to measure metabolic demands for 
magnesium, which may well be increased in the metabolic turmoil follow­
ing aggressive chemotherapy, as discussed in Chapter 5 and in the 
first part of this Chapter.
Compliance of the patients in taking the supplenents was difficult 
to assess. All patients received intravenous supplements according to 
the chemotherapy regime followed (Fig. 27). Many patients, however, 
did not volunteer or even admit when directly questioned by the doctor 
(although they might later confess to the dietician) that they were 
not taking the oral supplements when at home between courses.
There were a number of problems in finding an acceptable oral 
supplement. An initial trial using magnesium gluconate tablets (2 
nmol magnesium/tablet) required five tablets to be taken three times 
daily to supply the required amount of magnesium. The tablets 
themselves were of medium size and quite palatable to the 
patients. The manufacturers, however, discontinued production. A 
search was made for an acceptable alternative magnesium supplement for 
use in this study. The Department of pharmacy, Gartnavel General 
Hospital, made up a number of different suspensions of magnesium (Fig. 
32). The first, a magnesium chloride mixture formulated at Glasgow 
Royal infirmary, proved unacceptable to all but tiie most stoical 
patients due to its bitter metallic taste. Two further mixtures were 
tested; a magnesium chloride and a magnesium citrate suspension, both
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1. Magnesium chloride mixture (Glasgow Royal infirmary)
Magnesium chloride Lemon syrup Raspberry syrup 
Distilled water to
40.6 g 60 ml 
60 ml 
200 ml
expiry 2 weeksprovides 5 nmol magnesium in 5 ml
Magnesium chloride mixture (Strathclyde University)
Magnesium chloride Sodium citrate 
Orange syrup 
Distilled water to
40.6 g 7.2 g 120 ml 
200 ml
expiry 2 weeksprovides 5 mmol magnesium in 5 ml
Magnesium citrate suspension (Strathclyde university)
Magnesium citrate 31.18 gMagnesium chloride 1% w/v solution 12 mlOrange syrup 40 ml
Chloroform water to 200 ml
expiry 4 weeks
provides 5 mmol magnesium in 5 ml
Directions to patients
Take two teaspoonfuls three times daily after meals.
FIGURE 32: FORMULATIONS OF ORAL MAGNESIUM SUPPLEMENT MIXTURES USED
 ■  : : 1 ■ ■  ' ■____
formulated at Department of pharmacy, Strathclyde university, 
Glasgow, Of these, the second proved to be most palatable ; to ; the 
patients, and most acceptable to both medical and pharmacy staff as 
its expiry date was 4 weeks following formulation, thus allowing the
supply for each patient between inpatient chemotherapy cycles to be 
given to the patient on discharge from the ward. This helped to 
avoid problems when patients were seen at outpatient clinics by
medical staff other than those directly involved in the study, who
might emit to provide a further supply of supplements for then,
A number of patients, however, felt after five days as an in­
patient receiving Cisplatin, with the accompanying anorexia, 
nausea and vomiting, that to take an unpleasant-tasting mixture three 
times a day, was too difficult to do. In some cases, the taste of 
the supplanents added to the nausea and anorexia experienced; and to 
many patients the supplements provided no immediately obvious 
benefits for then.
That some patients did take the supplement is shown by the improved 
levels of plasma magnesium in the supplemented group. However a 
priority for the future must be to find a palatable oral supplement for 
use between treatment cycles.
Discussion and Conclusions
There is no evidence that magnesium supplements have any adverse
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effects on final outcome or have any effects on tumour growth, 
indeed, although not statistically significant, patients may benefit 
from magnesium supplementation with fewer treatment delays, fewer 
neutropenic episodes and with improved electrolyte balance for 
potassium and magnesium. Renal damage may also be less in patients 
receiving magnesium supplements. This work contradicts the evidence 
presented by parsons et al. (1972) which suggested that magnesium 
deficiency may benefit the host by reducing tumour growth and causing 
tumour regression. Following that suggestion. Mills (1974) proposed 
that the induction of a state of magnesium deficiency in the 
tumour-bearing host, followed by magnesium repletion with cytotoxic 
or radioactive drugs linked to magnesium supplements, would result in 
tumour regression with no deleterious effects on the host.
On the contrary, the results obtained agree more with the views of 
Blondell (1980) x^ ho demonstrates that on a world-wide basis the levels 
of magnesium present in water, food and air are inversely proportional 
to the cancer mortality for each region studied. Magnesium supplements 
would, in his view, be positively beneficial.
I
The use of magnesium supplements does maintain more normal levels
of serum magnesium and potassium during treatment, and despite
magnesium losses in the urine there is conservation^ of some of the 
magnesium administered. It appears also that there are marginal
benefits from magnesium supplements with patients having fev^ r
neutropenic episodes and hence fewer treatment delays, and less
142.
 :  '
microscopic renal damage, as shown by N-acetylglucosamine and Beta-2- 
microglobulin levels. The reasons for these beneficial effects are 
obscure: it may be that the intracellular and intramitochondrial role 
of magnesium is particularly important in leucocytes and in renal 
tubular cells; deficiency of magnesium, which is the second most 
abundant intracellular cation, may affect these cells more than 
some less metabolically active cells which are slower to reflect 
changes in intracellular composition. From the animal studies, 
the kidney is particularly susceptible to Cisplatin damage.
The effects of Cisplatin on appetite, nausea, vomiting, 
weight loss and anaemia are not improved by magnesium supplements. 
These effects are most clearly seen in those patients with the 
narrowest therapeutic margin for the drug: the patients who received 
"high dose" Cisplatin, and those who had pretreatment radiotherapy. All 
of these patients had neutropenic episodes and low magnesium levels,and 
may have benefitted from increased magnesium supplementation.
Those patients with most weight loss had lowest dietary intakes 
and most anorexia. The effects of Cisplatin on dietary intake have 
been shown to be prolonged in some patients, with very few days 
of normal intake between courses of treatment to compensate for 
the anorexia.
There is general nutritional depletion in most patients receiving 
Cisplatin for teratoma, most of whom are young men who were fit and a
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healthy prior to developing tumours, in the past this has been allowed 
to pass unnoticed, since if there is complete response to treatment 
patients quickly regain appetite and weight. This was seen in the 
patient who did gain weight during the study and who had complete 
response to treatment^and confirms the conclusions of Chapter 5* 
Nutritional depletion should, however, now be regarded more seriously 
as many patients lose weight, often more than 10% body weight, and this 
is significant nutritional depletion, which, may contribute to immune 
suppression, decrease the therapeutic margin for chemotherapy, and may 
add to the general malaise of the patient.
The decreased magnesium intake together with the nausea and 
vomiting and increased magnesium excretion - vhich was found in all 
patients on this study, will contribute to the hypomagnesaemia which 
occurs in most patients receiving Cisplatin for teratoma. Supple­
ments of magnesium are necessary and of benefit to patients and it 
will be important to find an acceptable, palatable oral supplement* 
MacAuley et al., (1982) suggest routine intravenous supplementation 
of magnesium of 12 mmol daily during in-patient treatment ^ for 
all patients receiving Cisplatin. However, it is difficult to see 
how this will compensate for the great decrease in dietary intake 
of all nutrients, including magnesium, during and between courses
of treatment, which has been shown in these patients.
It will be important also to look for evidence of myocardial 
problems in hypomagnesaemic patients. Williams & Whitehouse (1979)
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report a 10% incidence of cardiac arrhytlimias in patients receiving 
Cisplatin. However none of the patients studied showed overt evidence 
of myocardial damage; routine electrocardiographs or cardiac function 
studies were not undertaken,
in summary, therefore, magnesium supplenents are of no harm and may 
be of benefit to tlie patients by promoting fewer neutropenic episodes, 
fewer treatment delays and less damage to renal function. There is no 
evidence that supplements adversely affect outcome of treatment, rate 
of fall of tumour markers, or have any positive effects on the 
incidence of anorexia, nausea and vomiting or of anaemia requiring 
blood transfusion.
Appetite and dietary intake are depressed by Cisplatin treatment, 
and lead to weight loss and nutritional depletion.
Further studies should examine the effects of general nutritional 
supplementation on patients' outcome, side effects of treatment and 
well-being. Suitable oral magnesium supplements should be investigated 
and tested, as the supplements in the present study are unsuitable. 
Future work should also evaluate the effects of increasing levels of 
magnesium supplements on treatment delays and renal function. The 
effects of magnesium depletion on cardiac function, bearing in mind the 
evidence of myocardial damage from the animal experiment in Chapter 5, 
should be carefully examined. Future work should also look at ways of 
improving appetite, perhaps using prednisolone to stimulate appetite 
between courses (see Chapter 7).
 •__
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All patients receiving Cisplatin should be routinely monitored 
for serum levels of magnesium and potassium. The trace metals have 
been shown to remain within normal limits during treatment, and 
monitoring and supplementing of these is not routinely required for 
every patient. All patients should receive adequate magnesium 
supplements and intravenous and oral supplements should be 
considered, with the level of supplementation titrated against 
the plasma magnesium levels; and the effects of a normal serum 
magnesium on outcome, treaWent delays and renal function recorded to 
see if it is beneficial. Seme patients should be considered for 
more general nutritional supplements of calories, protein and vitamins 
and the effects of these on treatment toxicity and outcome should be 
monitored. The method of assessment using 24 hour dietary recall 
histories (as discussed in Chapter 2) would be of value in selecting 
appropriate nutritional supplements.
Renal function should be monitored using the more sensitive N- 
acetylglucosamine and Deta-2-microglobulin assays rather than the 
conventional serum urea and creatinine or creatinine clearance 
estimates, which do not reflect early, and possibly reversible, renal 
damage. The reversibility of any renal damage shown by Beta-2- 
microglobulin and N-acetylglucosamine levels should also be looked at 
in patients who have successfully completed Cisplatin treatment.
in conclusion, Cisplatin is indeed a useful and successful 
cytotoxic drug, provided that it is treated with respect, and adequate 
monitoring and supplementation of patients is performed.
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SECTION 3: METHODS OF IMPROVING THE
NUTRITIONAL STATUS OF CANCER PATIENTS
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CHAPTER 7: ANOREXIA AND APPETITE STIMULATION
Introduction
Anorexia is a major problem in cancer patients and contributes to 
cachexia, malnutrition, weight loss and general malaise (Chapter 1). A 
survey in the Department of Clinical Oncology, Gartnavel General 
Hospital, Glasgow revealed a 43% incidence of this complaint in llo 
consecutive oncology outpatients (Willox et al.,1984). This agrees 
with the 42% incidence of anorexia found in a study of cancer patients 
by a general practitioner in Southampton (Woodbine, 1982).
Patients and relatives are often extremely worried by the lack of 
appetite, and are eager to try any measures to improve it (Theologides,
1976) . If the cancer persists, improved nutrition will allow more 
aggressive treatment of it (Wesdorp et al.,1981); and a logical step 
towards improving nutritional status would be by stimulating appetite.
Appetite stimulants have been in use for many years to treat a 
variety of conditions; although there have been very few clinical 
trials of their effectiveness in cancer patients, despite the frequency 
of anorexia in this group.
Among proposed appetite stimulants are hormones; and thyroid g: 
extract and insulin have been shown to increase food intake in
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experimental animals (Garattini et al., 1980; Williams, Williams 
& DeWitt, 1966; Morrison, 1973) . The mechanism of action of
these hormones on appetite stimulation has not been elucidated. There 
may be a direct effect on the feeding and satiety centres, or changes 
in host and tumour metabolism causing appetite alteration. The 
effectiveness of these hormones on appetite stimulation in man, and 
particularly in cancer patients with altered metabolic responses,is 
not known (Garattini et al., 1980).
Some of the anabolic steroids have been used and are effective in 
anorexia and cachexia. These include methylandrostenolone-enantate and 
androstanazol; however no controlled trials of their effectivness have 
been performed. Methyltestosterone increases body weight and
stimulates appetite, although side effects such as masculinisation are 
a problem (Fruehan & Frawley, 1963).
The antiemetic groups of drugs improve appetite by preventing or 
decreasing nausea and vomiting. Haloperidol, a butyrophenone, 
relieves radiation-induced vomiting, nausea and anorexia in 75-96% 
patients when compared to placebo (7.5-20%), and has few side effects 
(Cole & Duffy, 1974). It may also be effective in relieving 
D-amphetamine-induced anorexia (Garattini et al.,1980). phenothiazines 
prevent vomiting in patients receiving chemotherapy or radiotherapy 
and increase the rate of eating (Strain, 1981). Their side effects of 
hypotension and extrapyramidal symptoms make them unsuitable for use 
purely to stimulate appetite, Metochlopramlde which acts via mainly
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peripheral mechanisms to prevent nausea and vomiting, has very little 
effect on appetite (Middleton, 1972).
Delta 9 tetrahydrocannabinol has some antiemetic effects in 
patients receiving chemotherapy; and has analgesic, euphoric and
appetite stimulating effects. Holland et al. (1977) reported that
thirty-four patients with advanced cancers had stimulation of appetite, 
weight gain and mood elevation after receiving delta 9 
tetrahydrocannabinol. However 25% found unpleasant side effects such as 
dizzyness, somnolence and mental dissociation.
Among the antidepressant drugs which produce documented appetite 
stimulation are lithium and Amitriptyline, Amitriptyline may produce 
its effect via its role as a serotonin antagonist, serotonin being an 
important neurotransmitter with effects on the feeding and satiety 
centres (Morley & Levine, 1983). Both these drugs have produced weight 
gains in non-cancer patients (Strain, 1981; Garattini et al., 1980). 
The benzodiazepines increase food intake in experimental animals 
(Randall et al., 1960) and are known to produce weight gain and in­
creased appetite in man (Strain, 1981). The effect of the major and 
minor tranquillisers on relief of anxiety and alteration of mood is 
well known; however there is debate as to whether it is the relief of 
anxiety or the direct serotonin antagonist effects of these drugs which 
causes the appetite improvenent (Garattini et al., 1980; Strain, 1981), 
Antihistamine agents are used to prevent nausea and vomiting
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associated with cancer treatment. A number of these drugs are also 
serotonin antagonists. Cyproheptadine, an antihistamine and
serotonin antagonist, is effective in stimulating appetite in 
asthmatic, underweight children and in underweight adults; with most 
improvement and weight gain seen in the first week of treatment 
(Silverstone & Schuyler, 1975; Pawlowski, 1975; Toth & Szonyi, 1976). 
There have been, to date, no clinical trials of cyproheptadine as an 
appetite stimulant in cancer patients (Garattini et al. , 1980).
Pizitofen, a drug used to treat migraine, is also an antihistamine 
and serotonin antagonist. it was found to be an effective appetite 
stimulant in patients with cancers of the brain or skull; and has been 
proposed as an appetite stimulant for all patients with cancer-induced 
anorexia (Garattini et al., 1980; Krause, Creep & Fisher, 1979).
Aminoguanidine, a histaminase inhibitor, was found to increase 
appetite in patients with medullary carcinoma of the thyroid. This 
tumour produces large amounts of histaminase (Baylin et al.,1970). Its 
value for other forms of cancer would be limited.
Among the compounds found by chance observation to improve 
appetite are the corticosteroids. These compounds have been used 
empirically for many years, and with reputedly good effect, in cancer 
patients receiving radiotherapy^and in those patients approaching the 
terminal stages of their disease (Oliver, 1983). High dose steroids 
such as dexamethasone and methy Ipr edn i s olone have been used as
l5l.
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effective antiemetics in patients receiving Cisplatin chemotherapy and 
in those receiving chemotherapy for lymphomas (Lee, 1981; Aaprot & 
Alberts, 1981). However, there have been no controlled trials of the 
effectiveness of low-dose corticosteroids as appetite stimulants.
■
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The aims of this study were to examine the effectiveness of a 
corticosteroid (prednisolone) against placebo in appetite stimulation, 
weight gain, calorie intake and well-being in cancer patients 
with anorexia.
Methods
patients were entered into the study if they complained to the 
doctor or dietician of poor appetite or weight loss. A check was made 
on each patient that there was no contraindication:'; to steroid therapy.
The study was conducted as a double blind crossover study; the 
patient being randomised by the pharmacist to receive prednisolone or 
placebo in the first three week study period, then receiving the 
alternative treatment in the the second three week study period, 
patients randomised to Arm A received prednisolone 5 mg , t.i.d. for 2 
weeks; then 5 mg. b.d. for 2 days, 5 mg. daily for 2 days and nil for 
3 days. This dose of prednisolone was chosen to minimise side effects; 
and a fixed dose was used to simplify treatment. After the first 
study period, patients received placebo tablets in the same way. 
patients randomised to Arm B received^  first, placebo tablets, 1 tablet
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t.i.d. for 2 weeks; then 1 tablet b.d. for 2 days; 1 tablet daily for 
2 days and nil for three days. After the first three week study 
period,these patients received the prednisolone course. The placebo 
tablets were provided by Roussel Laboratories and were an inert, chalky 
mixture which were identical in size, shape and markings to the 
prednisolone tablets. Neither the patients nor the observers (doctor
and dietician) knew which course of tablets was being assessed, 
patients were asked whether they would try two different types of 
tablets, and assess the effectiveness in improving appetite. If they 
consented to the trial, the pharmacist randomised them to Arm A or Arm 
B. patients were told to stop taking the tablets, should they notice 
any side effects or upset while taking then.
Assessment was performed prior to treatment, after two weeks of 
treatment and after five weeks. The assessments were timed to 
coincide with clinic visits and were made at the same time of day at 
each visit. On each occasion anthropometric measurements of weight, 
midann circumference and triceps and scapular thickness were performed. 
Weight was measured using the same set of scales on each occasion, 
the patients wearing lightweight clothing and footwear. Weight 
changes of less than 1 kilogram were not considered to be significant. 
Midarm circumference was measured by finding the midpoint of the upper 
arm between acromion and olecranon process, with the arm hanging 
loosely by the side, the elbow bent. From the midpoint, a tape measure 
was used to determine the circumference of the arm (plate 4). The 
non-dominant arm was used in most patients, although Burgert and
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Anderson (1979) have shown no statistical difference between 
measuronents using dominant and non-dominant arms, except in extreme 
cases where the dominant arm has been developed at the expense of the 
other, as in racquet games. From the midarm circumference, the midarm 
muscle circumference can be calculated.
Triceps skinfold thickness was measured using Harpenden skin 
calipers. With the patient's arm hanging loosely by his side, the 
skin 1 cm. above or below the midpoint of the arm was pinched, and the 
skin calipers placed on the midpoint for 3 seconds and the result then 
read (plate 5), An :average of at least three readings were used, or, 
preferably, measur^ents continued until three identical readings were 
obtained. Subscapular skinfold thickness was measured in a similar way 
1 cm. below the tip of the scapula. Historically, four sites have been 
used to estimate skinfold thickness: subscapular, triceps, iliac and 
biceps; and although Durnin & Womersley (1974) recommend the 
measurement of all four sites with averaging of the result, the triceps 
and subscapular skinfold thicknesses have been shown by Burgert & 
Anderson (1979) and Grant et al. (1981) to be sufficient for estimating 
skinfold thickness. Triceps and subscapular sites were used in this 
study as it was difficult in some patients to measure all four sites in 
the time available at the clinic. Two observers took all the 
measuranents in the study; the same observer saw the same patient on 
each occasion,
A 24 hour dietary recall history was recorded and computer 
analysis of this gave protein, carbohydrate, fat and calorie content of
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the diet {see Chapter 2). Each patient completed a questionnaire and 
visual analogue scales which assessed appetite, nausea, vomiting, mood 
and well-being (see Figs. 33 & 34). intake of calories was assessed 
in relation to the preceding recorded intake and differences of less 
than loo Kcal were not regarded as a significant change in intake, 
using the visual analogue scales, changes in each symptom were regarded 
as significant if the mark was greater than 1.0 cm, from the previous 
mark on the 10 cm. line.
Results
Of 61 patients complaining of poor appetite and agreeing to 
participate in the study, 41 were evaluable. Male;female ratio of the 
patients was 16:25; and ages ranged from 27 years to 80 years with a 
mean of 60 years. Twenty-three patients received no form of 
chemotherapy; and 18 patients received regular cycles of chemotherapy, 
timed to coincide with the study treatment periods. patients had a 
variety of solid tumours with the gastrointestinal tumours forming the 
largest group (Table 33). Within tumour groups, patients were assigned 
to Arms A and B in similar proportions; although the use of crossover 
in the study ensured that each patient evaluated both arms of the study 
in any case. No patient had had recent surgery or was hypercalcaoiiic.
The 20 patients who were excluded from the study dropped out for a 
variety of reasons (Table 34). Six patients died while on study; 
3 were admitted to hospital; and 4 had irregular cycles of chemotherapy^
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APPETITE STUDY
CODE:
NAME:
DATE OF B IR TH :
DIAGNOSIS:
CHEMOTHERAPY :
( Type and duration)
HOSPITAL NO
HEIGHT BEFORE 2/52 5/52
DATA COLLECTED
WEIGHT
MID ARM CIRCUMFERENCE
TRICEPS SKINFOLD
SCAPULA SK IN FO LD-
SYMPTOMS:
APPETITE (B ette r
Worse, Same )
PAIN (S ite , Type)
VOM ITING
NAUSEA
CONSTIPATION
DIARRHOEA
"INDIGESTION"
FLATULENCE
SIDE EFFECTS OF A or B
24 HOUR DIETARY RECALL 
(See attached sheet)
ANOREXIA ASSESSMENT 
( See attached sheet)
FIGURE 33: FORM USED TO COEEECT PATIENT INFORMATION FOR
APPETITE STUDY
CODE
APPETITE
VOMITING
NAUSEA
WELL-BEING
MOOD
NAME
L..... ................
DATE
-.....  ................ 1r
EATING
1
EATING
NORMALLY
1
NOTHING
11
NONE
1..................
1
CONSTANT  
..........  11
NONE
1
1
CONSTANT
............... -.- ............ 11
FEEL
1
FEEL
WELL
!....-______  _______
ILL
____________________ 1
HAPPY DEPRESSED
UNHAPPY
-SÎI
FIGURE 34: VISUAL ANALOGUE SCALE ASSESSMENTS
>:?rJ_____________________ ________ ___
Tumour Sites Number of patients
Gastrointestinal 20
Breast
Lung
Ovary
Others
TABLE 33: TUMOUR TYPES OF PATIENTS PARTICIPATING IN THE APPETITE STUDY
_____________
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which did not coincide with the study period and hence invalidated
the results. Of the 7 patients who stopped taking the tablets,
one patient felt better before taking any tablets and so did not start
the study; four patients on Arm B had no change in appetite during
the first treatment period of the study, and were unwilling to 
continue. Two patients on Arm A found no continued improvement ^en 
changed to placebo tablets, and stopped taking them. in all of these 
patients, appetite returned to pretreatment levels or became worse.
Response rates within the tumour groups and the chemotherapy and 
the no-chemotherapy groups reflected the response rates for the entire 
group of patients (Tables 35, 36, 37). The Chi squared test of
statistical significance was applied to the percentages obtained.
in all groups, appetite was significantly (p < O.OOl) improved in 
patients receiving prednisolone first, compared to those receiving 
placebo first (82% and 50% respectively). patients on Arm A showed 
decreased appetite when crossed to receive placebo tablets (from 
82% to 60% , respectively^ with appetite improvenent, p < 0.01).
patients on Arm B showed improved appetite when crossed over to receive
prednisolone (50% to 78% respectively, p < O.Ol).
Weight did not change significantly during either period of the
study. This agrees with the anthropometric data collected, which
showed no change over the 6 weeks of study.
Intake did not differ significantly overall; however the
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chemotherapy group shoved a significant (p < o.Ol) difference in intake 
between prednisolone and placebo groups. The trend for the entire 
group was towards increased intake when on prednisolone.
Well-being, which assessed whether the patients felt well or ill, 
and happy or depressed and miserable, was significantly (p < O.OOl) 
increased in all of the prednisolone groups, compared to placebo. 
This feeling was maintained, or increased slightly when patients on Arm 
A switched to receive placebo; those receiving Arm B increased the 
feeling of wellbeing when given prednisolone, although the change was 
not significant.
None of the patients reported any side effects from the treatment. 
Discussion and Conclusions
The results show that prednisolone is significantly better than 
placebo in improving appetite in cancer patients in the short term. 
There is a major placebo effect (50% overall), arid this, together with 
the trend towards improved well-being when on prednisolone, and = the 
well-known euphoric effects of prednisolone on predisposed patients, 
suggests there is a psychological component in the anorexia of at least 
a proportion of cancer patients.
As would be expected, the period of study is too short for any 
increased protein or fat synthesis to be reflected in changes in 
anthropometric measurements, and future studies of this duration could
Î : i'i .M
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dispense with measuroments of skinfold thickness in assessing 
effectiveness of therapy. There is no greater weight gain in 
patients on prednisolone compared to placebo, and this suggests there 
is no significant water retention on this dose of prednisolone, and 
over this length of study.
The major drawback to using prednisolone as an appetite stimulant 
is its long-term effects. Although there is an initial stimulation of 
appetite, steroids are catabolic hormones in the long-term, and may 
induce dependence, with upsets in fluid and electrolyte balance and 
Cushingoid side effects. The dose of prednisolone used was chosen in 
an attempt to minimise these unwanted problems.
A future study should examine the effectiveness of prednisolone 
used over a longer period of time in those patients who show an initial 
response to it with increased appetite and dietary intake. The study 
would examine the duration of effectiveness of prednisolone on appetite 
stimulation, the effect on nutritional state and on survival, and look 
for any side effects from steroid administration. It may be that, in 
these patients, the drawbacks associated with long-term steroid 
administration will be outweighed by the benefits of improved 
nutritional state, with increased safe therapeutic margin for cancer 
therapy, and, perhaps, prolonged survival.
Other studies should examine the effectiveness of other appetite 
stimulants such as cyproheptadine and pizitofen against prednisolone
158.
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on appetite and dietary intake in cancer patients. This study could 
also be extended to prolong the arm of the drug which proves to be most 
effective and to study its usefulness in the long-term.
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SECTION 4: CONCLUSIONS
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CHAPTER 7: GENERAL CONCLUSIONS AND FUTURE WORK
The aims of this thesis were to examine in detail some of the 
nutritional and metabolic problsns of cancer patients.
The problem of nutritional assessment was considered and dietary 
histories, clinical evaluation and biochemical estimations of 
deficiencies were compared and found to closely agree in assessing 
nutritional state in patients with significant depletion. The patients 
with deficiencies identified by all three methods were those vÆio were 
most nutritionally depleted. Clincial signs of deficiency and 
biochemical tests of body status of vitamins, minerals and nutrients 
are shown to reflect long-standing nutritional deficiencies; dietary 
recall histories will give an early indication of potential nutritional 
problems and will reflect improvements and fluctuations in dietary 
intake and nutritional state. From the results obtained, the best 
way of assessing nutritional state is to combine clinical, biochemical 
and dietary intake information. Weight loss and rate of weight 
change, together with assessment of brittle nails, dry skin and dry 
eyes are the most useful clinical examinations; 24 hour dietary recall 
histories provide information on recent intake and can be used with 
intake histories taken on several previous occasions to assess changes 
in intake and hence nutritional state; and biochemical estimations of 
serum total protein, albumin, calcium, zinc and iron are the most 
useful and reliable laboratory tests. All of these will together 
give a clear picture of a patient's nutritional status.
The results obtained show good correlation between dietary
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déficiences of energy and protein^and clinical measurement of weight 
loss and biochemical measurement of serum total protein and albumin 
levels. From these findings it is concluded that the 24 hour dietary 
recall histories with computer analysis provide a fast, easy and 
reliable method of anticipating future nutritional problems and thus 
allow their early correction. Repeated dietary histories give an
estimate of present dietary intake ^ and comparison with previously 
recorded intakes will allow assessment of nutritional status at any 
particular time, and permit fluctuations in nutritional state over
periods of time to be recorded. Low or decreasing intakes on a number
of occasions indicate deteriorating nutritional status; increasing 
intakes indicate improvements in nutritional state; stable levels of 
intake must be used with serial weights and other nutritional 
asessments to indicate nutritional status for each individual patient. 
In assessing nutritional state of cancer patients, tumour type and 
spread ^ and chemotherapy or other form of treatment must be considered 
together with the other nutritional assessments used.
Future studies using dietary assessments to pinpoint likely 
deficiencies could then assess, with the techniques described above, 
the value of early nutritional supplementation in slowing or preventing 
the metabolic decline to cachexia. The effects of early supplementa­
tion on tolerance to cytotoxic treatment and its side effects, and on 
tumour growth should also be evaluated.
Section two looked at the effects of cancer and chemotherapy on
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the nutritional and metabolic status of cancer patients and 
tumour-bearing animals.
A preliminary study of muscle biopsies in four cachectic cancer 
patients showed considerable disruption of the muscle fibres with 
particularly striking changes seen in the mitochondria. These changes 
are distinctly different from the changes seen in starvation, disuse, 
ageing and acute illness, and appear to be cancer-specific. This 
illustrates the unique metabolic changes seen in cachectic cancer 
patients. Future studies would aim to look at the changes in 
patients with less extreme nutritional and metabolic disturbances; 
and in those who have had no treatment^  to allow the effects of the 
tumour alone to be more easily evaluated.
The effects of cancer and chemotherapy on saliva production, 
composition and microflora content, which may account for some of the 
dry mouths, difficulties in chewing, swallowing and digesting, loss of 
taste, decreased enjoyment of food, and anorexia seen in cancer 
patients, were studied in a group of cancer patients before starting 
treatment, and after one and three months of cytotoxic treatment. 
Saliva volume, flow rate, amylase and igA content decreased as 
treatment progressed; and the incidence of bacterial and candidal 
infection increased over the period studied. Combinations of drugs 
which include Adriamycin, Cisplatin and Mitomycin C were particularly 
implicated in the increasing carriage of micro-organisms. Drug 
combinations including Cyclophosphamide and Methotrexate were more
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likely to produce decreased saliva flow rate and decreased saliva 
volume^causing dry mouths. The significant incidence of decreased 
saliva production and increased micro-organism carriage in the cancer 
out-patients studied, suggests that time should be taken to regularly 
examine the mouths of these patients, to try to alleviate dry mouths, 
and treat and prevent dental caries. The mouth should always be 
, considered a source of potentially virulent micro-organisms which may 
breech impaired host defences and produce life-threatening infections. 
Future work should examine the changes in saliva production and 
microflora in relation to alterations in taste sensations and the 
incidence of anorexia found in cancer patients.
The effects of tumour growth and chemotherapy on the metabolic and 
nutritional status of tumour-bearing Wistar rats were studied. 
Cyclophosphamide and Cisplatin were the cytotoxic drugs used. Drugs 
alone and in combination with tumour ^ and tumour alone groups were 
examined. All showed metabolic upset with weight loss, decreased 
carcass nitrogen content, decreased plasma protein, albumin and iron 
concentrations and increasing levels of ketone bodies and of liver 
enzymes. The tumour itself caused the greatest metabolic insult, 
improvement in the metabolic state occurs when the tumour responds 
to treatment; however if there is.no response to treatment there may 
be increased metabolic problems caused both by tumour growth and the 
cytotoxic drugs. This study provides a useful animal model for the 
human problem of cachexia and could be used for further studies of 
drugs which may modify tumour growth and the effects of tmmour
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on metabolism, while minimising unwanted drug effects. The effects of 
other cytotoxic drugs on metabolism may also be studied in the animal 
model, and a prediction of the likely nutritional and metabolic 
problems associated with their use in cancer patients may be made.
The effects of Cisplatin on nutrition and metabolism were studied 
in more detail in patients with teratoma who received Cisplatin as part 
of a chemotherapeutic regime, preliminary animal studies showed that 
Cisplatin affects mitochondrial function particularly in the kidney, 
but also in heart, skeletal muscle and liver tissue, and these 
effects are dose dependent. The electron microscopy studies showing 
mitochondrial disruption may help to explain some of the metabolic 
alterations found in the rats receiving Cisplatin; the intracellular 
disruption accounting for the weight loss, decrease in nitrogen content 
and in plasma proteins, and the altered levels of liver enzymes in the 
serum. Future animal studies should use electron microscopy and 
histochemical methods to look at the intracellular structure of 
organs from animals with tumour, Cisplatin or tumour^  and Cisplatin 
who show weight loss and nutritional depletion. This could be 
extended to look at other drugs using this model, it would then be 
possible to see whether a common intracellular mechanism is producing 
the metabolic alterations found, and ways of preventing the 
intracellular problem and, perhaps, the metabolic disturbance may be 
sought.
Clinical studies looking at Cisplatin examined the effects of the
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drug, in combination chenotherapy, on trace metal levels in patients 
with teratoma. Levels of the trace metals were measured during the 
courses of treatment; and comparisons between courses were made. 
Cisplatin was shown to induce nausea, vomiting and anorexia in most
patients. Trace metal levels were not particularly altered between 
first and fourth courses of treatment. plasma iron levels did 
rise in most patients during and between courses of treatment, 
iron levels were highest in those patients who required blood 
transfusions for anaenia: the cause of the anaemia being failure of 
iron utilisation following drug induced damage to erythroid 
precursors in the bone marrow.
Serum magnesium levels fell in the majority of patients over the
four courses of treatment, and in some cases supplenentation was
required to treat symptoms of hypomagnesaonia. Similar falls in serum 
magnesium were seen in patients with ovarian carcinoma treated with 
Cisplatin in a different combination of drugs.
Further clinical studies compared the routine use of magnesium 
supplements during and between the first four courses of 
Cisplatin treatment with the standard regime which contained no 
supplements. patients receiving routine supplements, which included 
intravenous supplements during inpatient chenotherapy and oral 
preparations between courses^  showed no difference in rate of fall of 
tumour markers, response to treatment, or tumour growth rate as 
determined clinically, radiologically and biochenically,compared to non
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supplemented patients. Nausea, vomiting and anorexia were found to 
occur with similar frequencies in both groups. The anorexia,which 
lasts for 8-12 days following ihtravenous Cisplatin administration, 
was mirrored by decreased dietary intake which affected all nutrients 
equally. Although not statisically significant, due to the low numbers 
of patients studied, there appears to be increasing duration of 
anorexia and poor dietary intake (which falls in some cases to less 
than 40% normal) with successive courses of treatment. This cumulative 
effect of Cisplatin on appetite causes some patients to become 
significantly nutritionally depleted and may decrease the safe 
therapeutic margin for Cisplatin in these individuals. Weight loss was 
common and paralleled decreased dietary intake and anorexia: those
patients with the greatest weight loss had the poorest intakes and the 
most prolonged anorexia. Weight loss also correlated with poor 
response to treatment; the group of patients who showed least response 
to treatment had the most weight loss. From these observations it 
would indeed appear that nutritional state is determined both by 
tumour growth and by the effects of cytotoxic drug treatment, as 
suggested by the animal studies on Cisplatin and metabolism. If there 
is response to treatment, nutritional state improves; if there is no 
response, the combined effects of tumour and drug on nutritional state 
cause continued decline. Further studies should examine the useful­
ness of early nutritional support in preventing extrene depletion and 
permitting prolonged, aggressive chemotherapy.
The magnesium supplaaented group had fewer treatment delays due to
167.
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neutropenic episodes than the non-supplemented group. This is 
important in allowing adequate and regular treatment to be given for 
what is often a successfully treated tumour. Serum magnesium levels 
were significantly higher, and serum potassium levels showed smaller 
falls, in the supplemented patients. Several of the non-supplemented 
patients required magnesium supplements by the end of the third course 
of treatment for serum magnesium levels below 0.45 mmol/1, and to 
prevent symptoms of hypomagnesaemia.
Renal function, as determined by serum creatinine and urea levels 
and by creatinine clearance levels, showed little change over the four 
courses of treatment. However measurement of N-acetyl glucosamine 
levels in urine showed deterioration in renal tubular function over the 
four courses of treatment. There was significantly less deterioration, 
however, in the supplemented group by the third course of treatment. 
This is an important observation since Cisplatin is an extremely useful 
cytotoxic drug whose use is limited by its nephrotoxicity. Future 
work should use N-acetyl glucosamine to monitor the reversibility of 
renal changes induced by treatment; and should continue the use of 
magnesium supplements to confirm their beneficial effects on renal 
function.
The methods of magnesium supplementation used were intravenous and 
oral. Both have advantages and disadvantages. The intravenous route 
is convenient when the patient is receiving inpatient intravenous 
chemotherapy; however it is difficult to administer in the sixteen
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days between treatment courses, when the patient is at home. 
Oral supplements are ideal for outpatients; less useful for inpatients 
who are vomiting. There was poor compliance in some patients 
taking the oral magnesium mixtures supplied for the study. part of 
the problem was the metallic taste of the supplenents; part was 
the residual nausea and anorexia following discharge from hospital. 
Future work should be directed to finding an acceptable oral
magnesium supplement; possibly in tablet form. Further studies would 
be useful to compare the effectiveness of intravenous inpatient
supplenents alone, with continuous inpatient intravenous,and outpatient 
oral, magnes ium supplements.
From the results obtained, if magnesium supplementation allows 
treatment with Cisplatin to continue regularly, with fever delays 
between courses and less effect on renal function, and if a suitable 
magnesium supplement can be found, it will be possible to use the 
drug more effectively to combat even the most aggressive tumours, 
while keeping the safe therapeutic margin of Cisplatin as wide as 
possible.
Section three looked at one way of improving nutritional state in
cancer patients, and examined the problem of anorexia and appetite
stimulation. Anorexia was a major complaint in 43% cancer patients
attending the oncology outpatients clinic at Gartnavel General
Hospital. prednisolone was found to be a highly effective appetite
stimulant when used over a 2 week period. A 50% placebo response.
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however, indicated the partial psychological basis for anorexia in some 
patients and demonstrated the power of the higher brain centres on the 
appetite centre. Further studies should examine the effectiveness of 
prednisolone in the long-term, in patients who have an initial 
response to treatment. Other appetite stimulants may also be compared 
against prednisolone, using a similar double-blind crossover study 
design.
in conclusion, this thesis has examined the implications of cancer 
and its treatment on some areas of nutrition and metabolism in patients 
and animals. There remains a great deal of work to be done, and many 
of the results obtained in this work merely provoke further questions.
The studies presented here demonstrate some of the far-reaching 
nutritional and metabolic effects of cancer and chemotherapy in man and 
experimental animals; and present a method for easy identification and 
early anticipation of nutritional and metabolic problems. Further 
work is required to assess the value of prompt and adequate nutritional 
support in preventing the metabolic alterations and nutritional 
deficiencies seen in the cancer patient.
It is sincerely to be hoped that the state of cancer cachexia 
will become a comparative rarity, and that doctors treating cancer 
may no longer have to watch as their patients grow "pale, and 
spectre-thin and die" (Keats, 1820).
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